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Abstract 
The viability of extending the present methodology designed for the solid phase 
synthesis of peptides has been investigated. Using the catalytic domain of stromelysin 
(SCD, 173 residues) as the model system a number of different factors affecting the 
preparation and purification of chemically synthesised proteins are examined. 
The purification SCD, prepared using stepwise solid phase synthesis is described. 
Following characterisation, it is evident that protein of the correct primary sequence 
has been prepared, furthermore, preliminary studies centred on the enzymatic activity 
of SCD indicate that active protease has been isolated. However, comparison of the 
conformational and biophysical properties of chemically synthesised SCD with the 
recombinant counterpart, suggests that there are problems associated with the folding 
of the synthetic SCD. 
The construction of chemically synthesised SCD via convergent protein synthesis is 
also described. Two different coupling strategies involving classical and azide 
fragment condensation are examined where it has been highlighted that the overall 
success of each fragment coupling is greatly dependent on the peptide length and 
sequence. As well as comparing methods for the preparation and coupling of fully and 
minimally protected peptides, general procedures for both solution and solid phase 
fragment coupling are discussed. 
A novel strategy for the convergent synthesis of peptides and proteins has been 
investigated. In this total chemical synthesis approach, two minimally protected 
peptides are joined through unique, mutually reactive functional groups, yielding a 
peptide analogue with a thioether replacement for the native peptide bond at the site 
of ligation. A general route to C-terminal sulfhydryl and N-terminal haloacetylated 
peptides is presented, accompanied with results of the preliminary ligation studies. 
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AAA amino acid analysis 
ABI applied biosystems 
actSCD activated SCD 
Acm acetamidomethyl 
AcOH acetic acid 
AMPA aminophenylmercuric acetate 
Boc tertiary-butoxycarbonyl 
Bum N'-tertiary-butoxymethyl 















FAB fast atom bombardment 
Fmoc 9-fluorenylmethyloxycarbonyl 
FPLC fast protein liquid chromatography 
Gdm.HCI guanidinium hydrochloride 
HBTU O-benzotriazol- l-yl-N,N, N', N '-tetramethyluronium- 
hexafluorophosphate 
HF hydrogen fluoride 
HFIP hexafluoro-2-propanol 
HIC hydrophobic interaction chromatography 
HIV human immunodeficiency virus 
HOAt 1 -hydroxy-7-azabenzotriazole 
HOBt 1 -hydroxybenzotriazole 
HOCt ethyl-i -hydroxy- 1 H-i ,2,3-triazole-4-carboxylate 
HOOBt 1 -hydroxy-3 -hydroxy-4-oxo- 1,2,3 -benzotriazine 
HPLC high performance liquid chromatography 
HRMS high resolution mass spectrometry 




MALDI matrix assisted laser desorption ionisation 
Mca methoxycoumarin 
MMA N-methyl-mercaptoacetamide 
MMP matrix metalloproteinase 
mRNA messenger ribonucleic acid 
MS mass spectroscopy 
Mtr 4-methoxy-2,3 ,6-trimethylbenzenesulfonyl 
Mwt. molecular weight 
Mwt.CO molecular weight cut off 
nm nanometre 
NMP N-methyl-2-pyrrolidinone 
NMR nuclear magnetic resonance 
PAGE polyacrylamide gel electrophoresis 
PGC porous graphitised carbon 
Pmc 2,2,5 ,7,8-pentamethylchroman-6-StllfOnYl 
proSCD preactivated SCD 
recomSCD recombinant SCD 
RT room temperature 
Rt retention time 
s singlet 
SCD stromelysin catalytic domain 
s.c.p side-chain protection 
SDS sodium dodecyl sulfonate 
SPFC solid phase fragment condensation 
SPPS solid phase peptide synthesis 
t triplet 
I tertiary 
Tbfmoc 1 7-tetrabenzo[a, c, g, ]]fluorenylmethoxycarbonyl 
TEA triethylamine 
TFA trifluoroacetic acid 
TFE trifluoroethanol 




TLC thin layer chromatography 
TOF time of flight 
Tris tris(hydroxymethyl)aminOmethafle 
Trt, Trityl triphenylmethyl 
UV ultraviolet 
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1. Solid Phase Peptide Synthesis 
Chapter One 
Solid Phase Peptide Synthesis 
1.1 Introduction 
Peptides and proteins play crucial roles in virtually all biological processes. The 
chemical and biophysical properties of these complex systems are completely diverse, 
thus the range of applications is extensive and extremely varied. For example, a 
number of these biologically active molecules are extremely toxic or responsible for a 
wide range of pathological diseases, while, on the other hand, other systems have 
been found to be of great therapeutic value. 
The breadth and depth of our understanding of how these biologically significant 
systems function has increased at an extremely fast pace. For a number of years, 
biologically active peptides have been objects of intense interest in the research 
community and are the subjects of thousands of research programmes. More recently, 
there has been an upsurge in interest in the much larger, more complex protein 
molecules which have now become more attainable. This has been as a result of the 
developments in modern molecular biology which has led to the availability of amino 
acid sequence data determined by the cloning of and cDNA sequencing of genes. 
The demand for these complex molecules is thus enormous and rising all of the time. 
Although the target molecule can normally be isolated from its native source or 
prepared using modern molecular biology, the development of an alternative, total 
synthetic approach has resulted in an effective and well-established method for the 
synthesis of biologically significant systems. Furthermore, chemical synthesis is now 
recognised as a highly versatile method, allowing systematic variation of the primary 
structure with the aim of developing second-generation products for therapeutic use. 
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1.2 The Chemical Synthesis of Peptides 
The preparation of a peptide from its constituent amino acids using conventional 
solution phase chemistry is far from trivial. The problems encountered can easily be 
illustrated with the synthesis of a simple dipeptide AB (Fig. 1.1). 
HR1 	 HR2 
	




HR1 	HR1 	 HR1 	HR2 
H2Nco -NH " OOH 	H2NcO -NW" COOH 
HR2 	H 9 	 HR2 	HR1 
H2NCO -NH  ~t  COOH 	H2NW -NHcOOH 
In addition: 
side-chain 	 2 extension of peptide 
cross-reactions chain 
NH CO —NH CO J 
Fig. 1.1 Uncontrolled synthesis of a dipeptide AB 
This clearly underlines the fundamental problem associated with the synthesis of 
peptides. Without control over these highly functionalised species, the coupling of 
two amino acids would result in formation of four possible dipeptides, accompanied 
by the uncontrollable extension of the N and C-terminus (contamination with 
tripeptides, tetrapeptides etc). Furthermore a number of side-chain functionalities are 
also capable of reacting in the coupling conditions, thus it is obvious that the number 
of possible cross-reactions and resulting by-products would be extensive. 
2 
1. Solid Phase Peptide Synthesis 
This problem can be avoided by the introduction of protecting groups (Fig. 1.2) which 
ensure the unambiguous synthesis of AB. In addition, if the protecting groups 
employed are labile under different conditions, selective deprotection of the a-amino 
or a-carboxyl moieties will allow subsequent elongation at either terminus of the 
peptide. 
H R1.Prot. 	H R2.Prot. 	 H Ri.prot. H 92.Prot.
Do 
Prot.HN 	OOH H2N 	cXO.Prot. 	Pnt.HN 	co—NH 	WO.Prot. 
Fig. 1.2 Controlled synthesis of a dipeptide AB 
Although the protecting group strategy permits the preparation of peptides with the 
correct sequence of amino acids, as with all solution phase chemistry, the 
intermediates require purification. As a result, even the assembly of a relatively short 
peptide sequence would be labour intensive, requiring the efforts of a number of 
highly skilled and experienced chemists. 
The potential for peptide and protein synthesis was therefore revolutionised when, in 
1963, Merrifield' presented the brilliantly simple idea of attaching the carboxyl group 
of the C-terminal amino acid to an insoluble support from which the chain of amino 
acids could be elongated (Fig. 1.3). 
Even at the onset of this solid phase peptide synthesis (SPPS), Merrifield' identified 
the underlining advantages of employing the solid support - 
• an excess of the incoming amino acid could be used to drive the reaction to 
completion. 
• since the support and covalently attached peptide would be insoluble, excess 
reagents, by-products and solvents could be removed by simple filtration and 
washing procedures. 
• all reactions could be conducted in a single reaction vessel so it seemed 
reasonable that the process would lend itself to automation. 
3 
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R2 	 RI 
PrOt.NH 	+ H2N1W—o1uble supp 
Couple 
F12 	 R, 
ot.NH1  CO—NH1  CO —insoluble 
Deprotect N  group 
111 __ Prot.NH 	COOH 	H2N 	CO—Ni-I 	CO—O-{insoluble suppor 
Repeat coupling and 
deprotection steps 
Fig. 1.3 The principle of Solid Phase Peptide Synthesis (SPPS) 
Since its initial design, the intervening 35 years has seen extensive research efforts 
worldwide, which have concentrated on the development of methodology and the 
design of a wide range of reagents to improve the synthetic capabilities of SPPS. The 
result is a highly efficient automated system capable of preparing polypeptides and 
small proteins which would be insurmountable using solution phase chemistry. 
Unsurprisingly, considering the advantages of SPPS, the general principle of solid 
phase chemistry has been extended to other fields leading to the now established solid 
phase oligonucleotide3  synthesis as well as the development of methodology for the 
synthesis of oligosaccharides 4  using insoluble supports. Furthermore, in organic 
synthesis, solid phase methods have led to the optimisation of a vast number of 
standard chemical reactions on insoluble supports. As well as providing a beneficial 
alternative to solution phase chemistry, solid phase organic chemistry is now 
considered to be of significant importance for the fast, simultaneous and multiple 
synthesis of many new organic compounds required in the search for lead drug 
candidates (combinatorial chemistry).' 
4 
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1.3 Solid Phase Peptide Synthesis (SPPS) - A General Overview 
The following sections are designed to summarise briefly how SPPS has advanced 
over the past three decades and presents some of the reagents and strategies which 
are considered to have made a significant contribution to its overall development. Fig. 








R2-Prot. 	R1 .Prot. 




1. Deprotect Na group 	Repeat sequence 
of events until 
92 .Prot. 	RI .Prot. 	
the synthesis is 
complete. 
'j~W-NACC)_0o-o 
Deprotect side-chain protection 
and cleave from solid sup port. 
Target Sequence 
Fig. 1.4 General operations involved in SPPS 
The following aspects shall be individually considered - 
• protecting group strategies 
• nature of the polymer support 
• the resin linkage 
• peptide bond formation (carboxyl activation) 
5 
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1.4 Protecting Group Strategies 
One of the most important considerations in SPPS (outlined in fig. 1.4) is that the 
deprotection protocols required for the Na  and side-chain flinctionalities are 
orthogonal. The side-chain protecting groups must maintain complete integrity 
throughout, whilst the appropriate N'-protection is cleaved at each cycle of the 
peptide synthesis. Fig. 1.5 summaries the two most effective protecting group 
strategies, Boc and Fmoc, both of which have been successfully utilised in automated 
sPPs. 
[Boc SPPSI 






z 	rFmoc sPPsI 
(H2HF 
(strong acid) 









Fig. 1.5 Protecting group strategies in SPPS 
1.4.1 Boc strategy 
The first of these two orthogonal protocols is based upon the acid lability of the t-
butoxy-carbonyl (Boc) group, the principles of which were established by Merrifield 
with the synthesis of bradykinin. 6  During assembly of the peptide chain, trffluoroacetic 
acid (TFA) treatment rapidly cleaves the Boc protection, ensuring the quantitative 
release of the Na amino functionality. Meanwhile, all side-chain functionalities remain 
blocked throughout by employing semi-permanent protection namely the 
benzyloxycarbonyl group (Z), benzyl ethers and esters. These benzyloxy groups are 
then cleaved from the side-chain functional groups at the end of the synthesis using 
much stronger acid conditions such as hydrogen fluoride (HF) or 
trifluoromethanesulfonic acid (TFMSA). 
Ell 
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1.4.2 Fmoc strategy 
The development of Fmoc SPPS arose out of the concern that repetitive TFA 
acidolysis in Boc group deprotection could lead to alteration of sensitive peptide 
bonds as well as acid catalysed side-reactions. In addition, the final deprotection and 
cleavage from the solid support requires very harsh acidolysis using highly corrosive 
BY. Not only do these harsh conditions clearly present the risk of affecting the peptide 
product, but there is also the requirement for specialised laboratory apparatus and 
very careful handling. 
Thus an alternative to Boc was presented with the design of the base labile 9-
fluorenylmethoxycarbonyl (Fmoc) (1) by Carpino 7 ' 8 which was elegantly applied 
independently by Meienhofer9 and Sheppar& ° to SPPS. This base labile protecting 
group not only provided an attractive alternative to Boc synthesis, but could also be 
described as a truly orthogonal approach to SPPS. In this milder, more specific 
strategy, the growing peptide is subjected to base treatment using piperidine which 
cleaves the Fmoc moiety via -elimination (Fig. 1.6). On completion of the peptide's 
synthesis, the base stable side-chain protection may then be removed by TEA 









(2) H—N \—I 
Fig. 1.6 Fmoc deproteclion using piperidine 
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1.4.2.1 Fmoc strategy - UV monitoring of coupling efficiency 
In addition to the milder reaction conditions, Fig. 1.6 highlights a further advantage of 
the Fmoc strategy. Once released from the growing peptide chain, the dibenzofulvene 
(2) is quenched with excess piperidine, forming the fulvene-piperidine adduct (3). The 
isosbestic point of (3) occurs at 302nm, therefore, a useful estimation of the coupling 
efficiency of each amino acid can be made by measuring the absorbance of the 
deprotection effluent. This is of substantial benefit to the peptide chemist as it 
provides an overall profile of the peptide synthesis as well as highlighting possible 
problematic areas within the peptide sequence. 
1.4.2.2 Fmoc strategy - protecting groups 
With the introduction of base labile Na protection, clearly the requirement for side-
chain blocking is to use protecting groups which are base stable and extremely labile 
under mild acid conditions. Although the majority of functionalities are efficiently 
protected using triphenylmethyl (Trt), t-butyl ethers or t-butyl esters, special 
consideration is necessary for the protection of the side-chains of arginine, cysteine 
and histidine. Table 1.1 summarises the most common protecting groups used. 
Amino acid Side-chain P.G 
Arg MtrfPmc 
AsnIGln Trt 




Ser/Thr/Tyr Bu ethers 
Trp Boc 
Table 1.1 Side-chain protection employed in Fmoc SPPS 
Arginine protection - The trilunctional guanidino side-chain group of Arg is strongly 
basic thus is easily acylated during SPPS if not protected. Unlike other amino 
functionalities, blocking the side-chain with Bo&' is not sufficient with the 
8 
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nucleophilicity of the guanidino function still capable of leading to undesired side-
reactions and subsequent intramolecular decompostion during acid deprotection.' 2" 3 
In contrast to urethanes, a single arene sullonyl based Arg protecting group has 
proved to be a successful alternative leading to the design of derivatives such as 4-
methoxy-2,3,6-trimethylbenzenesul-fonyl (Mtr)' 4" 5 (4), and 2,2,5 ,7,8-pentamethyl-
chroman-6-sulfonyl (Pmc) 16" 7  (5). Considering Mtr requires stronger acid treatment 
(TFMSA) for cleavage of peptides containing multiple Arg residues, Pmc is presently 







£ (4) Mtr J (5)Pmc 
Histidine protection - The most serious problem encountered with His is 
racemisation due to the basicity of the it-nitrogen in the imidazole ring. Fig. 1.7 shows 
how the basic nitrogen is capable of proton abstraction from the a-carbon at which 
point the stereochemical integrity is lost. 
R
V 
Ha Hz 	 c ~'~Q  
NH 0'— 	—NH C 	 —NH C 
II 	 I II 
o) o o 
Fig. 1.7 Racemisation of histidine 
This stereochemical problem has been shown to be completely avoided by blocking 
the it-nitrogen with t-butoxymethyl (Bum). 18  However due to its complex synthesis 
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and resulting cost, this derivative is not commonly employed. Alternatively, it has 
been found that the t-nitrogen, blocked with the bulky trityl group 19 significantly 
reduces the basicity of the imidazole. In addition, this proton abstraction can be 
suppressed even further by employing additives during synthesis. 2° 
Cysteine protection - The synthesis of cysteine containing peptides is often 
complicated because some peptide products require the cysteine residue to be in the 
free sulihydryl form while others require inter or intramolecular disulfide bonds. As a 
result, there are currently a number of protecting groups available, the choice 
depending on whether free or protected cysteines are required during purification. 
The most commonly used Cys protection is Trityl which generates the free thiol upon 
deprotection using TFA. Alternatively, Cys protection can be retained if the 
acetamidomethyl (Acm) 22  or t-butylthio (SBu') groups are used. Removal of Acm is 
achieved by treatment with silver trffluoromethanesulfonate 2 ' or mercury (II) 
acetate '22  while SBu' can be removed by reduction with thiols eg. - 
mercaptoethanol 23 or by using tributylphosphine. 24 
1.5 Nature of the Polymer Support 
The most fundamentally crucial consideration in SPPS has to be the solid support 
itself. In order for any chemistry to proceed effectively, the insoluble resin must 
possess a number of physical and chemical properties - 
• the support should be inert towards, and insoluble in, all solvents and 
reagents used. 
• functionality must be incorporated to allow attachment of the growing 
peptide chain. 
• structurally, the support must be microporous, swelling to expose the 
large surface area allowing rapid access to all reagents and solvents. 
The original resin used by Merrifield' was a cross-linked form of polystyrene 
containing reactive chioromethyl groups. This was prepared by polymerisation of 
10 
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styrene plus 1% divinylbenzene to produce a rigid cross-linked resin followed by 
chioromethylation. The C-terminal amino acid was fixed to the polymer via a 
nucleophilic substitution of the Cl by the carboxyl group (Fig. 1.8). 
polymer 
acH2{) —r support 
Pmt.MWOH 
Fig. 1.8 Attachment of an a-amino acid to the polystyrene support 
Following on from the success of the Merrifield polystyrene support, alternative resins 
have been designed and incorporated into SPPS. Possibly the most notable of these 
are the polyamide resins developed by Sheppard 
. 2 ' The proposed advantage of such a 
polyamide support was that by increasing the polarity of the linker, this more 
hydrophilic functionalised resin should aid the solvation of the growing peptide chain, 
hence improving the efficiency of the synthesis. 
1.6 The Resin Linkage 
As previously discussed, the original design of SPPS involved attachment of the 
peptide directly to the functionalised resin. This benzyl ester link to the support was 
complementary to the initial Boc strategy in that the bond withstood the repetitive 
TFA treatment. Additionally, both the benzyl side-chain deprotection and release of 
the peptide would be effected by final strong acid (HF) treatment. However, 
considering that the Fmoc strategy employs a final, milder acid treatment, clearly the 
incorporation of a more acid labile linker system was viewed as having a significant 
advantage. 
11 
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The introduction of linkers between the support and the peptide made it possible to 
alter the strength of the peptide-resin bond making it more or less labile depending on 
the synthetic strategy. The difference in acid lability can be demonstrated by 
considering two of the most commonly used linkers applied in Boc and Fmoc SPPS 
(Fig. 1.9). 
[Boc Strategy] 	Linker26  
Properties: ester bond formed 
NIH 	
with peptide is stable to TFA 
but cleaved in strong acid (HF). 
_ 	 Wang Linker 27 
[Fmoc Stratei 	 Properties: ester bond is stable 
to mild base (piperidine) but 
..,..__Q cleaved in mild acid (TFA). PeptideO  
Fig. 1.9 PAM and Wang linkers used in SPPS 
Although with both the Fmoc and Boc methodologies the peptide cleavage 
mechanism is ester hydrolysis by alkyl-oxygen fission, the Wang linker has a greater 
acid lability. This is due to the additional p-oxygen which aids the stabilisation of the 




Fig. 1.10 Carbocalion stabilisation of the Wang linker 
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Clearly the incorporation of these linkers makes it possible to closely control the acid 
lability of the peptide link. Subsequently a number of linkers have been designed 
which have a variety of applications. For example, depending on the linker, it is now 
possible to prepare peptides with a number of C-terminal modifications. In addition, a 
number of highly acid labile linkers have been developed permitting the preparation of 
peptides with the side-chain protection fully intact. Such side-chain protected, or C-
terminally modified peptides are of great importance for a number of strategies 
applied to peptide fragment coupling (chapters 3 and 4). Fig. 1.11 summarises a 






H3cO111ZI1 OH2  
SASRIN Linker28 
- acid labile (1% TFA). 
- used for the preparation 
of side-chain prot. peptides. 
2-C l-Trityl Linker 29 
- extremely acid labile 
(10% AcOH). 
- used for the preparation 
of side-chain prot. peptides. 
Dibenzocycloheptadiene 
Linker 30 
- acid labile (dilute TFA). 
- highly versitile linker used 
for the prep. of C-terminally 
modified peptides. 
Rink amide Linker 31 
- acid labile (dilute TFA). 
- developed for the synth. 
of C-terminal amides. 
Fig. 1.11 Examples of linkers employed in Fmoc SPPS. 
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1.7 Peptide Bond Formation 
As with all other aspects of peptide synthesis, the methodology associated with 
peptide bond formation has been extensively studied. Overall, optimal conditions 
should be such that amide bond formation is carried out rapidly and quantitatively 
under mild conditions, avoiding any side-reactions or changes in the stereochemical 
integrity. 
In general, the carboxyl group of the amino acid being coupled is initially activated; 
subsequent reaction with the Nc amino on the growing peptide chain results in amide 
formation (Fig. 1.12). The activation of the amino acid is simply the conversion of the 
carboxyl group to a more reactive derivative allowing the nucleophilic amine attack to 
proceed. The underlining requirement of such an 'activating group'(A) is that it has 
electron withdrawing properties thus increasing the electrophilicity of the carboxyl 
group making it more susceptible to nucleophilic attack. 
R 	 R 	 R 
Pnt NHI Activate 
	 _____ 
C— OH Pn:,t.NH 	
A) 	
-HA 
C— A H2N 	WCHR_F 	 II NW 	
Pmt.N 




Fig. 1.12 Formation of the amide peptide link 
1.7.1 Racemisation during activation 
Stereochemical considerations are the major underlining factor when designing 
effective activating and coupling procedures. Care must be taken to ensure that on 
activating, deprotonation of the a-carbon does not occur (Fig. 1.13). This would 
result in the racemisation of the amino acid (6) via the oxazolone intermediate (7, 9). 
Once formed, the chiral integrity is lost and subsequent reaction of the amine yields 
peptides containing both the L (8) and D (11) epimers. Fortunately this side reaction 
is not encountered to any extent in the chain assembly using the aforementioned Boc 
or Fmoc strategies where activation of the carboxylic acid is performed on the 
14 
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urethane protected a-amino acid which, using standard conditions, does not form the 
oxazo lone. 
H 	R 
\N_/ II H 	- 




R' 	 —O H2N 
	
RCONHCNHI 






c; -H R' 	/ 	0 	 R'cONHC-NH' II 
0 
(10) 	 (9) 	
IIWWW~ 
Fig. 1.13 Amino acid racemisation during activation and coupling 
1.7.2 Methods for carboxyl activation 
Unsurprisingly, the range of suitable activating groups and procedures is extensive, 
however this section shall concentrate only on some of the more general methods 
applied to Fmoc SPPS. Fig. 1.14 highlights the more commonly applied coupling 
techniques. 
R Y Q 
115 
or C (14) 	
.0 HN (18) 




Pmt.N1-r' C— O—C N—<' 















Fig. 1.14 General procedures for peptide bondfortnation 
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Carbodiimides 
Carbodiimides are undoubtedly the most important reagents of their kind used for 
carboxylic activation prior to amide bond formation. Ever since Sheehan and Hess 
presented the utility of NN'-dicyclobenzylcarbodiimde (DCC) 32 (14), carbodiimide 
reagents have been applied extensively for carboxyl activation. Subsequently the 
preparation of NN'-diisopropylcarbodiimide (DIC) 33  (13) provided a preferred 
alternative to DCC for SPPS. This is simply because the NN'-diisopropyl urea by-
product (19) is fully soluble in the solvents used in SPPS, compared with the 
relatively insoluble N,N '-dicyclohexylurea. 
As outlined in Fig. 1. 14, these diicarbodiimides are employed for activation using one 
of two strategies. The initial activated carboxylic acid derivative (15) can either be 
reacted directly with an amine or with a variety of nucleophiles to produce more 
stable activated intermediates such as the corresponding symmetrical anhydride (17) 
or activated ester (16). 
Symmetrical Anhydrides 
Due to the general ease of preparation and rapid, unambiguous acylation properties, 
amino acid activation using the symmetrical anhydride (17) is a highly popular method 
for amide bond formation, used in both Boc and Fmoc SPPS. 
Unfortunately there are two major drawbacks associated with anhydride activation. 
Firstly, the preparation of symmetrical anhydrides is far from cost effective since two 
equivalents of amino acid are required to form one equivalent of activated species. 
Considering the expense of Fmoc protected amino acids, a minimum of 50% loss of 
reagent will be costly. The other serious problem encountered with both the 
carbodiimide (15) and symmetrical anhydride (17) derivatives is the undesired side-
reaction involving the side-chain of asparagine and glutamine. DIC is the sole reagent 
used for carboxyl activation yielding (15) and (17). Unfortunately DIC can also act as 
a dehydrating agent with the side-chain amides of Asn and Gin leading to the 
irreversible nitrile formation (Fig. 1.1 
5)•34 
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H 
NH, 	NH 
DIU 	 ____ OH +DIC O 	
_ 
0 	 o 	
NH—< Pmt.NH ç 	Prot.NHg'0 Pmt 	 Prot. 
Fig. 1.15 DIC induced dehydration of the asparagine side-chain 
Activated Esters 
The final amino acid derivatives to be discussed in this review are the activated esters 
(16). Considering the disadvantages of aminolysis via carbodiimides or symmetrical 
anhydrides, namely side-chain dehydration and 50% reagent inefficiency, a practical 
alternative would be extremely beneficial. 
Originally designed by Konig and Geiger to inhibit racemisation, 35 electronegative 1-
hydroxybenzotriazole (HOBt) (21) was soon employed as a highly effective coupling 
reagent. Such HOBt esters of protected amino acids are easily prepared in situ from 
one equivalent of Fmoc-amino acid, one equivalent DIC and one equivalent HOBt. 
Although less reactive than the corresponding symmetrical anhydride, these activated 
esters proceed unambiguously to form the peptide link on aniinolysis without side-
chain rearrangement. 
Using the highly successful HOBt as a structural template, a number of analogues 
have been developed as coupling reagents, these currently include 1 -hydroxy-7-azo- 
benzotriazole (HOAt) 36  (20) and ethyl 1 -hydroxy- 1 H- 1,2,3 -triazole-4-carboxylate 
(HOCt)20'37 '38 (22). 
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1.8 The Chemical Synthesis of Proteins 
Advances in synthetic and analytical methodology over the last 35 years has resulted 
in a highly optimised automated stepwise SPPS which is capable of the rapid and 
reproducible assembly of long protected peptide chains. In general, the coupling and 
deprotection efficiencies are >99% effective thus the total chemical synthesis of large 
polypeptides and small proteins is now considered a practical and accessible goal. 
In recent years, the growth in our awareness and understanding of protein structure 
and function has been extensive. To date, the majority of proteins studied have been 
isolated from their natural source or prepared by exploiting recent advances in 
molecular biology. However, considering the continuous improvements in SPPS, it is 
clear that chemically synthesised proteins have a substantial contribution to make. In 
summary, the advantages of preparing proteins using chemical methods are - 
the reproducible construction of the target protein. 
ease of primary structure variation. 
1.8.1 Preparation of the target molecule 
To help build up the complete characterisation of a protein ideally sufficient quantities 
for full conformation and functional assessment (eg. three-dimensional NMR studies, 
x-ray crystal structure, biological assays etc) should be available. In practice this is not 
always possible. For example, consider the isolation of a protein from its native 
source. This is often a highly laborious task resulting in only minute quantities of 
material. However, provided the genetic information for the protein is available, more 
acceptable quantities may be prepared using recombinant technology. The isolated or 
synthesised gene can be translated into protein in large quantities by inserting the gene 
into an appropriate expression system. Once expressed, the protein is then isolated 
from the fermentation medium and purified. Although this is a significant 
improvement on native protein isolation, there are still problems encountered. Firstly, 
there is minimal control over protein expression. Complications may arise during 
translation resulting in the incorrect amino acid being incorporated into the peptide 
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chain. Secondly, isolation from the cell debris, DNA and host proteins may prove 
difficult, especially on large scale purification. 
If however the protein is prepared from its constituent amino acids using chemical 
synthesis, the researcher has complete control over the construction of the target 
protein. Considering the ease and speed of synthesis, SPPS is often the most practical 
method for providing useful quantities of material. 
1.8.2 Specific site alteration 
To help provide further information on how individual residues contribute to the 
overall activity or conformation of a peptide or protein, alteration of the molecule at 
specific sites of interest is highly beneficial. 
The sophisticated DNA technology now available is capable of making point 
mutations, leading to the expression of a range of modified proteins (site directed 
mutagenesis). However, the chemical synthesis approach to primary structure 
variation is a more flexible and controlled method which guarantees the incorporation 
of non-genetically encoded structures at the required site. For example by means of 
SPPS, artificial amino acids with isosteric side-chains can be used to investigate the 
functional importance of particular residues. In addition, NUR probe nuclei can be 
incorporated at any predetermined single atom site aiding INllv[R structure elucidation. 
Finally, leading on from primary structure variation, more recently chemical synthesis 
has been employed for the preparation of completely unnatural molecules. The 
ultimate goal of this de novo design of protein synthesis is the construction of artificial 
proteins which, like the naturally occurring molecules, fold specifically, adopting 
predetermined conformations and exhibit tailor-made chemical and biological 
properties. This provides the peptide chemist with a greater understanding of the 
complex mechanisms associated with protein folding and scope for the development 
of a new generation of therapeutic products. (de novo reviews see refs39 ' 40) 
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1.9 Chemically Synthesised Proteins - A Brief History 
Although very much still in the exploratory stages of development of SPPS, the first 
protein to be prepared using chemical methods was reported almost 30 years ago. 
This demonstrated that a protein molecule with true enzyme activity could be 
prepared from its constituent amino acids. 
In the original publication, Gutte and Merrifield described the stepwise synthesis of 
ribonuclease A (RNAse). 4 ' This was selected as the target because the 124 amino acid 
sequence had been determined 42  and its crystal structure was 
.43 The initial 
report was soon substantiated with a full and more detailed account which presented 
clear analytical data for protein homogeneity, composition and sequence. 44 Not only 
did Gutte and Merrifield show that the synthetic RNAse A was indistinguishable from 
natural bovine pancreatic RNAse A, but also presented evidence that the synthetic 
counterpart had comparable specific activity (78%) and correct substrate specificity. 
The chemical synthesis and characterisation of RNAse A was a considerable research 
achievement and this was reflected by the lack of publications in the following years 
describing the SPPS of other proteins of similar size. This clearly underlined the 
viability and limitations of the SPPS methodology 30 years ago. However the aim of 
protein synthesis has become much more accessible with the continuous advances in 
SPPS. This has been accompanied by the development of powerful purification 
strategies and highly accurate instrumentation for product analysis. In recent years 
numerous reports describing the stepwise synthesis of proteins have been published. 
Some of the more notable examples include ubiquitin (76 residues) 45 '46 , HIV-1 
protease (99 residues) 
,47,41 and interleukin-3 (140 residues). 49 
1.10 Purification of Chemically Synthesised Proteins 
The objective of protein synthesis is undoubtedly the production of homogeneous 
molecular species. However, in addition to obtaining protein with the correct primary 
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structure, to be biologically active the molecule must have defined secondary and 
tertiary structure. In the normal biologically active form, the protein chain is folded 
into a thermodynamically preferred three-dimensional structure, the conformation of 
which is maintained by relatively weak interatomic forces such as hydrogen bonding 
and hydrophobic and charge interaction. 
Overall the target molecule can be separated from impurities by exploiting the 
differences in their physical and chemical properties, ie charge, molecular weight, 
hydrophobicity and biospecificity. Presently there is a vast range of techniques 
available which can be employed for chromatographic separation - 
• ion exchange or isoelectric focusing 
• gel filtration 
• hydrophobic interaction 
• HPLC 
• affinity chromatography (eg. Tbfmoc purification - section 3.5.4) 
Due to the diversity in their chemical and physical properties, no single purification 
strategy can be applied to all proteins. Instead the purification of each molecule is 
assessed individually with view to the development and optimisation of a suitable 
tailor-made protocol. Chapter 2 describes the isolation and purification of one such 
protein, the catalytic domain of stromelysin (SCD, 173 residues), prepared using 
stepwise solid phase methods. In addition to presenting the design of the purification 
strategy, the results of the protein conformational studies are discussed. 
The most serious downfall of stepwise SPPS is that purification is only possible at the 
end of the synthesis. Consider the preparation of a 100 residue protein; every cycle 
comprises three chemical reactions, coupling, capping and deprotection. Following 
300 chemical steps it is certain that the mixture will contain a number of side-products 
and impurities. Potentially the most problematic side-products are peptides or proteins 
containing deletion sequences. This occurs due to non-quantitative coupling, capping 
or N" deprotection giving rise to amino acid deficient sequences (Fig. 1.16) which can 
be too closely related to the target molecule in physical properties to allow separation. 
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ot.NH1cOOH + H2NCO ................... NH1 O—O 
Activate 
Couple 





resulting in free amine'\ ). 
group present. 	H2N 	CO ................... NH 
Cap free amine groups by reaction 
with acetic anhydride. 
H3C-CNHCO ................... NHCO—O 	 H2N 	W ................... NH1 - 
Amino functionality acylated 	 " Insufficient capping, amine capable of 
preventing further coupling, coupling with next amino acid. 
[Truncated peptide 
[i5ietion sequence 
Fig. 1.16 Possible route to the formation of deletion sequences 
1.11 Convergent Protein Synthesis - Fragment Coupling 
One solution to such problems encountered with the stepwise construction of proteins 
involves the individual preparation of small peptide segments of the protein which are 
then linked together to produce the target sequence. This convergent synthesis has the 
advantage that the smaller peptide fragments are more manageable. Before coupling, 
each fragment can be purified and analysed confirming its sequence. Therefore, on 
coupling, the correct sequence is constructed in the absence of single amino acid 
deficiencies. Fig. 1.17 outlines a number of strategies for fragment coupling that have 
been previously applied successfully in the preparation of both peptide and protein 
chains. 
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Fragment Condensation - (Chapter 3). 
Prot.NH-[itide_Frag.-C 	 I-I2N-{itide_Fragj-COO.PrOt. 
QA 
coupling conditions analogous to amino acid coupling (section 1.7) 
maximum side-chain protection necessary 
• peptide fragment 1 can be in solution or fixed to a solid support 
• due to low fragment solubility, couplings generally carried out in DMF or 
1 ,4-dioxan 
Azide coupling - (Chapter 3). 
Prot.NH-fPeptide Fr} 	 Frj-cOOH 
• coupling via amine attack of C-terminal azide 
• minimum side-chain protection; only Lys and Cys side-chains require blocking 
improved solubility compared with original fragment condensation, 
couplings performed in DMF, 1 ,4-dioxan etc 
Chemical Ligation - (Chapter 4). 
Prot.NH-{ieptide Fra-X 	+ 	Y-[iiide FOOH 
• coupling reaction between two mutually reactive functional groups X and Y 
• dependent on ligation design, side-chain protection may not be necessary 
• generally fragments are soluble in aqueous conditions, buffer systems 
employed for coupling 
Fig. 1.17 Summary of the principal methods used for convergent synthesis 
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The viability of such convergent methods has been clearly demonstrated with the 
successful syntheses of a number of proteins including prothymosin-a 5°  (109 residues, 
fragment condensation), ribonuclease A 51 '52  (124 residues, azide coupling), human 
interleukin-8 53  (72 residues, native chemical ligation) and analogues of I-IIV-1 
protease 54,15  (99 residues, chemical ligation). Examples in the literature describe 
methods using a variety of fragment lengths, using both protected and fully functional 
segments, with the couplings proceeding in solution or on a solid phase. Furthermore, 
a number of reports have illustrated that such methods are not restricted to amide 
bond formation but can be used to construct novel molecules with a wide range of 
possible backbone modifications. 
54.55,56 
 
In the proceeding chapters, different aspects concerning chemically synthesised 
proteins are discussed. Using the catalytic domain of stromelysin (SCD) as the model 
protein, chapters 2 and 3 deal with protein preparation and purification using stepwise 
and convergent SPPS respectively. In addition, chapter 2 describes the results of 
conformational and biological activity analysis of SCD compared with the 
recombinant counterpart. Finally, chapter 4 presents a new strategy, devised and 
developed at Edinburgh, for the chemical ligation of peptide and protein fragments, 
with the results of the preliminary studies. 
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Chapter Two 
The Chemical Synthesis of the Catalytic Domain of 
Stromelysin (SCD) 
2.1 Background 
Stromelysin (MIMP-3) is a member of the matrix metalloproteinase (MIIv1P) family 
whose collective physiological function is the controlled extracellular matrix 
degradation during tissue remodelling and wound healing.' However, an uncontrolled 
imbalance in metalloproteinase activity can lead to extensive tissue degradation 
resulting in the breakdown of cartilage and the eventual impairment of joint function 
associated with a number of inflammatory diseases. Although the precise role of each 
protein involved has not been determined, research has shown the concentration and 
proteolytic activity of stromelysin to be dramatically increased in joints afflicted by 
osteo and rheumatoid arthritis. 2 ' 3 
Inhibition of stromelysin and other members of the family has therefore become the 
focus of considerable therapeutic interest. 4  Clearly the aim is to obtain detailed 
information on the three-dimensional structure of the protease from which a good 
understanding of the catalytic mechanism involved can be obtained. In addition, this 
structural template will be invaluable for the design of specific MW inhibitors to 
combat a wide range of tissue degenerative diseases. 
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2.2 Isolation of the Active Enzyme 
Stromelysin is secreted from cells as a 57kDa monomeric proenzyme and consists of 
a signal peptide for secretion (Met'-Ma''), a propeptide for maintaining latency 
(Tyr ' 8-His99) 5 , a catalytic domain (Phe 99-Thr272) and a C-terminal fragment (Pro 273-
Cys477) believed to be involved in substrate and inhibitor binding 6 (Fig. 2.1). 
MKSLPILLLL' ° 














S LYGP P P DS P2 70 
DRHFWRKSLR320 
WAIRGNEVRA370 
FDEKRNSME P 420 
NAKKVTHTLK 47 C 
DGAARGEDTS 3° MNLVQKYLEN 4° YYDLKKDVKQ 5° 
LGLEVTGKLD8° S DTLEVMRKP 9° RCGVPDVGHF' °° 
YT PDLPKDAV' 3° DSAVEKALKV' 4° WEEVTPLT FS 15° 
FYPFDGPGNV' 8° LAHAYAPGPG 19° INGDAHFDDD20° 
GHSLGLFHSA23° NTEALMYPLY 24° HSLTDLTRFR2 ' ° 
ETPLVPTEPV26° PPEPGTPANC 29° DPALSFDAVS 30° 
KLEPELHLIS 33° SFWPSLPSGV 34° DAAYEVTSKD35° 
GYPRGIHTLG38° FPPTVRKIDA 39° AISDKEKNKT 40° 
GFPKQIAEDF43° PGINSKIDAV 44° FEEFGFFYFF45° 
SNSWLNC 
Fig. 2.1 Primary sequence of siromelysin (MMP-3) 
The protease is activated on removal of the 82 residue propeptide. On activation, the 
45kDa form of stromelysin further cleaves itself in an imprecise fashion yielding a set 
of heterogeneous forms of M11v1P-3 without loss of activity. 7 Closer analysis, using N-
terminal sequencing, highlighted that those lower molecular weight fragments had the 
same N-terminus (Phe' 00-Arg-Thr-Phe' 03 ...). From this observation it was postulated 
that a C-terminally truncated MMP-3 may be responsible and sufficient for the 
proteases activity. 8 
In order to solve the problem of heterogeneity and determine the contribution of the 
C-terminal domain to the enzymatic activity, a 29kDa truncated form comprising the 
propeptide (82 residues) and catalytic domain (173 residues) was expressed.' 
Following purification, it was found that on removal of the prosequence, the 
enzymatic activity of the 20kDa proteinase was comparable to that of the intact 
protein. 
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Finally, Ye et af described the expression and purification of the 20kDa catalytic 
domain in absence of both the prosequence and C-terminal domain. In the same 
report, it was shown that not only was the catalytic domain stable, maintaining the 
homogeneity, but it clearly retained full enzymatic activity with no preactivation 
necessary. With this substantial evidence indicating active site preservation,, the 
catalytic domain of stromelysin (SCD) was considered an appropriate model for the 
structure design of inhibitors of the full length enzyme. With a mass of 20kDa, SCD 
was now a challenging, but manageable size for three-dimensional structure 
determination. In addition, the use of molecular modelling could help visualise the 
active site, thus providing insight into the enzyme-inhibitor interactions. 
2.3 Structural Analysis of SCD 
The NMIR structure of SCD has been solved.' 0" In addition, a number of reports 
have described the three-dimensional X-ray crystal structure of SCD complexed with 
a number of inhibitors ' 2" 3" 4" 5  or the catalytic domain with the propeptide intact. 
16 
Fig. 2.2 shows a schematic representation of the inhibited protease, clearly displaying 
the secondary structure which comprises of a five stranded n-sheet (one antiparallel 
and four parallel strands) and three a-helices. Furthermore, the catalytic domain 
contains two tetrahedrally co-ordinated Zn 2  ions (green) and three octahedrally co-
ordinated Ca2  ions (red) that influence the enzymatic activity. 9" 3 " 7 
Situated at the top right-hand side of the ribbon drawing is the active site of SCD. 
Characterised by the groove with a catalytic zinc lying at the centre, structurally this 
region is of importance for inhibitor design. Illustrated in purple is an example of an 
inhibitor which is held in position by means of metal chelation. However, in order to 
enhance enzyme-inhibitor interactions, inhibitor design should also take advantage of 
the amino acid residues lining the groove. The ultimate aim is to obtain irreversible 
binding, which could be achieved by increasing the hydrogen bonding and 
hydrophobic interactions, in order to hold the molecule strongly in position. 
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Fig. 2.2 The catalytic domain of stromelysin (SCD): A schematic representation. 
2.4 Inhibition of SCD 
Based on the three-dimensional structural information centred on the catalytic site, 
various substrates have been developed. This has been accompanied by a number of 
reviews, highlighting the advances in Mtv[P inhibitor design.' 8,19,20  These studies have 
demonstrated that the most selective and effective substrates have been found to be 
small peptide derivatives. 
Presenting the detailed crystal structure of the active site complexed with a N-
carboxyalkyl peptide inhibitor 21 (23), Becker et at demonstrated why peptide 
derivatives displayed suitable properties as substrates. This was illustrated by 
comparing the structure of the active site complexed with the inhibitor to the active 
site of stromelysin in the latent, preactivated form. In the report, the three-dimensional 
structure of two forms of stromelysin were described 16:  the catalytic domain with the 
82 residue prosequence intact and the complex of SCD with (23) (Fig. 2.3). 
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Overall, the structure of SCD is not affected with the incorporation of the 
prosequence. The prodomain exists as a separate folding unit containing three CC-
helices with the peptide chain extending into the active site preventing the enzyme 
from functioning (Fig. 2.3B). 
Fig. 2.3 A: SCD coinpiexed with (23) (inhibitor shown in red). B: Stromelysin with 
prosequence intact. Zn 2 and C4 2 ions represented by the purple and blue spheres. 
Present in the prosequence is a cysteine residue (Cys 92) which functions as the fourth 
ligand of the catalytic zinc: the other three ligands comprising the side-chains of 
jjs218 His222 and His228 This cysteine is critical for maintaining latency, therefore 
protease activation can be achieved by disrupting the Cys-zinc bond. In vitro SCD 
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activation has been found to proceed on treatment with a number of reagents such as 
proteases, organomercurials, oxidants and detergents. One of the most common 
reagents employed is aminophenylmercuric acetate (AMPA). 5 '7 In a mechanism 
described as the 'cysteine switch', 22 mercurials activate the protease by complexing 
with the thiol releasing cysteine from the zinc, thereby exposing the active site. 
Comparison of the alignment of the prosequence in the active site with the SCD-
inhibitor complex highlights a number of structural and conformational similarities 
(Fig. 2.4). In both the proenzyrne and inhibited protein,, the groove is occupied by an 
extended peptide chain which interacts with the enzyme via several n-structure-like 
C 
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Fig. 2.4 A: Active site interactions with inhibitor. B: Active site of proenzyme. C 
and D: Specific residues involved in enzyme-inhibitor interactions. Dashed lines 
indicate hydrogen bonds between the substrate and enzyme. 
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fourth ligand for the catalytic zinc ion. Closer analysis of the hydrogen bonds formed 
(Fig. 2.4 C and D) reveals that both the propeptide and inhibitor interact with the 
same residues in the catalytic core with the exception of Pro 235 . 
With the interactions of the inhibitor backbone considered, finally the attention is 
centred on the involvement of the side-chain groups P' and P 2 (Fig. 2.4C). Crystal 
structure analysis suggests favourable hydrophobic interactions with a number of 
14 15 16 	1 	 2/4 	2/5 	235 	23' 	238 	 24(1 
	
residues 	: P is surrounded by Le u Val Leu , Tyr , Pro and Tyr 
2 	. 	 1'9 	180 	 1/ while P m is close contact with residues such as Asn . Val and Leu 
Furthermore, the hydrophobic pocket in which P' lies is extensive in volume, spanning 
into the hydrophobic core. 16  Considering the phenylalanine group (P') barely half fills 
this hydrophobic region, greater exploitation of this pocket may lead to the design of 
more potent and more specific inhibitors of SCD. 
The availability of SCD has made it possible to obtain three-dimensional structures of 
the enzyme through N1*vlIR and X-ray analysis. As a result of detailed active site 
analysis, inhibitors with excellent in vitro potencies have been reported. 
Unfortunately, the majority of inhibitors developed share a common drawback; they 
are derived from peptides and therefore have limited oral and bioavailability. 
However, building from the extensive knowledge already obtained centred on the 
enzyme-inhibitor interactions, it is anticipated the near future developments will 
produce a new generation of inhibitors with excellent therapeutic application. 
2.5 Research Overview 
The previous sections have highlighted why SCD is of such great therapeutic interest. 
Considering the active enzyme has been isolated as a 20kDa stable and homogeneous 
protein, SCD appeared a viable target for chemical synthesis with respect to both 
structural and functional interests. 
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There are a number of reasons why SCD is viewed as a suitable target for stepwise 
SPPS. With recombinant SCD available, comparison of the synthetic protein with the 
recombinant counterpart would be possible throughout purification. In addition, a 
number of simple in vitro experiments are available to assess enzymatic activity. 2324 
Such simple assays are invaluable for protein purity and structure evaluation. 
The initial aim of this study was to show that SCD could be prepared using SPPS. 
Subsequently, efforts concentrated on the development of a purification protocol for 
the isolation of homogeneous protein. Clearly the research objective was to show that 
the synthetic protein had comparable biophysical properties to its recombinant 
counterpart. Therefore studies comparing the structure and proteolytic activity of 
recombinant and synthetic SCD were performed. The eventual aim was to prepare 
analogues of SCD by chemical synthesis. Variation of single or multiple residues 
centred at the active site would be of significant interest, aiding inhibitor design and 
extending investigations into the mechanism of the enzyme action. 
2.6 The Chemical Synthesis of the Catalytic Domain of Stromelysin 
Illustrated by the successful preparation of human erthropoietin (166 residues). 25 
interferon-y (143 residues) 26 and leptin (146 residues) .2' research at Edinburgh has 
demonstrated how by using stepwise chemical methods, the synthesis of proteins 
>150 amino acid residues is attainable. In each of these syntheses, the coupling 
reagent employed was HOCt (section 1.7 (22)), designed and developed at 
Edinburgh. 28 Previous research has presented examples where HOCt has proven 
superior in coupling abilities to HOBt and as a result, the stepwise preparation of 
large polypeptides and proteins has become more feasible. 
The primary sequence of SCD (Fig. 2.5) was prepared from the constituent amino 
acids using the aforementioned stepwise SPPS. Beginning with Fmoc-Thr 
functionalised Wang resin (0.1 SmmoL'g), the synthesis involved the coupling of 173 
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Phe-Arg-'fhr-Phe-Pro-GIy-lle-Pro-Lys-Trp 10-Arg-Lys-Thr-Uis-Leu-Thr-Tyr-Arg- IIe-Va1 20-Asn-Tyr-Thr-Pro- 
Asp eu-Pro-Lys-Asp-AIa 30-Va-Asp-Ser-A1a-Va-Gtu-Lys-AIa.Leu-Lys 40-VaI-Trp-GIu-GIu-Va1-Thr-Pro-Leu- 
Thr-Phe50-Ser-Arg-Lcu-Tyr Glu-GIy-GIu-Ala-Asp-11e 60-Met-IIe-Ser-Phe-Ala-Va]-Arg-GIu-His-G1y 70-Asp-Phe 
Phe-Asp-Asp-Mp-GIu-Gln-Trp-Thr-Lys-Asp-Thr Thr-G1y 1 ' °-Thr-Asn-Lcu-Phe-Leu-VaI-A1a-A1a-His-GIu- 
He- ily-His-Ser-Leu-GIy-Leu-Phe-His-Ser 130-Ala-Asn-Thr-Glu-AIa-Leu-Met-Tyr-Pro-Leu' 40-TyT-His-Ser-LeU- 
Thr-Asp-Leu-Thr-Arg-Phe °-Arg-Leu-Ser-GIn-Asp-Asp-IIe-Asn-GIy 1Ie' °-GIn-Ser-Leu-Tyr-GIy-Pro-Pro-Pro- 
Asp-Ser' 70-Pro-(ilu-Thr 
Fig. 2.5 Primary sequence of SCD 
amino acids via their 1-lOCt activated esters and took approximately 18 days for 
completion. The progress of every coupling was monitored throughout using the 
Fmoc-UV method (section 1.4) enabling areas of unsatisfactory coupling to be 
identified. On completion of the synthesis, a reaction profile was prepared (Fig. 2.6). 
Overall the synthesis proceeded very well, with an estimated final percentage coupling 
of 71% (based on the initial functionality) and no significant drops in the coupling 
efficiency. The region between '-Ghi' °2 and -Lys40 where the percentage coupling 
rose to almost 200% has been previously observed in the synthesis of other peptide 
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Fig. 2.6 Synthesis of SCD: IVY' Deprotection profile 
On completion of the synthesis, the ratios of each amino acid on the resin bound 
sample were assessed. The results obtained from amino acid analysis overall were in 
good agreement with the expected composition (Table 2.1). 
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Ala 13.54 - 13 Lys 4.21 - 6 
Arg 
- 
5.3 7 Met 2.41 2 
Asx 18.86 21 - Phe 9.65 - 	 10 
GIx 13.26 13 Pro 12.94 
14 
Gly 13.88 13 Ser 6.14 
9 
His 8.22 8 	- Thr 8.73 
14 
lie - 	 7.48 8 Tyr 6.42 
8 
Leu - 14.18 16 Val 7.15 
- 	 8 
Table 2.1 Amino acid analysis of resin bound SCD 
Prior to purification, the protein was cleaved from the solid support and the side-chain 
protection removed by treating the resin with TFA in the presence of a number of 
scavengers (present to 'mop up Bu' and trityl carbocations). It is essential that the 
protein's exposure to the acid conditions is minimal, therefore the optimum cleavage 
time was established by periodically removing samples from the TFA mixture. HPLC 
details showed no further change in the profile after 3-4 hours suggesting complete 
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Fig. 2.7 Progress of SCD cleavage and deprotection 
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2.7 Purification and Characterisation of SCD 
2.7.1 Gel filtration chromatography 
Following chemical synthesis and TFA cleavage, the crude protein sample would 
undoubtedly contain a number of lower molecular weight impurities such as 
truncated peptide sequences, residual TFA and scavengers. The majority of these 
were removed using size exclusion chromatography where the rate of elution is 
dependent on molecular size. Crude SCD was loaded onto a Superdexrm 75 column, 
pre-equilibrated with 8M urea, 50mM Tris pH 7.5. All fractions absorbing at 280nm 
were assessed for protein content. HPLC analysis confirmed the initial fractions to 
elute contained protein of interest (shaded area Fig. 2.8 A). Compared with the crude 
SCD, the HPLC profile was now found to be considerably cleaner (Fig. 2.8 B and C). 
A. 




30 	time (mm) 	12 	 30 	time (mm) 	12 
Fig. 2.8 A: FPLC profile of material eluting from Superdex r1w 75. B: HPLC 
profile of crude SCD. C: HPLC profile of SCD after size exclusion. 
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2.7.2 Characterisation of SCD. 1. Molecular weight determination 
Following size exclusion, the molecular weight of the synthetic protein was assessed. 
Molecular weight standards (ovalbumin Mwt. 43,000, chymotrypsin Mwt. 25,000 and 
ribonuclease Mwt. 13,700) and recombinant SCD were loaded onto the SuperdexTM 
column and their individual elution volumes recorded. A graph was plotted displaying 
the logarithm of the molecular weight against the elution volume parameter (k u .) for 
the three standards, where: 
Ve = elution volume 
kay = Ve Vo / V-V0 	 V = total column bed volume 













Synth . 	 Choti-ypsin 
Recom. I 
Ovalbumin I 
4.15 	42 	4.25 	4.3 	4.35 	4.4 	4.45 	4.5 	4.55 	4.6 	4.65 
Log Mwt. 
From the straight line plot the estimated kay for SCD was between 0.09 and 0.1 
which was in good agreement with the experimental value of 0.095. In addition, the 
elution volumes of the recombinant and synthetic proteins were almost identical (V e 
9.7 and 9.8 respectively). Both pieces of evidence gave a clear indication that the 
synthetic protein was of expected molecular weight, therefore the protein was 
analysed further to confirm that SCD had been isolated. 
2.7.2.2 MALDI-TOF MS and N-terminal sequencing 
Both the pro and activated recombinant SCD have been characterised by MALDI-
TOF mass spectroscopy (Fig. 2.9). However, analysis of the synthetic counterpart 
proved difficult with no signal observed throughout purification. 
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'I 
1 
29im 	 3OJ 
Fig. 2.9 MALDI- TOF MS of the proenzyme (MwL 29,011.13) and activated SCD 
(Mwt. 19,632.31) 
An alternative method for protein characterisation by mass spectrometry is to digest 
the sample using a proteolytic enzyme followed by examination of the lower 
molecular weight fragments. With the ability to withstand denaturing conditions (4M 
urea), and specific cleavage site of Lys and Arg, trypsin was used for the selective 
breakdown of SCD. Considering the number of sites for digestion (highlighted in Fig. 
2.5), not all possible fragments were pinpointed, however fragments from throughout 
the protein's sequence were identified (Table 2.2). 
Fragment Molecular Observed Fragment Molecular Observed 
weight value  weight value __ 
Thr'3-Lys37 2,847.48 —2,820 Val 41-Arg67 3,158.59 3,155.02 
Ile' 9-Lys40 2,405.23 ---2,400 Glu 68-Lys' °6 4,256.86 4,254.08 
Ile"-Lys" 9,801.74 --9.800 Asp ' °7-Arg'5 ' 5,030.53 ---5.050 
Ala38-Arg52 1,775.97 1 1 870.54 1  eu 152-Thr173 1 	2,343.10 2,344.15 
Table 2.2 Tryptic digest of SCD: Analysis by MALD1-TOF mass spectrometry 
From the digest, no fragments corresponding to the initial residues at the N-terminus 
were identified. However, this was unsurprising considering there are three sites of 
cleavage within Phe'-Lys yielding a variety of low molecular weight fragments. N-
terminal sequencing however clearly illustrated that the first three residues of the 
synthetic protein were Phe-Arg-Thr with no apparent secondary sequences present. 
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2.7.2.3 Isoelectric point (p1) determination 
Finally, prior to further purification, the p1 value of the synthetic SCD was 
determined. The isoelectric point (p1) of a protein is defined as the pH where all the 
individual charges of the protein exactly cancel out and the overall net charge is zero. 
Considering that SCD contains a large number of acidic amino acids (eg. 14 Asp and 
10 Glu) compared with basic groups (eg. 6 Lys and 7 Arg), it is unsurprising that the 
estimated p1 value is between 4 and 529 
Using the technique of isoelectric focusing, the p1 of SCD was examined. The Biorad 
Rotofor® cell was used, which consists of a focusing chamber, where the protein 
sample and a selection of ampholites are exposed to an electric field. Ampholytes are 
aliphatic amino acids with a range of p1 values which, on introduction of the charge 
across the cell, arrange to establish a pH gradient. With a p11 gradient set up, the 
protein then moves within the charged solution until reaching a p1-I where the overall 
net charge is zero. The protein is then described as focused at its isoelectic point. 
Initially ampholytes with a broad pH (3-10) range were used. After focusing, the pH 
of each fraction was measured and analysed for protein content (l-IPLC). The majority 
of protein was isolated from fractions of p1-1 between 4 and 5 (Fig. 2.10 A). 
Subsequently, SCD was focused using a narrower ampholite range (p1-1 4-6). The pH 
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Fig. 2.10 Isoelectric focusing of SCD. Ampholyfe range - A: 3-10. B: 4-6. 
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accurate p1 value could be determined. Once focused. from the HPLC analysis the 
estimated p1 of SCD was 4.5, with the majority of protein accumulating in three 
fractions centred at pH 4.5 (Fig. 2.I013). Considering little material was found in the 
other fractions, isoelectric focusing also gave a valuable account of the overall purity 
of the protein after size exclusion. 
2.8 Folding and Further Purification of SCD 
After removal of the lower molecular weight species, efforts concentrated on the 
folding of SCD. It was proposed that in suitable conditions correctly sequenced SCD 
would fold into the defined conformation, meanwhile other incorrectly sequenced 
protein would remain unfolded. Subsequently, by means of ion exchange or 
hydrophobic interaction chromatography, isolation of the active protease would be 
feasible. 
Following size exclusion, SCD was in a solution of 8M urea, 50mM Tris pH 7.5. The 
urea was employed here as a denaturant ensuring protein solubilisation. As a result, at 
this point SCD existed as the long chain of amino acids randomly fluctuating in 
solution without defined conformation. 
The rate and extent of protein folding in solution is greatly dependent on the 
conditions used. Therefore, initially efforts centred on folding synthetic SCD using the 
conditions employed to refold the recombinant protein. For recombinant SCD, 
enzymatic activity was shown to be recovered when denatured protein was refolded in 
Tris buffer at pH 7.5, containing both calcium (10mM CaCl 2 ) and zinc (0.1mM ZnC12 ) 
ions. 9  Furthermore, folding is normally performed at low protein concentrations (0.1-
0.01mg/mi) in order to minimise potential side-reactions such as aggregation. 
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2.8.1 Folding of SCD in solution 
Attempts to fold SCD in solution were examined. SCD in 8M urea solution was 
added dropwise to a large volume of folding buffer. This satisfied the general 
requirements for folding: the concentration of urea was at a minimum, and SCD 
concentration was sufficiently low allowing each molecule to arrange the groups of 
amino acids with minimal interactions from surrounding molecules. 
The progress of folding was monitored using HPLC. It was predicted that on folding 
the original broad peak on I-[PLC would sharpen as the protein molecule arranged and 
folded into the defined conformation. Unfortunately this was not observed. Instead, 
the HPLC profile reduced in size over time, and, after two days the majority of 
protein had precipitated out of solution. Even at low protein concentrations, 
competitive intra- and intermolecular interactions and protein misfolding were 
apparent, clearly interfering with the folding process. 
Folding of SCD in solution was repeated examining the effect of protein 
concentration and temperature. In addition, an alternative approach, dialysis, where 
urea is gradually removed over time, was studied. Unfortunately, the recurring 
problem of aggregation and protein precipitation was encountered. Furthermore, litres 
of buffer were necessary for the folding of small quantities of protein. 
2.8.2 Matrix assisted folding of SCD 
A different approach for protein renaturation, where the potential for protein 
aggregation is minimised has been illustrated by Creighton. 3° This involves fixation of 
the protein, in its urea-denatured state, onto an ion exchange matrix with subsequent 
elution using a gradient of folding buffer. Supplemented with a number of examples. 
Creighton has demonstrated the utility of matrix assisted protein folding for the 
recovery of sufficient quantities of active protein. 
The recovery of non-covalently immobilised synthetic SCD from an anion exchange 
support (DEAE Sepharose) was examined. First, the protein in the urea solution was 
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mixed throughout a sample of DEAE matrix. By mixing the protein through a portion 
of matrix, concentration of protein molecules at the gel surface was avoided. 
preventing potential intermolecular interactions. 
Once loaded, the gel was equilibrated using 8M urea. removing unbound components 
such as DTT (used for reducing Met) or impurities still present. The gradual removal 
of the denaturant and introduction of folding buffer proceeded overnight. In this 
slowly changing environment, it was envisaged that protein precipitation would be 
less likely. In addition, it was anticipated that removal of the denaturant would lead to 
the protein molecule arranging into a thermodynamically stable folded conformation 
(Fig. 2.11. stage 2). Once the urea solution had been completely replaced. the protein 
was finally eluted on introduction of a salt gradient (NaC1) (Fig. 2.11. stage 4). 
W
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Fig. 2.11 Schematic representation of matrix assisted protein folding 
The recovery of protein from the column was encouraging. On loading 32.5mg of 
protein, an estimated 21.5mg eluted in the salt gradient. Furthermore, protein 
containing fractions of '-1mg/mi were obtained without precipitation. Subsequent 
HPLC analysis displayed a peak which appeared to have sharpened compared with 
SCD in 8M urea (Fig. 2.12) suggesting that the protein had folded to some extent. 
Further evidence that the protein displayed folding characteristics was presented on 





changes occurring. Clearly further structural assessment was necessary. 
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broaden over several days, indicating that over time there were conformational 
Fig. 2.12 HPLC profile of SCD before and after DEAE purification 
2.8.3 Characterisation of SCD after ion exchange 
Protein which eluted from the ion exchange column was assessed prior to structural 
analysis. N-Terminal sequencing confirmed that the initial residues were Phe-Arg-Thr 
with no apparent secondary sequences present. Amino acid analysis was in good 
agreement with the expected composition however, considering the size of the 
molecule and the length of acid hydrolysis, it was unsurprising that overall a more 





















Asx 21 22.01 20.73 
21.01 
GIx 13 14.07 
14.01 12.42 	- 
13 / 13.24 
13.59 
- 	Gly 
His 8 - 9.83 8.76 
8.82 
lie 8 7.85 
7.63 7.54 
Leu 16 16.61 
15.43 15.84 
Lys 6 5.76 
- 5.68 4.42 - 
Met 2 2.50 / 
1.43 
Phe 10 8.92 8.99 
8.97 
Pro 14 13.15 12.58 
10.13 
Ser 9 6.77 6.29 
5.89 
Tbr 14 10.82 9.98 	
- 10.04 
Tyr 8 / 6.69 
6.15 
Val 8 7.50 7.48 
6.99 
Table 2.3 Amino acid analysis of SCD following DEAE purification 
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Finally, samples of SCD were assessed using SDS gel electrophoresis (Fig 2.13). In 
general, the synthetic protein samples were inclined to streak down the gel, possibly 
due to incomplete removal of TFA. urea or NaCl. However, overall Fig. 2.13 gave an 
indication of how the purification was proceeding. 






1 	2 	3 	4 	5 
Fig. 2.13 SDS gel analysis of SCD. Lane 1 - molecular weight standards. 
2- Crude SCD. 3- SCD after size exclusion. 4- SCD after ion exchange. 
5- Recombinant SCD. 
2.9 Enzymatic Activity of SCD. Recombinant and synthetic compared 
2.9.1 Hydrolysis of Substance P 
To help determine whether SCD had been isolated and was of correctly folded 
conformation, the protein's biological activity was assessed. If the synthetic protease 
had folded correctly, it was anticipated that the resulting activity would be comparable 
to that of the recombinant counterpart. 
Substance P (24), a known substrate for the enzyme, 
21 is cleaved exclusively at Gin 6 -
Phe on incubation with SCD. Using HPLC analysis, both the recombinant and 
synthetic protein clearly displayed hydrolysing capabilities, with MALDI-TOF MS 
confirming the identity of the hydrolysed fragments (Fig. 2.14). Unfortunately it was 
also evident from 1-IPLC analysis over time that the recombinant protein was distinctly 
more active, however an accurate assessment of the situation was not possible from 
the non-continuous HPLC assay. 
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Fig. 2.14 Activity of SCD: Substance P hydrolysis (Arg' -Met" Mwt. 1,349.67, 
Arg' -Gin 6 Mwt. 613.80, Phe 7-Met" MwL 753.88) 
2.9.2 Hydrolysis of fluorogenic substrates 
SCD is known to cleave at specific sites in various peptide sequences. Building from 
this, a number of fluorogenic substrates have been designed .24 ' 31 '32  The advantages 
over the Substance P assay are two-fold. Firstly, with the incorporation of a highly 
fluorescent marker, very dilute protein samples can be assessed. In addition, the 
change in fluorescence can be monitored continuously from initial incubation, 
therefore the extent and rate of hydrolysis can be calculated. 
One of the most effective fluorogenic substrates for SCD is the novel coumarin-
labelled peptide (25).2431 In addition to the highly fluorescent 7-methoxycoumarifl 
(Mca) and specific site of hydrolysis, this substrate has a 2,4-dinitrophenyl group 
incorporated that acts as a fluorescent quencher. It is proposed that prior to 
hydrolysis, the fluorescent energy is greatly dampened due to internal resonance 
transfer along the peptide backbone to the 2,4 DNP moiety. 24 ' 32  However, the 
20 	time (mm) 	0 
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quenching effect may simply be due to the interaction of the two groups through 
space considering their close proximity. Regardless of the interaction, on hydrolysis 
the coumarin is released from the quenching effect and a rise in fluorescence is 
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hydrolysis. 
Following ion exchange purification, a number of samples of synthetic SCD were 
incubated with the Mca-peptide. Protease activity was confirmed with a clear rise in 
fluorescence, the extent of which was shown to be concentration dependent. 
Furthermore, on mixing SCD with 8M urea, no further change in fluorescence was 
observed. Clearly in suitable conditions, synthetic SCD displayed properties that were 
comparable with those of the active enzyme. 
Examination of the synthetic protease compared with recombinant SCD. however. 
demonstrated that problems associated with the folding of synthetic SCD were still 
apparent. Fig. 2.15 highlights the differences, with an estimated 150 fold increase in 
activity for recombinant SCD compared with the synthetic protein. Further 
assessment of the protease activity, examining the effect of the protein and substrate 
concentration underlined that the difference in activity was quite considerable. 
One possible explanation for this was that the matrix bound protein was prevented 
from folding correctly. This protein misfolding could be the result of ionic and 
hydrophobic interactions between the unfolded or partially folded protein and the ion 
exchange support. The problem of protein folding was therefore examined further by 
denaturing and refolding the recombinant and synthetic proteases in solution. It was 
proposed that, in the absence of matrix interactions, renaturation in solution would 
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Fig. 2.15 Proteolylic activity of synthetic and recombinant SCD compared 
Change in fluorescence on incubation with 0. 1,uM Mca-peptide at 37 °C. 
2.9.3 Chemical denaturation and refolding of SCD 
Recombinant and synthetic SCD were denatured by overnight incubation in a solution 
of 8M urea, 50mM Tris. Complete loss of enzymatic activity was confirmed by the 
Mca-peptide assay. Protein refolding was then performed in solution, adding the 
denatured SCD dropwise to folding buffer. Although slight precipitation on refolding 
of synthetic SCD was observed, after concentrating, the calculated loss was 
negligible. From the Mca-peptide assay, it was evident that proteolytic activity was 
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Fig. 2.16 Refolding of SCD. Proteolytic activity compared 
600 
49 
2. The Chemical Synthesis of SCD 
These results displayed that enzymatic activity was recoverable after chemical 
denaturation. However, with only an estimated one third of the original activity, the 
folding problem for synthetic SCD was not resolved by refolding in solution. Clearly a 
more detailed study of the overall conformation of synthetic SCD was necessary. 
2.10 Conformational Analysis of SCD 
2.10.1 Circular Dichroism (CD) studies on SCD 
CD is a convenient and widely used method for the quantitative assessment of the 
secondary structure content of a protein molecule. This technique involves exposing 
the protein sample to plane polarised light. As an asymmetric molecule, the left and 
right-handed circularly polarised light will be unequally absorbed, the extent of which 
depends on the optically active molecule being studied. The transmitted light which 
emerges from the sample will have rotated through an angle 0 relative to the 
polarisation of the incident light, providing information on the chirality of the 
molecule. 
The CD spectra for SCD was recorded between 260-1 9Onm. The CD signals in this 
region are dominated by contribution of the amide bonds and will therefore provide 
information on the secondary structural characteristics of the protein. Fig. 2.17 shows 
the CD spectra obtained for two samples of SCD obtained after DEAE purification, 
compared in each case with the recombinant protein. 
The far UV spectra for both the recombinant and synthetic samples appeared to be 
relatively similar. The secondary structure content in each case was determined using 
the CONTIN procedure, devised by Provencher and Glockner 33 (Table 2.4). 
a-helix p-sheet Remainder 
Recombinant ProSCD 21±0.53% 28±0.71% 51±1.0% 
Recombinant ActSCD 8±0.47% 37±0.63% 54±0.9% 
Synthetic SCD Fract. 1 6±0.92% 28±1.6% 65±2.3% 
Synthetic SCD Fract. 2 22±0.57% 30±0.97% 49±1.4% 
Table 2.4 Calculated secondary structure content from CD results. 
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Fig. 2.17 Circular Dichroism (CD) spectra of recombinant (green) and synthetic 
(purple) SCD. 
The results presented two main points of interest. Firstly, considering the X-ray 
crystal structure for recombinant SCD displayed three large a-helices (Fig 2.2), it was 
surprising that the estimated cc-helical content was, on average, less than 10%. This 
underestimated calculation was proposed to be due to the buffers used. Both Tris and 
cr ions are known to absorb light in the wavelength range in which the experiment 
was carried out. 34 The signal-to-noise ratio below 200nm was so strong that it was 
only possible to examine data from 260 to -210-200nm. Unfortunately the region 
below 200nm is of importance to allow full calculation of the a-helical content. 
However it was still concluded that CD could provide a good representation of the 
conformational changes. For example, considering the prodomain of SCD is 
predominately a-helical in structure (Fig. 2.3B), the calculated value was clearly an 
underestimate (Table 2.4). However, on comparison with active SCD, the calculated 
decrease in a-helical content on activation helped illustrate the structural changes. 
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The second point of interest was the difference in the secondary structure content for 
the two synthetic SCD samples. Both fractions, isolated and analysed following 
DEAE purification, displayed comparable enzymatic activity. On analysis of the CD 
spectra however, the cc-helical content was clearly different. Initially it was uncertain 
why two fractions of similar enzymatic activity displayed such structural diversity. 
However, proceeding conformational studies presented some interesting results 
providing further information on the overall structure of the synthetic SCD. 
2.10.2 Conformational changes on chemical denaturation. CD analysis 
CD is an extremely valuable tool for monitoring structural variations during 
progressive denaturation., thus changes in secondary structure became more apparent 
on further analysis by CD. On incubation of SCD with increasing concentrations of 
denaturant, the CD of each sample was recorded and compared (Fig. 2.18). 
0 - 
210 	 220 	 230 	 240 	 250 	 260 
Wavelength (nm) 
Fig. 2.18 The effect of Gdm.HCI (OM black, IM red, 2M blue, 4M green) on the 
CD signal of recombinant (top) and synthetic (bottom) SCD. 
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It was envisaged that on introduction of a denaturant. the overall secondary structure 
content would decrease. With synthetic SCD, addition of Gdm.HC1, even at low 
concentrations. reduced the magnitude of the CD signal indicating that protein 
denaturation was occuring (Note - On mixing with I M Gdm.HCL a white precipitate 
was formed. The resulting signal for synthetic SCD will therefore be misleading). 
The recombinant counterpart however displayed different structural characteristics. 
Surprisingly the initial CD signal, in the absence of Gdm.HC1, was clearly much 
smaller than that obtained for the synthetic protein under identical conditions. In 
addition. at low concentrations of denaturant (IM, 2M Gdm.HCI). the CD signal 
increased, indicating secondary structure enhancement. Finally, in the stronger 
denaturing conditions. the CD signal for recombinant was comparable to the synthetic 
protein and it was clear that, overall, the secondary structure of SCD had been 
disrupted. 
It was concluded that although the synthetic SCD had clearly arranged to display 
secondary structural characteristics, the molecule had not folded completely to form 
the hydrophobic core with a defined tertiary structure. Evidence for this was based on 
a number of observations made from the CD spectra. The profile for recombinant 
SCD suggested that initial introduction of the denaturant opened up the hydrophobic 
core, exposing the centre of the molecule therefore a clearer estimation of the a-
helical content could be made. This could explain why at 2M Gdm.HC1 the intensity 
of the CD signal was similar to the signal for the synthetic protein at OM Gdm.HC1. In 
the absence of these tertiary interactions and stabilising hydrophobic core however, 
the secondary structure of the synthetic SCD was clearly disrupted, even in low 
concentrations of Gdm.HC1. Furthermore, with CD analysis presenting two differing 
accounts of the a-helical content (Fig. 2.17), overall the three-dimensional structure 
of the synthetic molecule was concluded to be undefinable and unstable with obvious 
structural deviations. Further evidence that synthetic SCD had not completely folded 
was provided by the tryptophan emission spectra. 
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2.10.3 Conformational changes on chemical denaturation. Fluorescence analysis 
The fluorescence of proteins originates from the three aromatic amino acids which can 
be used as spectroscopic probes to investigate conformational changes. Fluorescence 
is usually dominated by the contribution of the tryptophan residues which display the 
strongest absorbing and emitting properties. With the crystal structure of SCD 
illustrating that all three tryptophan residues are buried in the hydrophobic core (Fig. 
2.19), it was predicted that on denaturing SCD, there would be an obvious change in 
the fluorescence spectra. On incubation with various concentrations of denaturant, the 
fluorescence spectra for recombinant and synthetic SCD were recorded and compared 
(Fig. 2.20). 
Fig. 2.19 Schematic representation of the carbon backbone of SCD (white) with 
the proenzyme intact (red). The three tryptophan side-chains (W2, 124,  W 86) are 
shown in yellow. 
The results of the fluorescence experiment provided additional evidence that there 
was a problem with the folding of synthetic SCD. The fluorescence spectra obtained 
for recombinant SCD in the absence of denaturant displayed how, in a hydrophobic 
environment, the tryptophan emissions occur at shorter wavelengths. On exposure to 
solvent, the intensity of fluorescence was increasingly quenched, accompanied with a 




























300 	310 	320 	330 	340 	350 	360 	370 	380 	390 400 
Wavelength (nm) 
2. The Chemical Synthesis of SCD 
Fig. 2.20 Tryptophan emission spectra for SCD incubated with GuHCL Top: 
Recombinant SCD - OM red (Amax 328nm), iMpurple (327.5nm), 2M black 
(340nm), 4M green (354nm). Bottom: Synthetic SCD - OM red (A,nat 343nm), IM 
black (346nm), 2Mgreen (353.5nm), 4Mpurple (355.5nm). 
The fluorescence spectra for synthetic SCD also showed an increase in the emission 
maximum (343-355nm), indicating that the environment of the tryptophan residues 
changed on denaturing. However, neither the wavelength nor intensity of the emission 
maxima of SCD without Gdm.HC1 were altered to the same extent as the recombinant 
protein, confirming that the hydrophobic core was not fully established. 
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2.11 Final Investigation into the Activity of Synthetic SCD 
Evidence from the CD and fluorescence spectra clearly highlighted that synthetic SCD 
had not folded completely. As a result. the origin of the proteolytic activity of the 
synthetic protein was uncertain and required further assessment. Two proposed 
explanations were examined - 
• a small proportion of synthetic SCD had folded completely, but was largely 
masked in spectroscopic examination by the partially folded material. 
• although folding was incomplete, the active site was sufficiently formed 
to display enzymatic characteristics. 
2.11.1 Chromatographic analysis of active SCD. Comparison of recombinant 
and synthetic protein 
If a small proportion of correctly folded SCD was wholly responsible for enzymatic 
activity, it was expected that further chromatographic separation could isolate the 
active protein from the mixture. 
Hydrophobic interaction chromatography (HIC) is based upon interactions between 
solvent accessible non-polar groups in the protein molecule and the hydrophobic 
ligands attached to the uncharged gel matrix. It was predicted that HIC would be 
sensitive enough to differentiate between the non-polar groups buried within the fully 
formed hydrophobic core of SCD and hydrophobic regions present on the protein 
surface due to incomplete folding. 
On loading recombinant SCD onto a Phenyl Sepharose column (Resource PheTM) in a 
buffer of high ionic strength (50mM Tris pH 7.5. 10mM CaCl2 , 0.1mM ZnCl2 , 0.5M 
(NH4)2 SO4), the protein was found to elute, with an almost quantitative recovery, 
over a small volume during progressive removal of (NH 4 )2 SO4. However, when 
synthetic SCD was loaded using identical conditions, no material absorbing at 280nm 
was observed to elute. It was evident that with synthetic SCD, the majority of 
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hydrophobic regions were still largely exposed to solvent, binding strongly to the 
hydrophobic support. 
Ion exchange chromatography was employed to provide further evidence that the 
synthetic protein had not folded. Once more, when loaded onto the ion exchange 
support (Mono QTM), recombinant SCD was found to elute almost quantitatively over 
a small volume. In addition, the recombinant protein was found to bind only very 
weakly to the matrix. On loading synthetic SCD using identical conditions, no protein 
was observed to elute in these low salt conditions. At higher salt concentrations, good 
protein recovery was obtained. Furthermore, fractions collected from this region all 
displayed enzymatic activity. 
Both methods of chromatography confirmed the theory that synthetic SCD was not 
completely folded, with hydrophobic and ionic regions still largely exposed. This 
would explain the significant increase in the matrix binding properties for both of the 
chromatographic techniques. In addition, as no synthetic protein was found to co-
elute with the recombinant SCD, there was no evidence that the proteolytic activity 
was a result of completely folded SCD. 
2.11.2 Enzymatic activity of chemically denatured recombinant SCD 
Following the extensive conformational analysis of synthetic SCD, the question of the 
origin of activity still remained unanswered. CD and fluorescence analysis of SCD 
during chemical denaturation demonstrated how, although the hydrophobic core was 
disrupted, recombinant SCD maintained the secondary structure at low concentrations 
of Gdm.HC1. It was therefore proposed that if these chemically denatured 
intermediates of recombinant SCD displayed activity, it could be concluded that the 
active site was still sufficiently formed in the partially unfolded molecule. 
Incubated with increasing quantities of urea, the activity of recombinant SCD was 
assessed using the Mca-peptide fluorescence assay (Fig. 2.21). From the fluorescence 
spectra it was clear that the enzymatic activity decreased with increasing 
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concentration of denaturant as expected. Furthermore, it was evident that the active 
site of SCD was particularly robust, with the recombinant protein still clearly 
displaying enzymatic activity at concentrations where the tertiary structure would 
undoubtedly be disrupted. This could be attributed to the presence of the catalytic 
zinc at the enzymatic site which may help to maintain the structure of the groove by 
metal chelation. This finding substantiated the proposal that, although incompletely 
folded, the active site of synthetic SCD had arranged sufficiently to display the 
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Fig. 2.21 Proteolytic activity of recombinant SCD in urea. Change in 
fluorescence on incubation with 11uMMca-peptide at 37°C. 
2.12 Folding of SCD. Conclusions and recommendations 
This study has illustrated how the present methodology for the solid phase synthesis 
of peptides can now be extended, allowing the stepwise preparation of large 
polypeptides and proteins. The catalytic domain of stromelysin (SCD) has been 
prepared using chemical methods and, following chromatographic purification, under 
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suitable conditions proteolytic activity was clearly observed. Comparison studies with 
the recombinant protein has, however, highlighted the fundamental problems 
associated with the folding of the synthetic protein. 
The question of how the amino acid sequence of a protein determines the three-
dimensional structure and folding pathway is still the centre of extensive research 
efforts. Although a detailed account of the protein folding pathway have not been 
deduced, it has been established that folding occurs through a number of intermediate, 
non-random conformations, defined as the pre-folded state. Although unstable 
compared with the completely folded protein, this pre-folded state is envisaged to 
contain elements of conformation similar to these in the native structure. 
It is clear from the enzymatic activity, CD and fluorescence spectra that the 
underlying problem with synthetic SCD is that the protein has not folded completely. 
It appears that the synthetic molecule has not fully established the hydrophobic core 
which is considered to be the most critical aspect for stability of the normal folded 
state. Considering the synthetic protein displays proteolytic activity and has 
comparable secondary structure to the recombinant counterpart, it could be concluded 
that synthetic SCD has arranged to form intermediates in the folding pathway. 
One explanation for this folding problem could be that from their denatured forms, the 
two proteins adopt specific conformations, via different folding pathways. For 
example, on incubating recombinant SCD in strong denaturing conditions, it is 
uncertain whether the protein is in a fully denatured state. Conformations may still be 
present which, on removal of denaturant, initiate the folding process, following a 
definite pathway. Without these previous folding properties, the folding process for 
synthetic SCD may be inherently more random. Although the synthetic molecule 
arranges to display secondary structural characteristics, in the absence of a non-
random folding pathway, the assembly of the final compact tertiary structure may 
prove unattainable. 
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Clearly a more detailed study of the folding pathway of SCD is necessary to help 
identify the underlining differences in the folding of the recombinant and synthetic 
proteins. With the proposal that the folding pathway for synthetic SCD may be highly 
random, it may prove beneficial to introduce agents into the folding mixture. In some 
cases, such additives promote the adoption of a proteins native structure by directing 
the initial conformations, and, on a whole, reduce incorrect folding which can result in 
aggregation and precipitation. For example, molecular chaperones such as GroEL 
have been invaluable in assisting the assembly of a number of proteins . 3537 Binding 
only to unfolded proteins, the conformation of GroEL-bound protein resembles that 
of the 'molten-globule state', an intermediate in the folding pathway where the 
hydrophobic groups are buried in the centre of the compact molecule. Considering the 
problem with synthetic SCD appears to be with the incomplete formation of the 
hydrophobic core, the introduction of such agents may prove invaluable, facilitating 
the correct folding of the synthetic protein. 
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Chapter Three 
The Convergent Synthesis of the Catalytic 
Domain of Stromelysin (SCD) 
3.1 Introduction 
It is evident from the previous chapter that the highly optimized SPPS can now be 
successfully applied to the assembly of proteins over 150 residues in length. However, 
in the case of the catalytic domain of stromelysin (SCD), the problem of protein 
folding still remains unresolved, with further investigation necessary to pinpoint the 
source of the protein's inability to fold completely. 
One possible explanation could be that the chemically synthesised SCD, although 
purified to yield enzymatically active protein, may still be heterogeneous in nature, 
containing single or combination amino acid deletions (section 1.10). It is clear from 
the Fmoc deprotection profile and characterisation of chemically synthesised SCD 
that, overall, the protein molecule was of expected composition. However, it is not 
possible to completely rule out the presence of even a small proportion of amino acid 
deficient sequences which could hinder the protein folding. Unfortunately, due to their 
almost identical chromatographic behavior, these closely related impurities, if present, 
could remain undetected, therefore complete separation of the correctly sequenced 
SCD may prove impossible. 
Considering the problems encountered with the conventional stepwise protein 
synthesis, the convergent approach (section 1.11) appears to be an attractive 
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alternative which avoids the problem of single amino acid deficiencies. The original 
and presently still the most flexible and extensively studied method for peptide 
coupling is the fragment condensation approach (Fig. 3.1). Here the target sequence is 
subdivided into a number of peptide segments which are individually synthesised using 
stepwise SPPS. The target peptide is then prepared by building up the peptide chain 
from smaller fragments using conditions analogous to single amino acid coupling. 
Side-chain protection - 




Carboxyl group blocked 1. 	I Activate carboxyl group 
	by protecting group or 
Couple 	 fixed to a solid support. 
Remove N protection 
Pmt.Prot. 	 Pmt. 	Prot. 	Prot. 	t. 
I 	I o 	
Pro 
I I I I 	0 
Prot.NH—Peptide_Fragmen]—C'+ HN—[ Peptide Fragmen]—{Peptide Fragment I 
OH 	- 	 0—Prot. 
I Repeat sequence of events until 
target sequence prepared. 
Fig. 3.1 The principle ofpeptide fragment condensation 
In theory this should improve the quality of the final product. Prior to peptide 
assembly, the purity of each fragment can be checked at this intermediate stage and 
purified if necessary. Furthermore, on building of the target sequence, incomplete 
coupling results in impurity peptides that should be sufficiently different from each 
other in physical properties, enabling chromatographic separation. 
In summary, the protecting groups, coupling reagents and general strategies for 
fragment condensation are the same as those used for stepwise peptide synthesis. The 
necessary orthogonal protecting group strategy can be provided by both Fmoc and 
Boc methodologies, thus the range of available reagents and linkers is extensive, 
resulting in a highly flexible and adaptable convergent approach. Furthermore, as 
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outlined in Fig. 3. 1, fragment condensation can proceed with either both fragments in 
solution or with the growing fragment chain still attached to the solid support. As 
with stepwise SPPS, the solid phase fragment condensation (SPFC) is highly 
beneficial for peptide assembly, permitting the use of an excess of the activated 
peptide which is easily removed by simple filtration. 
This review shall focus only on the SPFC of peptide segments using the Fmoc 
methodology which is of relevance to the research described in this chapter. For a 
much broader overview, describing a wide range of reagents, strategies and literature 
examples of peptides and proteins prepared using both solution and solid phase 
fragment condensation, reviews by Benz,' Lloyd-Williams,' and Sakakibara 3 are 
recommended. 
3.2 Solid Phase Fragment Condensation (SPFC) 
This section deals with a number of strategic considerations which are of importance 
in SPFC. These are - 
. the solid phase synthesis of fully protected peptides. 
. division of the target sequence preventing racemisation. 
preparation of suitable coupling conditions which avoid peptide insolubility. 
3.2.1 Preparation of protected peptide fragments 
To ensure unambiguous fragment coupling in the absence of any side-reactions, it is 
essential that the side-chain functionalities are blocked to avoid interference. 
Therefore, unlike stepwise SPPS, on detachment from the solid support the side-chain 
protection on the fragment must be inherently stable in the resin cleavage conditions. 
Section 1.6 describes the development of a number of linker-resins (Fig. 3.2) which 
allow extremely mild and selective acidolytic cleavage of the peptide-linker bond. 
Some of the most commonly used linkers which have been successfully employed in 
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the preparation of fully protected peptide derivatives include the SASRIN, 2-
chlorotritylchloride and Rink linkers (Fig. 1.11). All three are highly acid labile and 
are therefore compatible with the FmocfBu' strategy which avoids acid treatment 
throughout the peptide synthesis. Furthermore, during mild acid resin cleavage (e.g. 
1% TFA, 10% AcOH), all of the side-chain protecting groups (Bu', Trityl, Pmc etc.) 
are retained. 
Acid labile side-chain 
( 	
protection 
But Trt 	Pmc 
I 	 10  11 	
er FmocNH-A.An+i-A.An............A.Ar—-O-1LJ Resin 
Base labile J Highly acid labile 
Na protection 	 10% AcOH 	linker 
or 1% TFA 
But Trt 	Pmc 
I 	I I 
FmocN}I-A.A+i-A.A ............ A.Ar—C' 
OH 
Fig. 3.2 Synthesis offully protected peptides 
3.2.2 Choice of peptide fragment 
The most important consideration in SPFC is dissection of the target sequence into 
suitable fragments. In summary, the requirements are - 
synthesis and purification of the protected fragment must be feasible. 
fragment assembly onto the growing peptide chain should proceed 
rapidly and efficiently. 
. racemisation of the C-terminal of each peptide must be suppressed. 
This final point is of great importance and is normally the determining factor for 
fragment choice. In the absence of the N'-urethane protection, racemisation of the C-
terminal amino acid on activation (via an oxazolone intermediate, section 1.7.1) is 
possible. This can be circumvented if the fragment contains a C-terminal glycine or 
proline. Unfortunately, depending on the target sequence, this may not always be 
possible without preparing fragments containing a large number of residues. 
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There are numerous literature examples of successful fragment condensation 
strategies where C-terminal residues other than Gly or Pro are used."' The coupling 
efficiency and extent of racemisation has been shown to vary greatly depending on the 
C-terminal residue and the coupling reagents and conditions used 
.
4- ' Generally, low 
temperature activation of fragments containing small, non-functionalised C-terminal 
residues (e.g. Ala, Leu and Ser) are considered to be the best approach. Furthermore, 
it has been demonstrated that the addition of such coupling reagents as I-
hydroxybenzotriazole (HOBt), originally developed to suppress racemisation, 8 '9 or 
3,4dihydroxy-3-hydroxy-4-oXO-1,2,3-beflZotfla 2me (HOOBt), minimise the loss of 
chiral integrity during activation. 
1-7 
3.2.3 Insolubility of protected peptides 
The other major obstacle in SPFC is that the protected fragments are often only 
sparingly soluble in the organic solvents used for coupling. It is important when 
coupling onto the solid phase that the solvent swells the microporous support, 
exposing all of the reactive sites. However, depending on the protected fragment 
sequence, solubility in solvents such as DMF, DCM and NIvIP can be low, leading to 
unsatisfactory coupling. It is now generally accepted that the increase in fragment 
insolubility occurs not only as a consequence of the bulky hydrophobic protecting 
groups but also as a direct result of the transition from a conformationally unordered 
solvated species to an ordered inter- and intra-molecular hydrogen-bonded species 
with a 3-sheet like structure. To dissolve such peptides, the n-structure must be 
disturbed. Narita et al investigated the influence of various solvents on hydrogen-
bonding interaction.' 0" It was reported that low concentrations of fluorinated 
alcohols eg, hexafluoro-2-propanol (HFIP) and trifluoroethanol (TFE) have a strong 
potential for disrupting n-sheet aggregation, with 10-20% HFIP or TFE sufficient to 
enhance fragment solubility and improve the coupling efficiency. 4 ' 5 
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3.3 Literature Examples of Fragment Condensation 
Accompanied with the growing understanding of suitable strategies and coupling 
procedures, the number of reports describing the successful preparation of larger 
polypeptide and protein chains have now been published. Table 3.1 summarises a 
selection of these syntheses which have employed either solid or solution phase 
fragment condensation. 
A. Solid phase fragment coupling 
Target No. of No. of C-terminal Coupling 
Protein residues fragments residue conditions 
Androctonus DCCIHOBt 
austrlis hector 64 8 Gly, Pro DMF 
Toxin 1112  
-Cro. DCC/HOBt 
DNA binding 66 6 Gly, Ser DMF 
protein 13  
HIV4Bni tat14 72 5 Gly, Lys, Ser 
DICIHOBt 
DCM 
Prothymosin 109 9 Glu, Gly, Lys 
DCC/HOBt 
(ProTa)'5 DMSO 
B. Solution phase fragment coupling 
Target No. of No. of C-terminal Coupling 
Protein residues fragments residue conditions 
Porcine C5a WSCl/HOOBt 
anaphylatoxin 74 9 Ala, Glu, Gly DMForNIMP 
16 
Human Ala, Gin, Glu WSCl/HOOBt 
parathyroid 84 13 Gly, Leu, Pro DMF or NMP 
hormone 17 
WSCl/HOOBt 
 Human 121 13 
Ala, Gin, Gly TFE/DCM 
midkine'8 Lys, Pro (1:3) 
DCC/HOBt or 
Angigenin' 9 123 15 
Ala, Mn, Glu 1-10013t 
Gly, Leu, Pro DMF or NMP 
Table 3.1 Outline of strategies used for protein fragment condensation 
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3.4 Research Overview 
The catalytic domain of stromelysin (SCD) was considered a suitable target protein to 
investigate whether the present methodology for fragment condensation could be 
extended to prepare proteins over 150 amino acids in length. Having previously 
demonstrated that the 173 residue protein could be prepared using stepwise chemical 
synthesis, a direct comparison between the stepwise and convergent syntheses would 
be of great interest. In addition, considering the present folding problem with 
synthetic SCD, it would be invaluable to compare the purification and resulting 
biological activities of the two proteins. It is anticipated that in the absence of any 
single amino acid deficiencies, purification after convergent synthesis would lead to a 
homogeneous protein. If however the extent of proteolytic activity was still low it 
could be concluded that the folding of synthetic SCD was a mechanistic problem and 
not one of protein purity. 
3.4.1 Coupling strategy 
It was uncertain whether the preparation of SCD from small fragments starting at the 
C-terminus would be feasible, however, the synthesis of a 173 residue protein from 
peptides averaging 10 residues in length would require an extensive research effort 
which was considered unattainable without any preliminary investigation. Obviously 
proteins up to —100 residues can be prepared using SPFC, therefore by starting with a 
significantly large peptide chain attached to the solid support, the optimum fragment 
length and coupling conditions at this more advanced stage could be investigated. 
Stepwise synthesis of Pro"-Thr' 73 As a starting point, the first 84 residues of SCD 
beginning from the C-terminus (Thr' 73 to Pro90) were prepared using stepwise SPPS. 
This would act as a foundation onto which the remaining 89 residues could be 
assembled from a variety of protected fragments. Using the coupling reagent HOCt 
(section 1.7), the stepwise synthesis of peptides -80 residues in length is generally 
straightforward. At Edinburgh this has been illustrated with the synthesis of a variety 
of small proteins including ubiquitin 2°  (76 residues) and a number of chemokines 2 ' 
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(74-76 residues), all of which have been successfully purified to homogeneity and 
folded correctly. 
Dissection of the target sequence Fig. 3.3 shows the primary sequence of SCD 
from which a number of potential sites for condensation which completely avoided 
racemisation were identified. However at the onset of the project, it would be 
impossible to predict the outcome of any fragment synthesis or coupling, therefore 
these sites could only act as guidelines. 






Fig. 3.3 Primary sequence of SCD. The first 84 residues prepared using stepwise 
SPPS are underlined with the potential sites for fragment condensation in bokL 
3.5 Solid Phase Fragment Condensation. Preliminary Investigation. 
Before commencing the convergent synthesis of SCD, a number of factors affecting 
fragment condensation were investigated with the view of developing effective 
coupling conditions. This section deals with the results of these preliminary studies 
3.5.1 Preparation and characterisation of H 2N-Pro
90  -Thr173  -OH (26) 
The 84 residue peptide was prepared from the constituent amino acids using stepwise 
SPPS. Beginning with Fmoc-Thr functionalised Wang resin (0.2mmollg), the peptide 
chain was built up, coupling each amino acid via the HOCt activated ester. Prior to 
the coupling study, the polypeptide was assessed to ensure the synthesis has been 
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Therefore, on completion of the solid phase assembly, the peptide was deprotected 
and cleaved from the solid support by stirring the resin in TFA in the presence of a 
number of scavengers. Following overnight incubation with N-methyl-
mercaptoacetamide (MMA) to reduce any oxidised methionine, Pro 90-Thr
173  was 
isolated from the crude mixture using preparative HPLC. 
Purified Pro 90-Thr' 73  was readily characterised by MALDI-TOF MS and the 
calculated amino acid ratios were found to be in good agreement with the expected 
composition (Fig. 3.4). Furthermore, N-terminal sequencing clearly illustrated that the 
first five residues of the synthetic peptide were Pro-N/D-Ile-Asn-Gly with no apparent 







Ala 5.54 5 
Arg 2.01 2 
Asx 11.88 13 
Gly 6.45 7 
GIx 6.99 7 
His 5.36 5 
Ile 3.86 4 
Leu 9.89 10 
Lys 1.12 1 
Met 0.89 1 
Phe 4.15 4 
Pro 6.20 6 
Ser 4.41 6 
Thr 6.31 8 
Tyr 2.89 3 
Val 1.12 1 
Fig. 3.4 Amino acid analysis and MALDI-TOF MS of H2N-Pro90-Thr' 73-OH (26) 
(MwL 9,454.71) 
3.5.2 Synthesis and characterisation of fully protected FmocGIy 79-G1y89-OH (27) 
Following the successful preparation and analysis of Pro 90-Thr' 73 , a small peptide 
corresponding to residues-79-89 of SCD was prepared. This sequence contained a 
number of side-chain functionalities which required protection during fragment 
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condensation to ensure unambiguous amide bond formation, therefore the peptide was 
assembled on the extremely acid labile 2-chiorotrityichioride resin (Fig. 3.5), coupling 
each amino acid via the HOCt activated ester. Detachment of the fully protected 
peptide from the resin was then performed using AcOH/TFEIDCM (1:1:8). 
Trt 	 Trt 	But 
I I I 
AcOHTFFEIDCM 
(1:1:8), RI, 30 mm. 
Trt 	 Trt 	But 
I I I (27) 
Resin 
Fig. 3.5 Preparation of side-chain protected FmocGly79-G1y89-OH 
(2 7)  
Analysis of the crude peptide by HPLC displayed a single peak which absorbed at 214 
and 300nm (Fmoc absorbs at 300nm). Eluting at -80% acetonitrile, the peptide was 
clearly hydrophobic indicating that the side-chain protection was intact. Further 
evidence of this was provided by comparing the HPLC profile of the fully protected 
peptide with the same peptide treated with TFA (Fig. 3.6A). Finally, fully protected 
FmocGly79-G1y89-OH was characterised by FAB MS (Fig. 3.6B). 
AN 
/ 	 deprotected 
side-c 	1 
protected - - 
	
[GIy79-Gi8J 	- 









Fig. 3.6 A. HPLC profile offully protected and side-chain deprotected FnwcGly 79- 
G1y 89-OH (27). B. FAB MS of the protected peptide (MwL 1,589.78). 
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3.5.3 Coupling of FmocGly 79-G1y89-OH to H 2N-Pro"-Th r' 73-resin 
After characterising both the 84 and 11 residue peptides, their ability to couple 
together was investigated. In general, optimum fragment coupling conditions involve 
an excess of the incoming fragment, dissolved in a minimal quantity of solvent. 
Therefore, five equivalents of FmocGly' 9-G1y89-01-1 were dissolved in DMF at a 
concentration of 1 50mg/mI. Converted to the corresponding HOCt activated ester, 
the peptide fragment was then mixed with the resin bound Pro"-Thr' 73 . Throughout 
coupling, the mixture was sonicated under nitrogen ensuring that there was sufficient 
solvent to completely swell the resin. 
To assess the reaction progress during coupling, samples of resin were removed. 
After sonication in 20% piperidine, an estimation of the Fmoc content of the resin-
bound peptide was made by measuring the absorbance of the Fmoc-piperidine adduct 
at 302nm (section 1.4.2). Fig. 3.7 summarises the calculated change in the coupling 
efficiency over time. 
FmocNH-G1y79 ............... G1y89-OH 	± H2N-Pro9O ............... Thr173.__I 
(27) 	HOCtJDIC I (26) 	solid 
in DMF support 
Fig. 3.7 Fragment coupling of FmocGly 79-G1y89-OH to H2N-Pr0 90-Thr' 73-resin 
Clearly the incorporation of FmocGly 79-G1y89-OH onto the solid support had been 
successful therefore further attempts to increase the coupling efficiency were 
investigated. These included changing the solvent from DMF to DCM, adding TFE to 
the reaction mixture and using HOBt as an alternative coupling reagent to HOCt. 
Unfortunately, the overall coupling efficiency could not be improved. 
Coupling conditions Coupling efficiency 
1 hour sonication 41% 
3 hours sonication 57% 
overnight stirrin g 70% 
fresh G1y79-Gly8 
3 hours sonication 
79% 
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3.5.4 Tbfmoc purification and characterisation of H 2N-Gly 79-Thr' 73-OH (28) 
To confirm that the fragment condensation had been successful, efforts concentrated 
on the isolation and characterisation of the coupling product H 2N-G1y79-Thr 173-011. 
Affinity purification employing the N  protecting group tetrabenzo[a,c,g,i]fluorenyl-
1 7-methoxycarbonyl (Tbfrnoc) was used in order to separate the product from 
uncoupled H2N-Pro90-Thr173  -OH. 
Designed and developed at Edinburgh, 22 ' 23 Tbfmoc is incorporated onto the N-
terminus of the completed peptide or protein chain and possesses a number of 
properties which makes this base labile group a valuable tool for peptide and protein 
purification 24,21  (Fig. 3.8). 
Properties - large, essentially planar group is 
strongly adsorbed onto the surface 
0 	 of porous graphatised carbon (PGC). 
- valuable probe for affinity 
0 	 chromatography. 
"- peptide chain 
- hydrophobic group which 
specifically absorbs at 364nm. 
- aids HPLC purification. 
Fig. 3.8 Structure and characteristic properties of Tbfmoc 
Tbfmoc purification has a great potential for fragment condensation having the ability 
to isolate the product from uncoupled peptide which remains in the crude mixture. 
Fig. 3.9 presents a schematic representation for the Tbfmoc purification of H 2N-Gly79-
Thr173-OH, outlining the main steps involved. 
On completion of the coupling, the resin was first sonicated in the presence of acetic 
anhydride, capping any uncoupled H 2H-Pro 90-Thr' 73-OH still present in the mixture. 
The N'-Fmoc protection was then removed and replaced with the Tbfmoc which was 
selectively incorporated onto the free N-terminus of the coupling product only. After 
deprotection and detachment from the solid support using the standard cleavage 
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conditions, the coupling mixture, dissolved in 6M Gdm.}ICIIi-propanol (1:1), was 
mixed with PGC onto which the Tbfmoc-peptide was adsorbed. All uncoupled Pro 90-
Thr' 73  and other impurities remained in solution and were therefore easily removed by 
simply washing the solid support before H 2N-G1y79-Thr' 73-OH was finally released by 
sonicating the carbon with 10-20% piperidine. 
FmocNH-G1y79  ............... Thr 173 -resin+ H2N-Pro° .............. Thr'73-resin 
I 1. Ac2OIDIEA/HOBt 
in DMF/1,4-dixoan. 
FmocNH-G1y79  ............... Thri-resin+ CH3 CONH-Pro9° .......... Thr '73-resin 
I 1. 20% piperidine/DMIF/1,4-dioxan. 
2. Thfmoc-CIJDIEA in 1,4-dioxan. 
0 	NH-G1y79...............Thr' 73 -resin + CH3CONH-Pro° .......... Thr' 73 -resin 
Deprotection and cleavage 
from the solid support. 
TFA, mixture of scavengers. 
Thr173-OH + CH3 CONH-Pro° ............ Thr17 3 -OH 
Dissolve in 6M Gdm.HCl/i-propanol 
and mix with PGC. 
Thr173-OH + CH 3CONH-Pro9° ............ Thr'73-OH 
Do 
Lfter washing, 	Impurities and capped peptide 
GC treated with still in solution, easily removed 
0% piperidine. 	on washing. 
Axed to solid 	 * 
support 
[iN-Gly79 ............... Thr'73-OH 	Coupling product 
(28) 
Fig. 3.9 Tbfmoc purification of 112N-G1y 79-Th? 73-OH (28) 
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Following affinity chromatography and HPLC purification, H 2N-Gly' 9-Thr' 73-OH was 
characterised by MALDI-TOF MS and the amino acid ratios determined (Fig. 3.10). 
On comparison of the amino acid analysis before, and after coupling (original amino 
acid ratios that altered on coupling are given in parenthesis, Fig. 3.10) it was evident 
that the product isolated after purification was of the expected composition for the 







Ala 7.89 8 (5) 
Arg 2.04 2 
Asx 12.17 14(13) 
Gly 9.14 9 (7) 
GLx 7.60 7 
His 6.19 6 (5) 
Ile 4.07 4 
Leu 11.14 11(10) 
Lys / 1 
Met 0.86 1 
Phe 4.31 4 
Pro 7.23 7 (6) 
Ser 5.83 6 
Thr 7.32 8 
Tyr 3.05 4 (3) 
Val 2.14 2 (1) 
Fig. 3.10 Amino acid analysis and MALDI-TOF MS (TFA salt) of H2N-G1y 79- 
Thr' 73-OH (28) (MwL 10,500.44) 
3.5.5 Coupling of FmocGly 70-G1y89-0H (29) and FmocPhe 50-G1y89-OH (30) 
The previous sections have illustrated how it was possible to couple a fully protected 
peptide, 11 residues in length, to a 84 residue polypeptide fixed to a solid support. 
Efforts then concentrated on investigating whether, using the same coupling 
conditions, it would be possible to couple larger protected fragments. 
Two peptides corresponding to the next 20 (Gly 70-G1y89) and 40 (Phe 50-G1y89) 
residues in the SCD primary sequence were synthesised. Beginning with Fmoc-Gly 
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functionalised 2-chiorotrityichioride resin, both peptide chains were prepared from the 
corresponding HOCt activated amino acids. On completion of the syntheses, the two 
fully protected peptides, FmocGly 70-G1y89-OH (29) and FmocPhe' O-G1y89-OH (30), 
were detached from the solid support by stirring the resin in AcOHITFE/DCM (1:1:8) 
for 30 minutes. 
Following characterisation, the coupling abilities of the two peptides were 
investigated. Using 
 89g the same conditions as for FmocGly -Gly -OH, the fragments 
were individually sonicated with the peptide-resin. After coupling overnight, the resin 
was filtered and washed before freshly activated protected peptide was introduced and 
the coupling continued. The final percentage coupling for each reaction was then 
determined, examining the Fmoc content of the resin-bound peptide and measuring 
the ratios of the N-terminal amino acids. Table 3.2 sunimarises the estimated coupling 
efficiencies for the 20 and 40 residue peptides, comparing their results with the 
calculated fragment condensation efficiency of FmocGly 79-G1y89-OH. 
Coupling efficiency 
Fmoc N-terminal Fragment 
_____________ deprotection sequencing 
G1y 79-G1y89 (11 residues) 79% 86% 
(27) Mwt. 1,589.78  
G1y 70-G1y89 (20 residues) 14% 17% 
Mwt. 2,996.49  
Phe50-G1y89 (40 residues) / 
Mwt. 6,632.11  
Table 3.2 Effect offragment length on the coupling efficiency 
From these results it was concluded that protected fragments much greater than 10 
residues in length would not couple effectively. By doubling the size of the protected 
fragment, the coupling efficiency dropped considerably to an estimated 15-20%. As 
for the coupling of the 40 residue fragment, there was no detectable coupling 
observed. Both couplings were repeated varying the reaction conditions, however, 
there was no improvement on these initial results. 
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Considering the bulk associated with these protected peptides, it was not highly 
surprising that, as the fragment length and molecular weight increased, the coupling 
efficiency dropped to zero. Furthermore, as the size of any protected fragment 
increases, accompanied with a greater number of protecting groups, the generally low 
solubility is reduced further which would clearly affect the coupling efficiency. This 
was observed with FmocG1y 0-Gly89-OH which, on introduction of DMF, initially 
formed a 'gel-like' solution and required a large volume of solvent to completely 
dissolve the peptide. 
Overall literature examples where fragments of more than 15 amino acids in length are 
effectively coupled onto the solid support are extremely rare, with severe problems 
encountered with larger fragment purification and coupling. 
This is also the case with solution phase fragment condensation of larger 
polypeptides. Generally the target sequence is assembled by initially coupling 
protected peptides less than 10 residues in length together yielding blocks of peptide 
containing 20-30 amino acids. The target sequence is then finally prepared by 
coupling these larger 'blocks' in solution. It is proposed that in the absence of the 
bulky solid phase, the two large protected fragments are less hindered and more 
flexible, improving the overall coupling ability. However, examples in the literature 
reporting the solution phase preparation of polypeptides generally do not record the 
final coupling efficiency, therefore it is uncertain how successful this method of 
coupling is. 
3.6 The Convergent Synthesis of SCD 
After establishing suitable coupling conditions and investigating the effect of fragment 
length on the overall coupling efficiency, the preparation of SCD via convergent 
synthesis was studied. 
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3.6.1 Preparation of H 2N-Asp 71-Thr' 73-resin 
The first two fragments to be synthesised corresponded to the next 10 (Asn 80-G1y89) 
and following 9 (Asp"-Gly 79) residues of SCD respectively, both of which contained 
a C-terminal Gly, thus the problem with racemisation was avoided. On detachment 
from the 2-chlorotritylchloride resin, both peptides were individually characterised 
before they were successively coupled onto the polypeptide-resin, incorporating a 
capping cycle and Fmoc N  deprotection between the two condensation reactions. 
Fig. 3.11 outlines the strategy and presents the resulting coupling efficiencies. 
FmocNH-Asn8O ........... G1y89-OH (3 1) 
	
+ 	H2N-Pro9O .......... Thr 173 
FmocNH-Asp71 ........... G1y79-OH (32) 	 (26) 
HOCUDIC 
inDMF 
H2N-Asp7I ...........G1y79-Asn8O ..........G1y89-Pro9O ..........Thr 173_i 
I n 	 I 	 I 
Frag. 3 	Frag. 2 	Frag. I 
Coupling efficiency 
Fragment 
Fmoc deprotection N-terminal sequencing 
Asn 80-G1y89 (31) 73% 91% 
Asp 71 -G1y 79 (32) 77% 70% 
Fig. 3.11 Fragment condensation of Asn80 -
GI  y89 (31) and Asp 71-G1y 80 (32) 
Both peptide fragments were successfully incorporated onto the polypeptide chain. 
Unfortunately an accurate measure of the percentage coupling for either fragment was 
not provided by the two methods used. Although measuring the Fmoc content of the 
resin bound sample provided an almost instant estimation of any coupling reaction, 
the overall accuracy of this method when dealing with such large polypeptides was 
uncertain. N-terminal sequencing analysis however generally provided a more 
accurate account of the coupling, measuring the concentrations of the two N-terminal 
amino acids (coupled: uncoupled). Overall these results were found to be more 
consistent and reliable (Table 3.3 A and B). 
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Coupling of FmocAsn80-G1y89-OH (31) to H 2N-Pro90-Thr' 73-resin 
Residue Cycle 1 Cycle 2 Cycle 3 
Major Asn8° 610.5 lpmol Va18' 887.88pmoI Leu82 570.72pmol 
Minor Pro9° 66.56pmol G1y9 ' 95.82pmol lie92 39.34pmol 
% coupling 90% 90% 94% 
Coupling of FmocAsp 71 -G1y 79-OH (32) to H 2N-Asn80-Thr173-resin 
Residue Cycle 1 Cycle 2 Cycle 3 
Major Asp  Phe 72 119.86pmol Tyr 
73 75.18pmol 
Minor Asn8° 51 .44pmol Va!8 ' 41.4 lpmol Leu82 37.1 4pmol 
% coupling 75% 74% 67% 
Table 3.3 Results from N-terminal sequencingfoiowingfragment condensation 
3.6.2 Preparation of H 2N-G1u 57-Thr' 73-OH 
In order to avoid any problems with racemisation, the next fragment to be coupled 
was a peptide 14 residues in length, corresponding to residues 57 to 70 in the primary 
sequence Of SCD (Fig. 3.12). Considering the difficulties associated with coupling a 
20 and 40 residue peptide, it was uncertain whether a fragment of this size would 
couple effectively, however it was concluded that proceeding in one fragment would 
be preferable to dividing the fragment further. 
But 	But 	 But 	 Pmc But Trt 
I I I I 	II 
Fig. 3.12 The primary sequence of FmocGlu 57 	- -OH 
3.6.2.1 Stepwise synthesis of G1u 57-G1y 7° 
As with the other syntheses of protected peptides, Glu 57-Gly7° was prepared on Fmoc-
Gly 2-chlorotritylchloride resin. Unfortunately, from the Fmoc Na  deprotection 
profile, it was clear that the stepwise synthesis was unsatisfactory, highlighting a 
number of considerable drops in the amino acid coupling efficiency (Fig 3.13). 
Attempts to separate FmocGlu' 7-Gly70-OH from the deletion sequences by HPLC 
proved problematic, hindered by the insolubility of the sample. As a result, it was not 
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possible to isolate sufficient quantities of the peptide to proceed with the fragment 






Gly 	His 	Glu 	Arg 	Val 	Na 	Phe 	Ser 	lie 	Met 	lie 	Asp 	Na 
Amino acid residue 
Fig 3.13 Stepwise synthesis of G!u57-G1y 70. Fmoc ]Va deprotection profile 
3.6.2.2 Dissection of C 1u 57-G 1y 70 
Considering the problems encountered with the synthesis of Glu 7-Gly °, efforts 
concentrated on the preparation of smaller fragments within this sequence assessing 
their coupling abilities. Two smaller peptides Va1 66-G1y 70 and Phe64-Gly ° were 
synthesised and, following complete characterisation, both peptides were individually 
activated and sonicated with H 2N-Asp'-Thr' 73-resin using identical conditions. On 
completion, their coupling efficiencies were compared (Table 3.4). 
Coupling of FmocVal 66-G1y 70-OH (33) to 11 2N-Asp 71-Thr' 73-resin 
Residue Cycle I Cycle 2 Cycle 3 
Major Val 	638.7lpmol Arg 	122.78pmol Glu
68  171. 51pmol 
Minor Asp' 17.S3pmol Phe 
2  20.33pmol Tyr 	9.74pmol 
% coupling 97% 86% 95% 
Coupling of FmocPhe 64-Gly 70-OH (34) to H 2N-Asp 71-Thr' 73-resin 
Residue Cycle 1 Cycle 2 Cycle 3 
Major 64 Phe 	38.32pmol 
65 Ala 	25.6Spmol 66 Val 	15.58pmol 
Minor Asp' 17.5 6pmol Phe 
2  15.96pmol Tyr73 7.7lpmol 
% coupling 69% 62% 67% 
Table 3.4 Results of N-terminal sequencing following fragment condensation 
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Initially it was surprising that the coupling efficiencies of the two peptides were so 
different considering the 5 residues at the C-terminus were identical. However the 
two additional residues attached onto Phe 64-Gly70 are both hydrophobic, therefore it 
was concluded that the overall solubility of the fragment was reduced, hindering 
coupling onto the solid support. Attempts to further solubilise Phe 64-Gly ° were 
examined, measuring the coupling efficiency in different solvent systems. 
Unfortunately, the overall percentage coupling could not be improved with an 
estimated 20% drop in the coupling efficiency observed when DMF was replaced with 
DCM containing 10% TFE. 
3.6.2.3 Synthesis of Glu' 7 -Ala 65 
Because of problems encountered with the fragment condensation of FmocPhe" 4 - 
70 	 . 	 66 	0 	 71 Gly -OH onto the solid support, FmocVal -Gly -OH was coupled to H 2N-Asp - 
1 73 
 3-OH (estimated coupling efficiency was 93%) and the next fragment for 
coupling was prepared. However, the problems associated with the synthesis of Glu 57- 
Gly ° were still apparent in the stepwise synthesis of G1y 57-A1a65 , with a considerable 
drop in the amino acid coupling efficiencies observed in the region between Met 6 ' and 







Ala 	Phe 	Sec 	lie 	Met 	lie 	Asp 	Ma 
Amino acid residue 
Fig. 3.14 Stepwise synthesis of G1u57-A1a65. Fmoc ]V' deprotection profile 
From the HPLC and FAB MS of this hydrophobic peptide, it was evident that a large 
number of deletion sequences were present. Furthermore, due to the insolubility of the 
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peptide sample, the isolation of sufficient quantities of protected FmocGly 57-A1a65-01­1 
for a coupling reaction proved problematic. 
This region of the SCD sequence, which was proving difficult to assemble using 
fragment condensation, was finally prepared by initially coupling the small peptide 
FmocIle62-A1a65-OH (35) onto the solid support (estimated coupling efficiency was 
89%). Met61 , Ile 
6' and Asp59  were then individually coupled onto the polypeptide 
chain, thus the coupling efficiency of each amino acid could be measured. Fig. 3.15 
summarises the final coupling strategy used for the preparation of H2N-Asp59-Thr' '-
resin (Fig. 3.15). 
FmocNH-Va166 ........ Gly 70-OH (33) 
FmocNH-Iieo2 ........ A1a65-OH (35) 	
+ 	H2N-AsplI........Thr1 73 
FmocMet6l, FmocIIe6O then FmocAsp59 
I HOCt/DIC 
inDMF 
H2N-Asp 59-l1e 60-Met 61-tie62 ........ A1a 6 Vai66 ........ Gly-Asp7'........ThrH 
	
Frag. 5 	Frag. 4 	Frag. 1,2 & 3 
Fig. 3.15 Fragment preparation of H2N-Asp 59-Thr' 73-resin 
3.6.3 Attempted synthesis of Leu 48-A1a 58 
It was intended that once the amino acids centered at the problematic region had been 
coupled, fragment coupling could recommence with the preparation and coupling of 
the next protected fragment. Unfortunately, from the reaction profile for the synthesis 
of FmocLeu48-A1a58_OH (Fig. 3.16), it was obvious that the problems associated with 
the synthesis of these small peptides still remained, with the overall coupling efficiency 
dropping by an estimated 60% during the coupling of 4 residues (Arg 52 to Thr49). 
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Na Glu 	Gly 	Glu 	Tyr 	Leu 	Arg 	Ser 	Phe 	Thr 
Amino acid residue 
Fig. 3.16 Stepwise synthesis of Leu48-A Ia58. Fmoc IVa deprotection profile 
Once again the convergent assembly of SCD was hindered by the fragment 
preparation. To help provide an explanation of why certain peptide sequences proved 
difficult to prepare, the hydrophobicity index for SCD was examined (Fig. 3.17). 
Although stepwise chemical synthesis was performed in organic solvent and not in 
aqueous conditions, the solubilising effect of different amino acid side-chains still 



















0 	 50 	 100 
	
150 
N terminus 	 Amino acid residue 
	 C terminus 
Fig. 3.17 Hydrophobicity index of SCD 
85 
3. The Convergent Synthesis of SCD 
Fig. 3.17 highlights that the section centred between residues —50-70 of SCD is 
hydrophobic in nature. This would explain why such difficulties were encountered on 
synthesising fragments from this region. During the stepwise synthesis of the full 
length SCD, the amino acid couplings in this area did not appear to be problematic, 
with no significant drops in the coupling efficiency observed. In this case, the growing 
polypeptide chain on the solid support contained a number of hydrophilic regions 
which would aid the overall solubility of the protein chain. However, in the absence of 
this solubilising 'arm', the synthesis of the small peptide fragments, consisting mainly 
of hydrophobic residues, has proved problematic. 
As with the fragment preparation and coupling of the region between G1u 57-G1u 70, the 
strategy for the coupling of Ile 48 -Ala 58 would have to be revised, possibly dividing the 
peptide further into two smaller fragments, each of which would have to be 
synthesised and characterised before coupling could proceed. Considering the number 
of difficulties already encountered with the synthesis and coupling of protected 
peptides within a small region of SCD, it was decided to suspend this study. 
3.7 The Convergent Synthesis of SCD. Review of Initial Findings 
At the end of this preliminary investigation, it was concluded that when designing a 
convergent solid phase strategy for any peptide or protein, although guidelines for the 
division of a target sequence into fragments could be followed, changes in strategy as 
a direct result of unpredictable fragment preparation, solubility or low coupling 
efficiencies often have to be made. 
With the fragment assembly of the primary sequence of SCD, the continuous 
problems encountered all required close examination, which unfortunately protracted 
the research attention away from the initial project aim - to prepare SCD using 
chemical methods, in order to study the ability of the synthetic protein to fold 
correctly, and display the characteristic enzymatic activity. 
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On reflection, the underlying problem associated with the fragment coupling is the 
necessity for fully protected peptides. As a direct result of these bulky groups, this 
study has illustrated that fragment length is restricted in order to avoid severe 
problems associated with peptide insolubility. Furthermore it has been demonstrated 
that the overall solubility is highly unpredictable even for the smaller protected 
peptides. 
3.8 Convergent Synthesis Using Minimally Protected Fragments 
Arising from the inherent problems associated with fragment insolubility, alternative 
coupling strategies where the requirement for side-chain protection is minimal or 
completely unnecessary have been investigated. The remaining sections in this chapter 
shall briefly deal with one such strategy which was applied to the convergent synthesis 
of SCD. 
The azide condensation method (Fig. 3.18) is one of the most successful approaches 
for the coupling of minimally protected fragments via the native amide link. The 
flexibility of this approach for the convergent synthesis of proteins was initially 
demonstrated in 1969, when Denkwalter et al reported the total synthesis of bovine 
pancreatic ribonuc lease A (RNAse A) S-protein (104 residues) by the assembly of 
small minimally protected fragments via azide condensation. 26 Unfortunately, the 
product displayed little enzymatic activity and was not fully characterised. However, 
in 1980, Yamjima et al described the preparation of full length Rnase A (124 residues) 
using azide condensation to assemble 30 peptide fragments. 27 ' 28 Not only did this 
synthetic protein display full enzymatic activity, but it was also obtained in a 
crystalline form. 29 
3.8.1 Principles of azide condensation. 1. Side-chain protection 
Due to the design of the azide condensation, once the C-terminal azide or azide 
precursor has been incorporated, it is no longer necessary to block the carboxylic side 
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Co 





Fig. 3.18 Convergent synthesis using azide condensation 
chain functionalities of Asp or Glu during coupling. In fact, protection of the majority 
of the side-chain functionalities is now unnecessary apart from blocking the strongly 
nucleophilic amino functions of lysine and the N  terminus of the azide fragment, as 
well as the side-chain suilbydryl function of cysteine. 
3.8.2 Generation of the C-terminal azide 
Due to the reactivity and instability of azides generally, their preparation and isolation 
prior to coupling is not considered a practical approach. Instead, the C-terminal 
hydrazide, a precursor of the azide, is normally prepared. This C-terminally modified 
peptide is inherently more stable than the azide, allowing the fragment to be 
characterised and stored, if necessary, prior to coupling. 
The method that is generally adopted for conversion of the peptide hydrazide to the 
corresponding azide uses the conditions developed and optimised by Honzl and 
Rudinger3°  (Fig. 3.19). The conversion is carried out at low temperatures using 
anhydrous conditions in order to minimise potential side-reactions. The peptide 
hydrazide (36) is reacted with an alkyl nitrite such as t-butyl nitrite which generates an 
N-nitroso intermediate (37) before forming the corresponding azide (38) on loss of 
water. Due to its instability, the peptide azide is then reacted immediately in situ with 
the amino functionality on the other peptide fragment. 
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_ 0 	 _____ 0 
II HCI 	 II 
[Peptide FragjJ_C_NHNH 2 ± ONO-But 	10 [Peptide Frag. J—C—N1-fNFl-NO 
(36) 	
DMF/1,4-dioxan 	 (37) 
[Peptide Fraj—_N=N=N 	 (Peptide Frag. I —C-NH-N=N—OH 
(38) 
Fig. 3.19 Conversion of a C-terminal Izydrazide to the azide 
3.8.3 Preparation of the C-terminal hydrazide 
C-terminal hydrazides can be obtained by treating the corresponding C-terminal alkyl 
ester with hydrazine .3  Therefore hydrazinolysis can be incorporated into the solid 
phase preparation of the fragment as highlighted in Fig. 3.20. Reaction with the 
peptide-resin (39) would release the C-terminal hydrazide from the solid support 
which, upon standard TFA treatment, would then deprotect the side-chain groups 
(40). 
Pijot. 	Pljot. 
0 ____________ NH 2NH2 	Prrt. Pljot. 
	
0 ____________ 
Peptide Frag. IJ__o_.1 [peptide Frag. I J_t_NHNH 2 
(39) 	solid J 
support TFA 
0 
[Peptide Frag. J_c_NHNF1 2 
(40) 
Fig. 3.20 Preparation of a C-terminal hydrazide 
Unfortunately, there are a number of side-reactions associated with hydrazinolysis. 
These include removal of the NaFmoc32  protection and interference at the t-butyl 
protected Asp and Glu residues . 3 ' However, the development of a number of 
hydrazine resin linkers has completely eliminated the need for hydrazinolysis, thus 
avoiding these accompanying side-reactions. 
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At Edinburgh, the linker-resin used for the preparation of C-terminal hydrazides is the 
functionalised dibenzocycloheptadiene system (41) (Fig. 3.21). As with other 
hydrazide resin linkers, the hydrazide moiety is selectively incorporated onto the C-
terminus of the peptide chain at the beginning of the synthesis. On completion of the 
peptide assembly, the peptide is cleaved and deprotected from the solid support with 









cleavage from the 
solid support. 
FmocNH__r . 1 NHNFl2 
Fig. 3.21 Preparation of C-terminal hydrazides using afunctionalised linker 
3.9 Research Overview 
This chapter has already highlighted the problems associated with the convergent 
synthesis of SCD via the fragment coupling of fully protected peptides. The azide 
method of fragment condensation employs a minimal protection strategy, therefore it 
was proposed that the fragment solubility should be greatly improved and the 
coupling of larger fragments should be feasible. 
At Edinburgh, the utility of the azide method has already been illustrated with the 
successful preparation of salmon calcitonin I (SCT) a 32 residue peptide. Full-length 
SCT was prepared by coupling together two fragments FmocCys'-Gly' °-NHNH2 and 
11 	32 	 . 	 3435 H2N-Lys -Pro -NH2 using the azide method. 
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The aim of this study was to investigate whether the azide condensation methodology 
could be extended, permitting the successful coupling of larger peptide fragments. 
Two fragments of SCD were therefore separately prepared using stepwise SPPS and 
their ability to couple using azide condensation conditions was examined. 
3.10 The Azide Condensation of SCD 
Fig. 3.22 highlights the intended coupling strategy between two fragments of SCD, 89 
and 48 residues in length. Prior to coupling, both fragments were individually purified 
and characterised. 
Fmoclrp42 .......... GIy89 N1-1NH2 
ONO-Bu' /HCI 
DMF/I,4-dioxan 
FmocTrp 42 .......... G1y89-N3 	+ 	H2N-Pro 9O .......... Thr173-OH 
DIEAin 
DMF/1,4-dioxan 
FmocTrp42 .......... G1y89-Pro 9° .......... Thr173 -OH 
Fig. 3.22 Outline of the proposed coupling strategy 
3.10.1 Preparation of H 2N-Pro90-Thr173-0H (Lys 106_(2-CI-Z)) (26) 
The 89 residue peptide was identical to that prepared for the original fragment 
condensation study (see section 3.5.1 for the purification and characterisation), 
however, the sequence contains one lysine residue (Lys' 06) which would be required 
to be protected during the azide coupling. The Ncamino  functionality of Lys' 06 was 
blocked using 2-chlorobenzyloxycarbonyl (2-CI-Z) protection. This moiety is stable to 
both the base and acid cleavage conditions used in the Fmoc SPPS methodology and 
can be removed following coupling using stronger acid conditions eg. 
trimethylsilyltrifluoroacetate (TMSOTf) or trifluoromethanesulfonic acid (TFMSA). 
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3.10.2 Preparation and characterisation of FmocTrp 42-G1y89-NHNH2 (43) 
The C-terminal hydrazide peptide was assembled on the dibenzocycloheptadiene 
derived linker (41) (Fig. 3.23). The first amino acid FmocGly 89 was manually coupled 
to the resin via the acid chloride after which the remaining 47 residues were 
individually coupled using the standard Fmoc methodology. On completion, the 
peptide was deprotected and cleaved from the solid support by stirring the resin in 














Deprotection and ctooj 
(43) 	 cleavage from the 
solid support 
Fig. 3.23 Solid phase synthesis of FmocTrp 42-G1y 89-NHNH2 (43) 
Purified FmocTrp42-G1y89-NI{NH2 was easily characterised by MALDI-TOF MS 
where it was evident from the mass obtained that the peptide isolated had the 
hydrazide moiety intact. Furthermore, the amino acid ratios were found to be in good 
agreement with the expected composition (Fig. 3.24). 
3.10.3 Coupling of FmocTrp42-G1y89-NHNH2 (43) to H 2N-Pro90-Thr' 73-0H (26) 
After characterising the two peptide fragments, their ability to couple together was 
investigated. The first step, conversion of the hydrazide to the azide, was carried out 
at - 15°C to suppress possible side-reactions once the azide had formed. The IHPLC 
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Ala 4.86 5 
Arg 2.07 2 
Asx 4.20 4 
GIx 4.93 5 
Gly 5.14 5 
His 2.39 2 
lie 1.81 2 
Leu 3.00 3 
Met 0.30 1 
Phe 3.84 4 
Pro 4.47 4 
Ser 1.97 2 
Thr 1.83 2 
Tyr 1.44 3 






I 5000 	 6000 	I 
Fig. 3.24 Amino acid analysis and MALDI-TOFMS of FmocTrp 42 -G1y 89-NHNH2 
(43) (MwL 5,607.64) 
retention time of the peak corresponding to FmocTrp 42-G1y89-NHNH2 shifted on 
activation, indicating that the hydrazide had been converted. This conversion 
appeared to occur rapidly, therefore after 10 minutes activation, the amine fragment 
was added. 
Reaction conditions were maintained at 0 °C and the coupling progress was monitored 
using HPLC. After 3 hours coupling little change was observed in the HPLC profile, 
thus a second portion of hydrazide was activated and added to the reaction mixture. 
Following overnight incubation at 0 °C and addition of a third portion of azide, there 
was still little change in the HPLC profile with no new signal corresponding to the 
coupling product observed. 
Following 48 hours of coupling, the reaction mixture was analysed using MALDI- 
TOF MS and SDS gel electrophoresis. From the crude mixture, there was no 
evidence that any coupling had occurred. All components of the reaction mixture 
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were then separated using preparative H1PLC and individually assessed using amino 
acid analysis, MALDI-TOF MS and gel electrophoresis. Unfortunately, there was still 
no proof that the polypeptide FmocTrp 42-Thr' 73-OH with a molecular weight of 
15,000 had been prepared. 
The azide coupling was repeated, taking care to ensure that the low temperature and 
anhydrous conditions were maintained throughout. Unfortunately, following detailed 
analysis of the reaction mixture, it was evident that the azide coupling was not 
proceeding to any extent where even small quantities of the product could be detected 
or isolated. 
3.11 The Convergent Synthesis of SCD. Conclusions and 
Recommendations 
As part of the continuing study centred on the chemical synthesis of enzymatically 
active SCD, the feasibility of preparing the 173 residue protein using convergent 
synthesis was investigated. Two different strategies were examined which involved 
the coupling of fully and minimally protected peptide fragments. Both methods have 
been successfully applied for the preparation of small peptide sequences. Furthermore, 
there have been numerous reports in the literature describing the convergent synthesis 
of proteins, prepared by coupling small peptides using either of these methods of 
condensation. 
This study has highlighted a number of problems associated with convergent synthesis 
when the coupling of larger peptide fragments was attempted. Initially efforts 
concentrated on the coupling of fully protected peptides onto the solid phase, 
however the study was hindered not only by the general insolubility of the protected 
peptide which restricted the fragment length, but also by difficulties encountered with 
the stepwise preparation of a number of the peptide sequences. Consequently, the 
coupling strategy had to be constantly revised and it was envisaged that the complete 
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convergent synthesis would require a greater number of peptide fragments than was 
initially intended. 
Azide fragment condensation which involved the coupling of minimally protected 
peptides was then studied. It was anticipated that, in the absence of the side-chain 
protection, improved peptide solubility would result in more effective fragment 
coupling. Although this method has been successfully applied for the coupling of small 
peptides, the methodology could not be extended to large fragments with no coupling 
observed. The main reasons for the unsuccessful coupling were concluded to be due 
not only to the size of the two peptides, but also as a result of the low temperatures 
used to avoid azide decomposition over time. 
Despite the problems experienced, it is clear that both methods of convergent 
synthesis possess a number of properties which are beneficial for the chemical 
synthesis of proteins. Thus the design and development of a new, improved strategy 
which is a combination of these two methods is now the subject of ongoing research 
at Edinburgh20 (Fig. 3.25). 
HOCtfButONO 	 __________ 
[Peptide Frag. ___________ 
DMF, RT 	
Peptide Frag. 1C + H2NPeptide Frag. 2]
Oct 
(44) (46) 	 (47) 
0 I Peptide FragC+ - N Oa 
(45) 	1z: 
Fig. 3.25 Outline ofproposed coupling strategy 
Similar to the azide condensation, minimal protection is required as the C-terminal 
hydrazide functionality is incorporated at the beginning of the synthesis. Although the 
hydrazide (44) is converted to the azide (45) as before, HOCt present in the coupling 
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mixture, displaces the C-terminal azide affording the HOCt activated ester (46). 
Finally, coupling with an other fragment (47) proceeds with the usual N'-amino 
attack. 
Findings from the preliminary model studies are very encouraging. It has been shown 
that coupling does not need the low temperature conditions required for the original 
azide coupling, thus increasing coupling potential. Furthermore, the results show that 
when HOCt is present in the reaction mixture, the coupling proceeds more rapidly and 
the overall coupling efficiency is obviously improved compared with the azide 
coupling without HOCt. 
This study has now been extended to the coupling of small, minimally protected 
peptides where it has been clearly demonstrated once again that the addition of HOCt 
improves the rate and extent of coupling. With the present research efforts 
concentrating on the preparation of di-ubiquitin by coupling together two single 
ubiquitin units (76 residues in length), it is anticipated that this coupling strategy will 
soon prove invaluable for the preparation of large protein sequences. 
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Chapter Four 
The Chemical Ligation of Proteins 
4.1 Background 
The previous chapter has demonstrated how although the classical methods of 
convergent synthesis have been successfully applied for the chemical synthesis of 
proteins, there are still a number of significant problems associated with the coupling 
of large peptide sequences. Important advances in peptide synthesis over recent years 
however, have now made it possible to join two large, completely unprotected 
peptides in a specific and controlled fashion without any significant side reactions. 
The concept of this fragment ligation, although simple, has proved to be of substantial 
benefit for the convergent synthesis of peptides and proteins. By substituting the 
classical coupling approach used in peptide synthesis, namely the amination of the 
activated carboxylate, with an alternative strategy involving two unique, mutually 
reactive functional groups, fragment coupling can now proceed via a controlled 
chemoselective reaction which does not involve any other functional group present. 
One of the main distinctions from the aforementioned methods of convergent 
synthesis is that, in the absence of side-chain protection or anhydrous conditions, 
these chemoselective reactions can generally be performed in aqueous conditions. 
Therefore the coupling mixture can be buffered at a pH which complements the 
selective reaction and avoids side-chain involvement. Furthermore, denaturing agents 
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such as urea or Gdm.HC1 can be used to enhance the efficiency of the coupling by 
solubilising and denaturing the peptide fragment. 
Several research groups have reported a number of powerful ligation strategies which 
have been applied successfully for the coupling of large unprotected peptides. This 
chapter shall initially concentrate on a selection of these methods which clearly 
demonstrate both the flexibility and diversity of the chemical ligation, before 
presenting an outline of the ligation strategy designed and developed at Edinburgh 
with results of the preliminary studies. For a more extensive account of the various 
ligation methods that have recently been developed, reviews by Muir,' Kent,' and 
Hilvert3 are recommended. 
4.2 Protein Synthesis via Native Chemical Ligation 
Kent et al, considered to be leaders in the field of chemical ligation, have designed 
and developed a number of chemo selective strategies which have made the 
convergent synthesis of a number of proteins accessible. One highly powerful 
approach, referred to as native chemical ligation, results in the straightforward 
generation of proteins with native backbone structures from fully unprotected peptide 
fragments (Fig. 4.l). 
The initial step involves the chemoselective reaction at an unprotected C-terminal 
thioester peptide (48), with another unprotected fragment containing an N-terminal 
cysteine residue (49). The initial product of this attack is a thioester (50) which, 
without changes in the reaction conditions, undergoes a spontaneous intramolecular 
rearrangement to form the native amide bond with the regenerated Cys side-chain 
next to the site of ligation (51). 
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I 6MGdm.HCI 
pH 7.5 
[ H3N_f Pepti 	 I (50) 
Frag]—O 
native amide 
bond 	 (51) 
Fig. 4.1 The principle of native chemical ligation 
Model studies established that this native chemical ligation was applicable to peptides 
containing any of the natural functionalities, even the side-chain sulfhydryl function of 
cysteine. Although other internal cysteines can undergo the initial nucleophilic attack, 
there is no possible rearrangement to the amide bond. Furthermore, as the formation 
of the thioester is readily reversible in the conditions used (pH 7.5), this side reaction 
shall not binder the coupling process. Further evidence that this side reaction was 
unprogressive was illustrated by the successful preparation of interleukin-8 
,4 a 72 
residue cytokine containing 4 cysteines and turkey ovomucoid third domain (51 
residues) which contains 6 cysteine residues.' 
A second scheme for the selective coupling of unprotected peptides which results in 
amide bond formation was recently reported by Tam et al. 6 As with the preceeding 
method, fragment coupling employed the nucleophilic side-chain functionality on the 
N-terminal amino acid which was initially attracted to the activated C-terminal 
thiocarboxylic acid, essentially holding the two peptides together permitting 
rearrangement to yield the peptide bond. Here the imidazole group on the side-chain 
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of histidine, a weak base in acidic pH, was used instead of the sulihydryl moiety of 
cysteine. Following intramolecular rearrangement, the target peptide was generated 
with the recovered His side-chain at the site of ligation. 
Presently the success of this second coupling strategy has only been demonstrated 
using small unprotected peptides. However, it is anticipated that this fast, selective 
coupling can be repeated for the preparation of larger polypeptide chains. In 
summary, both these methods have illustrated the great potential for the native 
ligation of unprotected peptides by incorporating a nucleophilic moiety at the N-
terminus of the peptide fragment. 
4.3 Convergent Synthesis of Backbone Engineered Proteins 
One of the important advantages of chemical ligation is that the fragment coupling is 
not restricted to ligation via amide bond formation. A number of reports in the 
literature have clearly demonstrated that peptide and protein fragments can be joined 
by linkages other than the usual peptide bond, resulting in the construction of novel 
molecules with a wide range of possible backbone modifications. Replacement of the 
usual amide bond makes it possible to investigate how regions of the peptide 
backbone contribute to the proteins conformation and activity. Furthermore, with the 
development of a number of different strategies for the convergent synthesis of 
peptides and proteins, the choice of site for ligation within the target sequence should 
become more flexible. 
4.3.1 Convergent synthesis via thioester bond formation 
One of the initial methods of chemical ligation to be developed by Kent et al reported 
the coupling of peptide fragments, replacing the usual amide link with a thioester 
bond .7 Here the target sequence (52) was constructed by combining a completely 
unprotected peptide possessing a C-terminal thioester (53) with a second fragment 
comprising an N-terminal bromoacetyl moiety (54) (Fig. 4.2). 
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0 	 0  II 
H2 H-Pro ............... I1e°—NH-CH2 -C' + 	 Phe 53 ............... Phe-01 
SH 






H2H-Pro' ............... IIe°—NH-CH2 —S CH-— Phe ............... Phe-OH 
surrogate pept) 	(52) 
Fig. 4.2 Chemical ligation of backbone modified HIV-1 protease 
The success of this ligation was demonstrated with the preparation of an analogue of 
MV-1 protease, where a pseudo-peptide bond was incorporated into the molecule 
between Gil'-Gly52 . The two unprotected fragments, both -50 residues in length, 
were selectively joined rapidly and in high yield through the mutually reactive 
functional groups preparing an analogue which exhibited full enzymatic activity.' 
Once again the ligation strategy was shown to be compatible with all the side-chain 
functionalities. A further investigation performed by Kent et a!8 confirmed that even 
the nucleophilic sullhydiyl groups were compatible in the coupling conditions, ruling 
out the requirement for cysteine protection. This selectivity between the 
thiocarboxylate and the side-chain sulfhydryl was attributed to the acidic ligation 
conditions (pH 43)8  The thiocarboxylate group has a much larger pKa value, 
therefore under the conditions typically used for the thioester ligation, the thioacid 
was predominantly deprotonated. The sulfhydryl group in the same conditions 
however remained protonated and was therefore not sufficiently nucleophilic to attack 
the bromoacetyl moiety. 
0 	 0 
R—C" + H pKa 316 
SH 
RCH2SH 	 R- H2-S- + H pKa 9 
Fig. 4.3 pKa values for the thiocarboxyl and suljlzydrylfunctionalities 
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4.3.2 Chemical ligation three or more fragments 
Kent et al took this thioester ligation one step further in order to construct one of the 
largest synthetic protein analogues prepared completely using chemical methods (172 
residues). 9  This was made possible by assembling a total of four unprotected peptide 
fragments through an approach involving the use of the two mutually compatible 
thioester and oxime ligatio& ° strategies. 
The target sequence encompassed the two small protein units cMyc and Max that 
together play a central role in controlling mRNA transcription, generally associating 
to form the noncovalent heterodimer. Although it has been established that for full 
activity, both proteins were required to be present, preparation of this heterodimer by 
means of standard DNA technology has not been possible. However this unique, 
covalently bound cMyc-Max protein was chemically synthesised from the 
corresponding peptide fragments using the novel ligation strategy 9 (Fig. 4.4). 
11 
	
H2N- 2± Br-CH2--J 	.2 ONH2 H3C_4 -CCH2BT ± "C_f NH2 
SH 	 HS 
1i  
8M urea 	 SM urea 
pH 4.7 pH 4.7 
11
C- 	 ONH2+ NH2 
(55) 	 (56) 
8M urea 
pH 4.7 
0 	0 	 CH3 	0 	0 
11 11 
(57) 
Fig. 4.4 Synthesis of cMyc-Max using thioester and oxime ligation 
Firstly, using thioester-forming ligation, the two individual cMyc (55) and Max (56) 
domains, both 90 residues in length, were separately prepared. The two synthetic 
analogues were then joined in a regioselective manner via an oxime linkage to yield 
the heterodimer containing two N-termini (57). Once assembled, this unique cMyc-
Max heterodimer displayed the specific DNA binding properties as anticipated. 
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The findings of this study were invaluable, illustrating how powerful a technique 
chemical ligation was. It is clear that chemical ligation can be successfully applied for 
the synthesis of significantly large proteins, coupling relatively large peptide 
fragments. Furthermore, it is evident that chemical methods can prove suitable for the 
preparation of protein analogues with novel sequences or unusual backbone structure, 
which are not always attainable by recombinant technology. 
4.4 Research Overview 
4.4.1 Proposed strategy for chemical ligation 
After reviewing the literature reports describing a number of successful ligation 
strategies, a coupling approach was devised which was compatible with Fmoc peptide 
synthesis and of interest and relevance to ongoing research at Edinburgh (Fig. 4.5). 
Here the chemoselective reaction involves the coupling of a peptide fragment 
containing a C-terminal sulfhydryl (58) with a second peptide comprising an N-
terminal bromoacetyl functionality (59). The nucleophilic attack occurred via an SN2 
mechanism, yielding the target sequence with a thioether replacement (60) at the site 
of ligation. 





H2N—ftide Frag. I ]—NH—(CH2)2 
site of 	(60) ligation 
Fig. 4.5 Chemical ligation via ihioether bondformation 
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The principle of this chemoselective reaction is similar to the thioester ligation 
designed by Kent 7 (section 4.3.1), however it was anticipated that the thioether 
replacement would be inherently more stable at a higher pH (it was reported that the 
HIV-1 protease analogue containing the thioester link, although stable in acidic 
conditions, had a half-life of 2 hours at pH 7.5, rapidly undergoing thioester 
hydrolysis). 7 
The success of the thioether replacement has already been illustrated using a number 
of ligation strategies including the polymerisation of peptides," the preparation of a 
novel protein comprising two C-termini" and the synthesis of a second analogue of 
HIV-1 protease 3  with the surrogate peptide link again incorporated between Gly 51 -
G1y52 . 
4.4.2 Design of effective coupling conditions 
As with the other ligation methods discussed, the choice of a suitable pH, resulting in 
efficient and selective coupling, was crucial. Previous studies had revealed that no 
coupling occurred between the cysteine side-chain and bromoacetyl moieties at low 
pH  (section 4.3.1), the pH was clearly required to be sufficiently high to render the 
sulfhydryl group nucleophilic. In summary, thioether coupling have been reported to 
proceed effectively in solutions buffered between pH 7 and 8.' 
1-13 
Finally, due to the nature of the C-terminal moiety and the coupling conditions used, 
cysteine protection was now necessary. Furthermore, there was concern that the NE 
amino group of lysine would be suitably nucleophilic to attack the Nab romoacetyl, 
however, it has been demonstrated that the thioether ligation proceeds selectively in 
the presence of unprotected lysine at various pHs between 7 and 8.5 without side-
chain interference. 11,13 
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4.5 Preparation of Ligation Fragments 
4.5.1 Synthesis of the fu nctionalised resin-linker 
The thiol moiety (-NH-(CH 2)2-SH) situated at the C-terminus of the ligation peptide 
was incorporated into the fragment using the versatile dibenzocycloheptadiene-5-ol 
linker (61), designed and developed by Ramage and co-workers. 14 








Fig. 4.6 Preparation ofihefunclionalised linker 
N-Fluorenylmethoxycarbonyl-aminoethyl-2-thiol (62) was prepared starting with 
aminoethanethiol (64). To ensure that peptides with the intended C-terminus were 
prepared it was essential that the -SH functionality was selectively attached to the 
linker with the amine function available to couple with the first amino acid. Therefore 
the amine function was selectively protected with Fmoc (Fig. 4.7). 
Trityl-OH 
H2N—(CH2)2 ---SH 	 142N(CH2)2 —S—C---- 
TFA, 1 hour 









I hour 0 NH-(CH2)2 —S—C—o 
0 NI+-(CH2)2—SH 	 (66) 
Fig. 4.7 Synthesis of FmocNH-(CH2)r-SH (62) 
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Before incorporation of the thiol moiety, the linker was initially loaded onto the solid 
support. This was achieved by coupling the dibenzocycloheptadiene linker via its 
caesium salt (67) to chioromethylpolystyrene resin (Merrifield) (68), forming a stable 
ether link. By assessing the chlorine content of the resin, an estimation of the coupling 
efficiency was made, from which it was concluded that after 4 days, the loading was 
almost quantitative. Finally, after reduction of the ketone (69) to the corresponding 
alcohol (61), FmocNH-(CH2)2-SH was introduced onto the solid support (Fig. 4.8). 
0 
0 Otc~__Ucs 	DMF, 600C 
(67) 	 4 days 	01 
ci— CH2—(j----I 	 (69) 	
LiBH4 , THF 
(68) 	
i hour refiux 
FmocNFL..- 
QtP o I 
(63) 
FmOcNFLSH 	 OH 
(62) -0 	0 01 DCM,H,RT 
(61) 
Fig. 4.8 Synthesis of the FmocNH-(CH2)2-S-functiOflaliSed resin-linker 
Acid catalysis was used to load (62) onto the linker. Reaction conditions applied were 
analogous to those used previously to derivatise the resin-linker with protected 
hydrazine and amine functionalities.' 5 " 6  To assess the coupling progress, samples of 
resin were removed during coupling. After sonication in 20% piperidine, an estimation 
of the Fmoc content of the resin-linker was made, by measuring the absorbance of the 
Fmoc-piperidine adduct at 302nm. From this it was concluded that coupling was 
almost 100% effective after one hour (estimated resin functionality - 0.77mmolIg), 
thus completing the synthesis of the linker. 
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4.5.2 Synthesis of a C-terminal modified peptide 
In order to confirm that this derivatised linker could feasibly be used to prepare 
peptides with the intended C-terminal functionality, a small peptide sequence (70) was 
prepared on the modified solid support (63). Once assembled, the peptide-resin was 
stirred in aqueous TFA releasing the peptide from the solid support (Fig. 4.9). 
Ffl1OcNFLs 	 H2N-G1y-Phe-Ala-NFL,..--... S  
0~taol Stepwise peptide  G(t)D' OA assembly 
TFA, I  Detachment 
1 hour 	from the solid 
support. 
ocaol + 	 I 
(70) 
Fig. 4.9 Solid phase assembly of H 2H-G1y-Phe-A1a-NH-(CH2)2-SH (70) 
The resulting crude peptide was easily characterised using FAB MS confirming that 
the small peptide had been prepared with the C-terminal functionality intact. 
Furthermore HPLC and amino acid analysis confirmed that (70) was synthesised in 
the absence of any side reactions. However, there was evidence from both the HPLC 
and MS that, once the peptide was cleaved from the solid support, peptide 
dimerisation via disulfide bond formation had occurred to a small extent. 
4.5.3 Preparation of bromoacetylated peptides 
The bromoacetyl functionality was incorporated into the peptide at the end of the 
stepwise synthesis using bromoacetic acid, which was first converted to the 
symmetrical anhydride using DIC, before being coupled with the N-terminal free 
amide. Bromoacetylation of a small peptide sequence (71) assembled on Wang resin 
was successfully achieved (Fig. 4.10). Following removal of the final NaFmoc 
(63) 
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protection, the peptide resin was sonicated with bromoacetic anhydride for 1 hour 
after which time the reaction was complete. This was confirmed by the ninhydrin test 
for free amines which gave a negative result. 
0 
Br—CH2—c'- 
0 	+ 	H2N-Leu-Arg-Leu-Arg-GIy-Gly- 
	
B-CH2—C ' (71) 




cleavage from the 
* solid support. 
I Br-CH2-CO-NH-Leu-Arg-Leu-Arg-ay-ay-OH I 
(72) 
Fig. 4.10 Synthesis of a N-terminal bromoacetylated peptide 
Following deprotection and cleavage from the solid support, HPLC and FAB-MS 
analysis of the bromoacetylated peptide (72), confirmed that the correct peptide 
sequence had been prepared. 
4.6 Peptide Coupling via Thioether Bond Formation 
4.6.1 Chemical ligation - Preliminary investigation 
Following successful preparation of peptides containing the necessary functionalities, 
their ability to couple under suitable conditions was examined. Therefore two peptides 
were synthesised incorporating the bromoacetyl (72) and sulfhydryl (73) 
functionalities. Furthermore, Tbfmoc (section 3.5.4) was attached onto the N-
terminus of the C-terminal modified peptide (73). This should not only simplify 
purification at the end of ligation, but Tbfmoc is also a useful chromatographic probe 
(strongly absorbing at 364nm) which would help pinpoint both the sulfhydryl peptide 
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Br-CH2-CO-Leu' 	 (72) 
I Gdm.HCI pH 7/ trifluoroethanol (1:1) 
'-Mg- 
Leu-Arg-GIy-Gy' 6-OH (74) 
Fig. 4.11 Preparation ofpeptide analogue (74) via chemical ligation 
Once both peptides had been synthesised and characterised, they were separately 
dissolved in 6M Gdm.HC1 pH 7/TFE (1:1). The two solutions were then mixed and 
the progress of ligation monitored by analytical HPLC (Fig. 4.12). 
0 hour 	1ic-Thr I -Val 
J [Br.Leu I 1  -GI 6-OH) 
0 	20.00 	25.00 	30.00 	35.00 	40.00 
3 hours 






20.00 	25.00 	30.00 	35.00 	40.00 
16 hours 
20.00 	25.00 	30.00 	35.00 	40.00 
Fig. 4.12 The chemical ligation of a bromoacetylated (72) and C-terminal 
modified (73) peptide. The ligation progress was assessed using dual wavelength 
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The ligation occurred rapidly. Even the first sample, injected when the solutions were 
initially mixed, clearly displayed product formation. From the HPLC traces it was 
concluded that the majority of the coupling proceeded within the first few hours of 
reaction time. Furthermore, it was demonstrated that the coupling could be driven to 
near completion by adding an excess of one of the peptide fragments (a further 
portion of (72) was added after 3 hours of coupling). 
On completion of the coupling, the ligation peptide (74) was easily isolated from the 
ligation mixture by semi-preparative HPLC. The product was then characterised by 
MALDI-TOF MS, before and after removal of Tbfmoc, and assessed using amino 







Arg 2.46 2 
Asx 1.03 1 
Glx 1.03 1 
Gly 2.09 2 
His 1.02 1 
Leu 3.71 4 
Thr 1.94 1 
Val 0.91 1 
Fig. 4.13 Amino acid analysis and M4LDI-T0F MS of ligation product 
H2N-Thr 1-Gly 16-OH (74) 
4.6.2 Investigation into altering the rate of substitution 
Although the success of fragment coupling via the nucleophilic attack on a 
bromoacetylated peptide had been demonstrated, it was proposed that an increase in 
the rate of substitution could be achieved by substituting Bi with a better leaving 
group. 
An investigation into the varying rates of substitution was carried out, comparing the 
coupling of two haloacetylated peptides with aminoethanethiol (64). Two peptides of 
identical sequence containing the bromo (72) and iodo (75) functionalities were 
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synthesised, deprotected and cleaved from the solid support and finally separately 
dissolved in ligation buffer. A measured excess of the thiol (64) was then added to 
both solutions and the progress monitored using HPLC (Fig. 4.14). 
BrCH2 CO-Leu-Arg-Leu-Arg-GIy-Y-OH (72; 
H2N-(CH2)2 -SH 	+ 
ICH24u-Arg-Leu-Arg-(]y-G1y-OH (75 
(64)  
6M Gdni.HCI pH 7/ 
TFE (1: 1) 
(76) 
A. Bromoacetylated peptide 	 B. lodoacetylated peptide 
20.00 	20.00 	20.00 	 20.00 	20.00 
0 mill. 30 mm. 90 mm. 0 mm. 30 mm. 
Fig. 4.14 HPLC progress of the nucleophilic substitution reaction involving 
aminoethanelhiol (64) and A. the bromoacetylatedpeptide (72) B. the 
iodoacetylatedpeptide (75) 
From the HPLC traces it was evident that the substitution of the iodide ion proceeded 
more rapidly, with complete conversion to the thiol modified peptide (76) in less than 
30 minutes. Meanwhile, over the same period of time, only an estimated 50% of the 
bromoacetylated fragment had been converted. It was therefore easily concluded that 
the iodide ion was a faster, more effective leaving group. 
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4.6.3 Synthesis of an analogue of human proinsulin C-peptide 
To complete this study, an analogue of the human proinsulin C-peptide, a 31 residue 
peptide corresponding to position 33-63 of human proinsulin (77) was prepared. 
Containing a Gly4 -Gly-G1y47  situated near the centre of the sequence, this peptide 
was considered a suitable model for the thioether chemical ligation. 
(77) 
The two peptide fragments (78) and (79) were synthesised using the derivatised 
dibenzocycloheptadiene and Wang resin respectively. Once the iodoacetyl and 
Tbfmoc functionalities had been incorporated, the two peptides were individually 
deprotected and cleaved. On precipitation, the crude fragments were dissolved in the 
ligation buffer and the coupling progress was monitored (Fig. 4.15). 
From the HPLC profile, it was evident that, compared with the previous ligation, the 
rate of coupling was considerably slower to the extent that even alter 25 hours of 
coupling, there were still appreciable quantities of both peptide fragments present 
(Fig. 4.15). It was proposed that the rate of coupling was reduced due to the quality 
of the peptide fragments. 
Unfortunately, the stepwise synthesis of the C-terminal modified peptide (78) had 
proved problematic. A number of drops in the coupling efficiency were observed 
during peptide synthesis, as a result, the final product was contaminated with various 
deletion sequences. Due to the problems associated with C-terminal dimerisation, the 
crude peptide (78) was mixed with the iodoacetylated fragment (79) without 
purification. From the HPLC profiles, it was evident that a number of impurities were 
present which would not only hinder the coupling, but also make it difficult to 
estimate the actual concentration of (78) in solution. Clearly further investigation into 
the purification of the C-terminally modified peptide prior to coupling was necessary 
before the coupling of larger fragments could be examined. 
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GIu-Gly-Ser-Leu-G1fl 63-OH (80) 








1 20 	 20 	
20 	 1 
Fig. 4.15 Preparation of the proinsulin C-peptide analogue via the ligation of (78) 
and (79). HPLCprogres& 
Despite all these problems, isolation of the target analogue (80) was relatively simple. 
With the incorporation of Thfmoc, both the ligation product (80) and the C-terminal 
modified fragment (78) were easily removed from the reaction mixture on the addition 
of PGC. Then, on removal of Tbfmoc, the two peptides were separated using 
preparative HPLC and the proinsulin C-peptide was characterised by MALDI-TOF 
MS and amino acid analysis. 
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4.7 Final Conclusions and Recommendations 
Previously it has been established that by incorporating unique, mutually reactive 
functional groups into the peptide molecule, minimally protected peptides can be 
selectively coupled in the absence of side-chain interference. Furthermore, it has been 
demonstrated that large peptide fragments can be coupled together and that it is 
possible to construct peptide sequences via bonds other than the native amide link. 
This chapter has highlighted the great potential that the thioether ligation strategy 
presents for the total chemical synthesis of polypeptide and protein chains. Firstly, the 
preparation of two peptides incorporating the mutually reactive sullhydryl and 
haloacetyl functionalities has been shown to be straightforward and applicable to any 
peptide sequence. Furthermore, it has been demonstrated that the coupling of the 
tailored peptide fragments can proceed rapidly and selectively in the presence of a 
number of side-chain functionalities. Finally, with the incorporation of the Tbfmoc 
moiety, the final step involving ligation product isolation has been greatly simplified 
In summary, by employing the highly versatile dibenzocycloheptadiene linker and the 
novel Thfmoc system, the design of this particular thioether coupling strategy has 
become straightforward and manageable. It is anticipated that the present success 
with chemical ligation of small peptide sequences will be reproduced in future 
thioether ligations involving larger peptide fragments (>50 residues). 
Unfortunately, in the case of the human proinsulin C-peptide, a suitable biological 
assay was not available to compare the activity of the native peptide with the analogue 
containing the thioether replacement. However, it is generally accepted that the 
biological activity of any peptide or protein analogue can be affected by an unnatural 
peptide link, depending on the site of ligation. This has been illustrated by various 
literature reports where the unnatural bond is generally positioned in a region where 
the peptide bond is not critical for the protein's structure or activity. 7 ' 9" 3 
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Finally, at present the site of ligation is restricted to that between two glycines, 
however, considering the simplicity of the sullhydryl and haloacetyl moities, it should 
be possible to design analogues corresponding to some of the other simple amino 
acids. For example, the bromo/iodoacetic acid could be replaced with another a-
substituted bromo/iodoacetic acid. The major consideration of course is that all other 
amino acids are optically active, therefore care would have to be taken to ensure that 
the stereochemical integrity was maintained throughout the synthesis of the bromo or 
iodo components. If a number of amino acid derivatives containing either of the 
functionalities could be prepared, this thioether chemoselective ligation would become 
an extremely flexible and practical method for the convergent synthesis of a wide 
range of protein analogues. 
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All Fmoc amino acids were purchased from either Bachem or Novabiochem and are 
of L-configuration. ChloromethylpolystYrene-diViflYlbeflZene resin (Merrifield) and 2-
chiorotrity1chioride resin (Cl-Trt) were both purchased from Novabiochem., while the 
p-alkoxybenzylalcohol resin (Wang) was supplied by Bachem. Peptide synthesis grade 
dimethylformamide (DMF), 1 ,4-dioxan and piperidine were supplied by Rathbum 
Chemicals. NN-diisopropylethylamine (DIEA) and trifluoroacetic acid (TFA) were 
peptide synthesis grade and purchased from Applied Biosystems (ABI). 1-Hydroxy-4-
ethoxycarbonyl- 1 ,2,3-triazole (HOCt),' tetrabenzo[a, c, g, i]fluorenyl- 1 7-methoxy-
carbonyl (Tbftnoc), 2  and Substance P were all synthesised within the research group. 
Recombinant proMIMP-3 was supplied by Dr S.L. Irving, Pfizer Ltd, Kent. 7- 
Arg (Mca-peptide), 7methoxycoumarin-4-acetyl-Pro-LeU-GlY and p-aminophenyl-
mercuric acetate (APMA) were purchased from Sigma. 
Melting points were recorded in open capillaries using a Buchi 510 oil immersion 
melting point apparatus. Analytical thin layer chromatography (TLC) was performed 
using aluminium sheets precoated with silica gel 60 F254 (Merck) using the solvent 
systems indicated in text. Infrared (IR) spectra were recorded on a Bio-Rad SPC 
3200 instrument. Ultraviolet (UV) spectra were recorded on a Varian Cary 210 
double beam spectrophotometer, a Umcam UV/Vis double beam spectrophotometer 
or a Perkin Elmer single beam spectrophotometer in the solvents described in the text. 
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Proton nuclear magnetic resonance (NMR) spectra were recorded on either a Joel 
FX-60 (60M1-Iz) or a Brucker WP-200 (200MiHz). 
High and low resolution fast atom bombardment mass spectra (FAB MS) were 
measured on a Kratos MS50TC instrument, using either thioglycerol, 3-nitrobenzyl 
alcohol or glycerol as matrix. Matrix assisted laser desorption ionisation mass spectra 
(MALDI) time of ifight mass spectra (TOF MS) were recorded on a PerSeptive 
Biosystems VoyagerTM BiospectrometryTM Workstation using either a-cyan-4-
hydroxycinnamic acid or 3,5-dimethoxy-4-hydroxycinnamic acid as matrix. Amino 
acid analysis (AAA) were performed on a Pharmacia Biochrom 20 LKB 4150 alpha 
acid analyser on the hydrolysate obtained after heating samples in 6M HC1 at 110 °C in 
sealed Carius tubes for the length of time indicated in the text. Fluorescence spectra 
were recorded on a Perkin Elmer LS50 luminescence spectrometer fitted with a Grant 
LTD-6 thermostatic control. Protein N-terminal sequencing was performed on an ABI 
477A sequencer at the Welmet Protein Characterisation Facility (University of 
Edinburgh). This was performed by Edman degradation, labelling the N-terminus with 
phenyl isothiocyanate. 3  Circular dichroism (CD) spectra were recorded at 20 °C on a 
JASCO J600 spectropolarimeter (University of Stirling) in buffers stated in the text. 
All buffers described were prepared using Milli-Q grade water, Biochemika 
Microselect grade guanidine hydrochloride (Gdm.HC1) and urea (Fluka). High 
performance liquid chromatography (HPLC) was carried out using either an ABI 
system comprising 2x1406A solvent delivery systems, a 1480 injector/mixer and a 
1783 detector/controller, or a Gilson system comprising 2006 solvent delivery 
systems, an 811 c dynamic mixer, an 805 manometric module, a 119 UV/Vis detector 
and a Gilson 715 software-driven gradient controller. Peptides were eluted from 
various columns using a linear gradient of acetonitrile (}IPLC grade, Rathburn 
Chemicals) in Milli-Q grade water, where both solvents contained 0.1% v/v of HPLC 
grade TFA (Fisons). Fast protein liquid chromatography (FPLC) was carried out on a 
Pharmacia FPLC system with Liquid Chromatography Controller LCC-501 Plus using 
a SuperdexTM 75 HR 10/30 or 26/60, Mono-Q ® HR 5/5 or Resource PheTM column. 
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Anion exchange media diethylaminoethyl (DEAE) Sepharose was purchased from 
Pharmacia. Ion exchange was carried out using Pharmacia LKB apparatus comprising 
2xLKB 2138 TJVCords, a Pharmacia 2132 Microperpex peristaltic pump, a LKB 
2112 redirac fraction collector and a Pharmacia GM-1 gradient mixer. Isoelectric 
focusing (IEF) was carried out using the Bio-Rad Rotofor ®  system with ampholites 
purchased from Bio-Rad. Polyacrylamide molecular weight gels were run using 20% 
homogeneous SDS gels (Pharmacia) on a LKB Pharmacia PhastGel electrophoresis 
system. Dialysis tubing used, purchased from Spectrum ®, were Spectra/Por ® CE 
(cellulose ester) membranes with molecular weight cut-offs (MwtCO) as described in 
the text. Samples were centrifuged using MSE Mistral 2000R (Sanyo). Sample 
concentration employed Amicon centricon® cells or the Anlicon® Ultraffitration cell 
8050 using Spectrum MolecularfPor ®  membranes, MwtCO as indicated in the text. 
5.2 Solid Phase Peptide Synthesis 
All peptides were synthesised on an ABI 430A automated peptide synthesiser with 
on-line UV monitoring using an ABI 758A detector. All peptides were synthesised 
using the Fmoc strategy of N protection which involved the complementary use of 
orthogonal acid labile side chain protection and acid labile peptide-resin linkers. 
5.2.1 Side-chain protecting groups 
The side-chain protecting groups used were as follows: no protection for Ala, Gly, 
Ile, Leu, Met, Phe, Pro & Val; t-butyl (Bu') ethers for Ser, Thr & Tyr; t-butyl (Bu) 
esters for Asp & Glu; t-butoxycarbonyl (Boc) for Lys & Trp; 'r-triphenylmethyl (Trt) 
for Asn, GIn & His; 2,2,5,7,8pentamethy1chrOmafl6-sulPh0nyl (Pmc) for Arg. 
5.2.2 Loading of the C-terminal amino acid onto the solid support 
A number of resins were used depending on the particular peptide requirements. For 
example, it was necessary to use differing functionalised linkers for the preparation of 
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C-terminal thiol, hydrazide and amide modified peptides. These more specific 
procedures are described later (sections 5.5.2 and 5.6.3). 
However, all C-terminal acids were synthesised using either: 
4-alkoxybenzylalcohol (Wang) resin - for preparation of fully deprotected peptides. 
2-chlorotritylchloride (Ci-Trityl) resin - for preparation of side-chain protected 
peptides. 
Wang resin - a. For resin loadings 0.5 - 0.6 mmol/g 
The C-terminal Fmoc amino acid (6 equivalents) was dissolved in DMF (1 Omi) before 
DIC (3 equivalents) was added and the solution sonicated for 15 minutes. Following 
the formation of the symmetrical anhydride, the solution was added to Wang resin 
(ig) preswollen in a minimum quantity of DMIF, mixed with a catalytic amount of 
DMAP (approx. 10mg). The mixture was then sonicated for 2 hours at room 
temperature. The resin was separated by filtration and sequentially washed with 
copious amounts of DMIF, 1 ,4-dioxan, DCM and ether before being dried under 
vacuum. 
b. For resin loadings 0.1 - 0.2 mmol/g 
If a low resin loading was required, 2 equivalents of Fmoc amino acid and 1 
equivalent of DIC were used. Following addition to the preswollen resin, the mixture 
was left to stand for 1 hour before it was washed and dried as before. 
CI-Trityl resin - For resin loadings 0.5 - 0.6 mmol/g 
The C-terminal Fmoc amino acid (1 equivalent) was dissolved in the minimal quantity 
of DMF (up to imi) before DCM (lOml) was added. The solution was the added to 
CI-Trityl resin (1 g) before DIEA (2.5 equivalents) was gradually added dropwise over 
1-2 minutes. The mixture was then sonicated for ihour before HPLC grade MeOH 
(0.8m1) was added to the mixture and sonicated for a further 5 minutes (this ensured 
capping of remaining uncoupled Trityl groups). The resin was then sequentially 
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washed with copious amounts of DCM, DMF, DCM, MeOH and ether before being 
dried under vacuum. 
Note - The CI-Trityl resin is moisture sensitive therefore, for satisfactory coupling, it 
was found necessary to use dried glassware, dry DCM (CaC1 2) and the CI-Trityl resin 
and amino acid were dried under vacuum over KOH pellets. 
5.2.3 The Fmoc loading test 
The loading of the functionalised resin was determined by treating an accurately 
measured quantity of resin (typically '-5mg) with 20% piperidine/DMF/1 ,4-dioxan 
(lOmi). This solution was sonicated for 10 minutes before the UV absorbance of the 
supernatant was recorded between 280 and 320nm, measuring the absorbance at 
302nm. The coupling efficiency and resulting resin functionality (mmollg) was 
calculated by applying the Beer-Lambert law (c = 15,400 for the Fmoc-piperidine 
adduct). 
5.2.4 Automated SPPS 
All peptides and proteins described were synthesised using an Applied Bio systems 
430A automated peptide synthesiser. Every cycle, resulting in the coupling of a single 
amino acid, involved the following sequence of events - 
Capping - to irreversibly block any unreacted amino groups. 
Deprotection - removal of the Fmoc N' protection releasing the amino 
functionality for coupling. 
Coupling - 1. activation of the required amino acid. 
2. reaction with growing peptide on the solid support. 
After every step, the resin was washed repeatedly with copious amounts of solvent to 
ensure removal of all unreacted reagents. 
1. Capping 
The resin was vortexed with a solution of acetic anhydride (0.5M), DIEA (0.125M) 
and HOBt (0.2% w/v) in DMF/1 ,4 dioxan (1:1, 1 Omi) for 10 minutes before the 
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solution was drained from the reaction vessel and the resin washed with 6 portions of 
DIvIF/1,4 dioxan (1:1). 
Deprotection 
The resin was vortexed with a solution of 20%  piperidine DIvIF/1 ,4 dioxan (1:1, 
1 Oml) for 10 minutes before being drained, passing the solution through a UV 
detector*. After washing with DIvIF11 ,4 dioxan (1:1, 4 times), the resin was treated 
with a further two portions of piperidine solution (lOmi) vortexing for 1.5 minutes in 
each case. Finally, the resin was washed with 6 portions of DMF/ 1,4 dioxan (1:1). 
*Note - In order to monitor the progress of the synthesis, following every 
deprotection, an aliquot of filtrate was passed through the UV detector with on-line 
integration. The absorbance at 302nm is directly related to the concentration of the 
Fmoc-piperidine adduct and thus makes it possible to estimate the coupling efficiency 
of every amino acid. 
Coupling 
Activation - prior to coupling, every amino acid was converted to the 
corresponding activated ester using HOBt, HOCt or 1{BTU. 
Formation of HOBt ester - Fmoc amino acid (immol) was treated with HOBt 
(immol) and DIC (immol) in DMF/1,4 dioxan (1:1, 8m1). After 15 minutes, the 
activated ester was transferred to the reaction vessel. 
Formation of HOCt ester - the procedure was as for the HOBt activation for all amino 
acids with the exception of His. In the case of His, additional HOCt (2mmol) was 
added to the cartridge containing His amino acid. 
Formation of HBTU ester - Fmoc amino acid (immol) was treated with HBTU 
(immol), DIEA (2mmol) and HOBt (immol) in ME (8m1). After 15 minutes, the 
activated ester was transferred to the reaction vessel. 
Coupling - on addition of the activated amino acid to the resin, the mixture was 
vortexed for 30 minutes before the solution was drained and the resin washed with 
DMF/1,4 dioxan (1:1,4 times). 
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For the majority of syntheses, the above single coupling cycle was sufficient. However 
in the cases where problematic residues or sequences were encountered, resulting in 
unsatisfactory coupling efficiencies, a second coupling cycle was incorporated. For 
this double coupling cycle, an additional portion of Fmoc amino acid (immol) was 
activated and the above coupling procedure repeated. 
5.2.5 Preparation of Tbfmoc-peptides 
Loading of Tbfmoc onto peptide-resin 
On completion of the peptide's synthesis, the NaF moc  protection was removed 
(section 5.2.4.2) and the resin washed and swollen in 1,4 dioxan. Tbfinoc 
chioroformate (3 equivalents*), dissolved in 1,4 dioxan (lOmi for ig peptide-resin), 
was added to the resin followed by DIEA (1 equivalent to peptide-resin). The mixture 
was then sonicated in the dark for 2-3 hours before the resin was filtered and washed 
with copious amounts of 1,4 dioxan, DCM and ether. The resin was then stored under 
vacuum in the dark until required. 
*Note - on completion of the synthesis, the final Fmoc-amino acid loading was 
calculated using the Fmoc loading test. Based on the absorbance at 302nm, the overall 
resin functionality was determined and this compared with the theoretical final loading 
given 100% yield in every step of the synthesis (information provided using computer 
programme). This, in turn, provided an estimation of the overall success of the 
synthesis. 
The Tbfmoc loading test 
The loading of the functionalised resin was determined by treating an accurately 
measured quantity of resin (typically -.5mg) with 20% piperidine/1,4 dioxan (10n -fl). 
Alter sonicating the solution for 10 minutes, the UV absorbance of the supernatant 
was recorded between 320 and 400nm. The Tbffiioc-peptide-resin functionality and 
resulting coupling efficiency was calculated from the following equations: 
Resin functionality (Tbfmoc-peptide - mmollg) = 0.613 x AbS364nm/ 
weight of resin (mg) 
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Coupling efficiency of Tbfmoc (%) = resin funct. mmol/g (Tbfmoc-peptide) / 
resin funct. mmol/g (peptide) 
3. Tbfmoc purification 
Adsorption - Thfinoc-peptide, dissolved in 6M Gdm.HCl/i-propanol (1:1, 
-40mg/mi), was mixed with washed activated charcoal*. The solution was then 
stirred until HPLC indicated that all Thfmoc-peptide had adsorbed onto charcoal 
(disappearance of all material absorbing at 365nm). The mixture was then centrifuged 
and the supernatant removed. 
Wash - the charcoal was washed using 6M Gdm.HCl/i-propanol (1:1, 3 times) in 
order to remove all deletions and material still in solution. In each case, the mixture 
was shaken, centrifuged and the supernatant discarded. 
Cleavage - the charcoal was shaken vigorously in 10% piperidine/6M Gdm.HCl/i-
propanol (1:1) for 15 minutes, releasing the peptide from the Tbfmoc moiety. 
Following centrifugation, i-propanol was removed in vacuo and the pH of the 
solution was altered using AcOH (pH 6-7). Depending on the purification strategy, 
the product was either dialysed in order to remove the Gdm.HC1 followed by 
lyophilisation or purified directly using preparative HPLC. 
*Note - the quantities of carbon used depended greatly on the size of peptide/protein 
being purified and varied from 1-5mg carbon:peptide. The best approach involved 
using a small quantity of carbon initially, and, depending on the extent of adsorbance 
(indicated by HPLC), further carbon could then be added. 
5.2.6 Acidolytic treatment of resin bound peptide 
1. Wang resin - this general procedure for deprotection and cleavage was optimised 
depending on the particular peptide. N deprotected peptide-resin (ig) was swollen 
and stirred in a mixture of scavengers for 30 minutes. The choice of scavengers varied 
depending on the peptide being treated, overall the scavengers employed were: 
anisole (0.5m1); thioanisole (0.5m1); EDT (2m1); phenol (750mg); TIPS (0.25m1). 
Aqueous TFA (95%, 1 Oml) was then added to the resin and the mixture stirred under 
nitrogen at room temperature for the required length of time. The resin was then 
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removed by filtration and the cleavage mixture precipitated by adding dropwise to ice-
cold ether. The resulting white precipitate was then washed in ether (3 times), filtered, 
dissolved in aqueous AcOH (10-20%) and lyophilised. 
2. CI-Trityl resin -general procedure for the cleavage of side-chain protected 
peptides. Peptide resin (ig), previously swollen in DCM, was stirred in a solution of 
AcOH/TFE/DCM (1:1:8, 20nil) at room temperature for 30 minutes under nitrogen. 
The resin was then filtered and washed with the same solvent system before the 
solution was concentrated to 3-5m1 in vacuo. The crude peptide was then precipitated 
by triturating in ice-cold ether, washed and filtered. 
Note - 1. When concentrating, the mixture was not evaporated to near dryness. This 
would expose the protected peptide to neat AcOH which may result in side-chain 
deprotection. 2. The crude peptide was not lyophilised due to the general insolubility 
of protected peptides in aqueous media. 
5.3 The Chemical Synthesis of Stromelysin (SCD) 
Notes 
1. Protein concentration determination - Samples were analysed for their protein 
content using the method described by Edethoch. 4  By measuring the absorbance at 
280 and 288nni, it was possible to determine the content of tryptophan and tyrosine in 
the protein sample which relates to the concentration of the protein. The protein 
concentration could then be calculated by applying the following equations - 
= molar extinction coefficient 
g=AIC 
	
A = UV absorbance 
C = protein concentration 
F,280= NTrp 5690 + MT 1280 
	
N and M = no. of moles of Trp and Tyr 
6288 = NTp  4815 + M1 385 
	
per mole of protein. 
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Prior to the absorbance measurement, a blank sample (containing protein buffer) was 
run. All protein concentrations were converted to mg/ml. 
HPLC - Analysis of all the protein samples in this section employed a C 4 column. 
The conditions used were as listed - 
• Aquapore C4, 1 00x4.6mm, 7pm. 
• A=1120, B=CH3CN, 0.1%TFA. 
• 2m1 loop, lmI/niin. 
• 0-2min 10%B, 2-32mm 10-90%B. 
• ?=214nm. 
Activation of proSCD using APMA - To a imi solution of proSCD (1mg, 
34.49mmol) was added APMA (20p.1, from a MM stock solution (DMSO)). On 
mixing, the protein sample was incubated at 37 °C for 4 hours. The sample was then 
centrifuged to remove any precipitates before the lower molecular weight fragments 
and APMA were removed by spinning down the solution (Mwt.CO. 3,000), washing 
with 50mM Tris pH 7.5 containing 10mM CaC12 and 0.1mM ZnC12 (2m1, 3 times). 
The volume of the protein sample was then adjusted to imi using the same buffer 
system and stored at -20 °C until use (est. conc. 0.67mg/mi). 
m/z (MALDI-TOF) -'28,500-29,500 (MR' proSCD C i 295H 1 977N344O389S6Ca3Zn2 
requires 29,011.13), -49,200-19,800 (MH 1 actSCD C882H1311N228O264S2Ca3Zn2 
requires 19,632.31). 
Calculation of SCD activity - The extent of protein activity was determined by 
measuring the change in fluorescence over time on incubation of Mca-peptide with 
SCD. All assays were performed at 37 °C in a lOOp.l cuvette containing: 
lOp.l Mca-peptide in DMSO (10M stock solution) 
Xp.l SCD in 50mM Tris, 10mM CaC12 , 0.1mM ZnC12 
90-Xp.l Tris buffer 
On mixing, the sample was excited at 325nm and the change in fluorescence emission 
at 393nm was monitored (Ex./Em. slit width - 15 and 20nm respectively). 
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Activity calculation - The change in fluorescence as a result of the complete 
hydrolysis of 0.1 p.M Mca-peptide was determined by separately measuring the 
fluorescence of the fully intact Mca-peptide and completely hydrolysed Mca-fragment. 
1. lOp.! Mca-peptide (10M DMSO) 
90p.l Tris buffer 
(average fluorescence '-20units) 
2. 10.d Mca-fragment (10M DMSO) 
90p.! Tris buffer 
(average fluorescence -P270 units) 
Neither samples show any change in fluorescence over time. The protein activity can 
then be determined: 
Activity (units) = change in fluorescence/mm / change in fluorescence for total 
hydrolysis of Mca-peptide (0.1j.tM) 
(average value 250 units). 
The activity was quoted as units/mg of protein in the l00p.l sample. 
5. Substance P hydrolysis - To a solution of Substance P (4mg/nil) in 50mM Tris pH 
7.5, containing 10mM CaC12 and 0.1mM ZnC12  was added the activated sample of 
SCD. The rate of hydrolysis was monitored using HPLC analysis. 
HPLC (Vydac C 18, 250x4.6nim, 5p.m; 2m1 loop, lmI/min; 0-2min 10%B, 2-20mm 
10-50%B, 20-24mm 50-90%B; A=214nm) R=12.2min,, 32.5%B (Arg-Met"); 
R=10.8min, 29.50/oB (Phe 7-Met"); R=3.1min, 10.5%B (Arg'-G1n 6). m/z (MALDI-
TOF) 1,346.9 (MW Arg'-Met", 1,349.67), 610.98 
(MW Phe 7-Met", 613.80), 
753.28 (MW Arg'-GO, 753.88). 
Chemical synthesis of SCD (H2N.-Phe'-Thr' 73-OH) 
The synthesis was carried out on a 0.1 3mmol scale using Fmoc-Thr(Bu') 
functionalised Wang resin (850mg, 0.1 Smrnollg). The amino acids used had side-chain 
protection as previously described and were coupled via the corresponding HOCt 
activated ester. The first 153 amino acids were attached onto the solid support via 
single coupling cycles with double coupling cycles being employed for the last 20 
residues (with the exception of G1y). Approximately one half of the resin was 
removed after 72 residues (Asp '°') which was stored in 1 ,4-dioxan until required. On 
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completion of the synthesis, the resin was washed with copious amounts of DMF, 1,4-
dioxan, DCM then ether and dried under vacuum. Fmoc-SCD-resin was then stored in 
1 ,4-dioxan at 5°C until required. 
Amino acid analysis (64 hours hydrolysis) A1a13 13.54, Ar97 5.3, Asx21 18.86, G1x13 
13.26, G1y13 13.88, Hisg 8.22, Ileg 7.48, Leu 16 14.18, Lys6 4.21, Met2 2.41, Phe 10 
9.65, Pro 14 12.94, Ser9 6.14, Thr 14 8.73, Trp3 N/A, Tyr8 6.42, Vals 7.15. 
Deprotection and cleavage of SCD 
Prior to cleavage, the NaF moc protection was removed by sonicating resin (3 00mg) 
in 20% piperidinefDMF/ 1 ,4-dioxan (1:1, 1 0m1) for 15 minutes. On removal, the resin 
was filtered and washed using DMF, 1 ,4-dioxan, DCM then ether. The protein was 
then deprotected and cleaved from the solid support by stirring the resin in 95%aq. 
TFA (lOmi) containing phenol (750mg), EDT (2m1), thioanisole (0.5m1) and TIPS 
(0.25m1). The mixture was stirred under nitrogen for 4 hours after which time the 
resin was filtered and washed with TFA (5m1). The filtrate was then added dropwise 
to ice-cold ether and the resulting precipitate centrifuged and washed with ether (3 
times). The crude protein was dried, dissolved in 20% AcOH and lyophilised to yield 
crude SCD as a white solid (152mg). 
HPLC (Aquapore C4) Rt=18-20.5min, 54-59%B. Amino acid analysis (64 hours 
hydrolysis) Ala 13 13.03, Ar97 4.27, Asx21 18.18, G1x13 14.00, G1y 13 12.97, His8 7.6, 
11e8 6.60, Leu 16 13.04, Lyso 3.83, Met2 1.61, Phe 10 8.87, Pro 14 11.43, Ser9 4.63, Thr 14 
7.24, Trp3 N/A, Tyr8 6.95, VA 6.89. N-terminal sequencing (predominant peaks): 
cycle 1 - Phe 67.55pmol; cycle 2 - Arg 19.35pmol; cycle 3 - Thr 46.94pmol. 
FPLC Size exclusion purification of SCD 
Column conditions - Gel filtration was carried out using SuperdexTM 75 HR 26/60 
column. Prior to protein purification, the column was equilibrated with 8M urea, 
50mM Tris pH 7.5 buffer using a flow rate of 3m1/min. 
Following cleavage from the solid support, SCD (40mg) was dissolved in the 8M urea 
buffer (pH 7.5 - Imi), loaded onto the column and a flow rate of 3m1/min applied. 
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After lOOmi, fractions (9m1) were collected, monitoring the progress at 280nm. 
Fractions absorbing at 280nm were examined using HPLC (Aquapore C 4). 
HPLC - Fractions 5-10 absorbed strongly at 280nm and when analysed using FIPLC, 
eluted with the correct retention time (R=18-20min, 54-59%B), however fractions 6 
and 7 gave the sharpest, cleanest HPLC profiles. As a result, fractions 8-10 were 
combined, concentrated (Mwt.CO 5,000) and re-eluted. All protein which eluted 
between fractions 6 and 7 was combined for subsequent analysis and purification. 
UV concentration determination (section 5.3. 1) est. 0.45mg/mi, thus 8mg of protein 
recovered from 40mg crude. Amino acid analysis (64 hours hydrolysis) Ala 13 13.27, 
Ar97 6.2, Asx21 22.8, G1x 13 14.9, G1y 1 3 13.82, His8 8.6, 11e8 8.45, Leu 1 6 14.25, Lyso 
6.55, Met2 1.75, Phe 10 11.10, Pro 14 11.95, Ser9 8.5, Thr14 10.7, Trp3 N/A, Tyrg 8.2, 
Va18 9.1. N-terminal sequencing (predominant peaks): cycle I - Phe 47.67pmol; 
cycle 2 - Mg 15.85pmol; cycle 3 - Thr 16.49pmol. 
FPLC Molecular weight analysis of SCD 
Column conditions - Analysis was carried out using a SuperdexTM 75 FIR 10/30 
column which was equilibrated with 8M urea, 50mM Tris pH 7.5 buffer using a flow 
rate of 0.5mllmin. Blue Dextrin (Mwt. 2,000,000) was loaded to measure the column 
void volume (V 0 8.2). 
0.5mg of protein was dissolved in 8M urea buffer (200p.l), loaded onto the column 
and the elution volumes (Ve) recorded by monitoring at 280nm. The molecular weight 
standards used were ovalbumin (Mwt. 43,000, Ve 9.10±0.1) chymotrypsin (Mwt. 
25,000, Ve 9.45±0.1) and ribonuclease (Mwt. 13,700, Ve 10.5±0.1). The elution 
volumes for the recombinant and chemically synthesised SCD were 9.70±0.1 and 
9.80±0.1 respectively. 
Tryptic digest of SCD 
To a sample of SCD in 8M urea buffer (pH 7.5) (250 j.il, est. conc. 0.45mg/mi) was 
added trypsin (0.25mg dissolved in 250il 50mM Tris pH 7.5). After mixing, the 
solution was incubated at 37T, monitoring the progress of the digest using HPLC 
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(Vydac C8, 250x4.6mm, 5.xm; 2m1 loop, imi/min; 0-2min 10%B, 2-42mm 10-70%B, 
42-44mm 70-90%B; A.=214nm). After 5 hours, the solution was separated using 
analytical }{PLC and a number of samples were analysed by mass spectrometry. 
m/z (MALDI-TOF) 1,870.54 (MW Ala"-Arg52 , 1,775.97, TFA salt), -2,160 (MW 
Ile' 9-Lys", 2,074.07, TEA salt), 2,344.15 (MW Leu152-Thr' 73 , 2,343.10), 2,400 
(M1{ Ile' 9-Lys", 2,405.23), 2,820 (MH Thr' 3-Lys37, 2,847.48), 3,155.02 (MW 
Va141 -Arg67, 3,158.59), 4,254.08 (MH G1u68-Lys' 16, 4,256.86), 5,050 (MW Asp' °7- 
/9 	106 
Arg 1 51 , 5,030.53), -P9,800 (MIHI Ile -Lys , 9,801.74). 
Isoelectric point (p1) determination using IEF 
1. pH range 3-10 - As low salt conditions were necessary, SCD (10mg), dissolved in 
4M urea (50m1) was initially desalted overnight using dialysis (4M urea, Mwt.CO 
5,000). Ampholytes (Bio-Lyte®, pH range 3-10, 40% w/v, lml) were added and, 
following mixing, the protein solution was loaded into the focusing chamber of the 
Rotofor®  cell. The cell was first allowed to rotate without applying the power so the 
system could reach thermal equilibrium at the cooling temperature of -5°C. After 10 
minutes, the power supply was connected, running at a constant power of 15W. A 
large increase in the voltage was initially observed which gradually stabilised over 3.5 
hours. Once the voltage had completely levelled out, the 20 fractions were harvested 
and their individual pHs measured to ensure that a pH gradient had been established. 
All fractions were then examined by HPLC (Aquapore C 4) to assess the protein 
content. The majority of protein was found in fractions 5 and 6. 
Fract. pH Fract. pH Fract. pH Fract. pH Fract. pH 
1 2-2.5 5 4.5 9 6 13 7 17 8-8.5 
2 2.5-3 6 5 10 6-6.5 14 7-7.5 18 9 
3 3-3.5 1 	7 1 	5.25 11 6.5 1 	15 7.5 19 9.5-10 
4 3.5-4 8 5.5 12 7 16 7.5-8 20 10 
2. pH range 4-6 - The same procedure as part I was applied using a second batch of 
SCD (10mg) in 4M urea (50mi). The ampholytes ranged from pH 4-6 to employ a 
narrower pH gradient. After 3 hours, the fractions were harvested and the individual 
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pH values measured before being analysed by 1-[PLC. The majority of protein was 
found in fraction 5 indicating a p1 of 4.5. 
Fract. pH Fract. pH Fract. pH Fract. pH Fract. pH 
1 1 5 4-4.5 9 4.5-5 13 5-5.5 17 7 
2 2 6 4.5 10 4.5-5 14 5-5.5 18 10 
3 1 	3.5 7 4.5 11 5 15 5-5.5 19 10 
4 4 8 4.5-5 12 5 16 5.5-6 20 10 
DEAE ion exchange purification of SCD 
Adsorption onto matrix - Following purification by FPLC size exclusion, SCD in 
8M urea, 50mM Tris pH 7.5 (72m1, est. conc. 0.45mgIml, 32.5mg), was mixed with 
DEAE Sepharose (lOml, previously washed with 8M urea, 50mM Tris pH 7.5). After 
shaking for 10 minutes, the mixture was centrifuged and the supernatant examined 
using HPLC (Aquapore C 4) to confirm that all protein had adsorbed onto the gel 
media. 
Removal of urea - Following adsorption, the supernatant was discarded and the gel 
loaded onto a column which was then run isocratically in 8M urea, 50mM Tris pH 7.5 
(0.4m1/min) for 2 hours. A gradient of 8M urea, 50mM Tris pH 7.5 to 50mM Tris pH 
7.5 containing 10mM CaC12 and 0. 1mM ZnC12 (500m1) was introduced to gradually 
remove urea. This was run over 20 hours at a flow of 0.4mllmin monitoring at 226 
and 277nm. 
Protein elution - On removal of urea, the column was run isocratically of 50mM Tris 
pH 7.5, 10mM CaC12 and 0.1mM ZnC12  for 4 hours. Finally, a salt gradient of OM- 1 M 
NaC1 in 50mM Tris pH 7.5 containing 10mM CaC12 and 0.1mM ZnC12 (lOOmi, 
1 mI/mm) was applied to elute the protein. 1 Omi fractions were collected and their 
protein content determined using HPLC (Aquapore C 4). Protein containing fractions 
(5 and 6) were combined and repeatedly dialysed (3 times, Mwt.CO 10,000) against 
50mM Tris pH 7.5, 10mM CaCl2, 0.1mM ZnC12 to remove salt. 
UV concentration (section 5.3.1) est. 1.07mg/mi, thus 21.5mg recovered from 
32.5mg. Amino acid analysis - see section 2.8.3. N-terminal sequencing 




Denaturing and refolding of SCD 
Denature - SCD in 50mM Tris pH 7.5. containing 10mM CaC12 and 0.IM ZnC12 
(250p.l) was gradually added to a solution of 8M urea, 50mM Tris pH 7.5 (2.5m1). 
After mixing, the solution was left to stand overnight at RT. 
Refold - Following incubation, the urea solution containing protein was introduced, 
dropwise at RT, to folding buffer (15m1, 50mM Tris pH 7.5, 10mM CaC12, 0.1mM 
ZnC12) while ensuring the solution was thoroughly mixed during addition. Once 
complete, the solution was left overnight at 5°C after which time it was concentrated 
(Mwt.CO 3,000) to a final volume of-250pJ. The extent of the protein's activity was 









Recom. 0.028mg/mi 28.57 0.03mg 14.67 
Synth. 0.37mg/mi 0.17 0.32mg 0.053 
Fluorescence and CD analysis of chemically denatured SCD 
Denaturing experiments were all carried out using ultrapure grade guanidine 
hydrochloride (Gdm.HC1), preparing a stock solution of 8M Gdm.HC1, 50mM Tris 
pH7. 5. Stock solutions of recombinant (1.4mg/mi) and synthetic SCD (1mg/mi) were 
used. A number of samples were individually prepared and incubated at room 
temperature for 15 minutes prior to analysis. 
Gdm.HCI Conc. SCD 
(recom or synth)  
Buffer Gdm.HCI 
OM 90pJ 4101.11 01.11 
1M 901.11 347.51.11 62.51.1.1 
2M 90p.1 2851.1.1 1251.il 
4M 901.d 1601.1.1 2501.1.1 
Fluorescence measurements were made by exciting the sample at 290nm, monitoring 
the fluorescence emission between 300 and 400nm (Ex./Em. Slit width - Snm). The 
wavelength and value of maximum fluorescence for each sample was recorded. The 














OM 328 854.3 343 410.4 
1M 327.5 687.0 346 308.3 
2M 340 409.3 353.5 328.9 
4M 354 310 355.5 357.8 
CD spectra were measured between 260-21 Onm at 20 °C from which the molar 
ellipticity at 226nm was calculated. The values for synthetic SCD were adjusted based 
on the concentration difference. 
Gdm.HCI Conc. 0226 Recombinant 0226 Synthetic 
OM -2570 -4445 
1M -2954 -1777 
2M -3016 -2327 
4M -787 -1240 
Mono-Q analytical ion exchange of SCD 
Column conditions - Analysis was carried out using a Mono Q® HR 5/5 column 
which was equilibrated with 50mM Tris pH 7.5 containing 10mM CaC1 2 and 0.1mM 
ZnC12 . 
Protein samples, dissolved in the 50mM Tris buffer were loaded and the column was 
run isocratically for 5 minutes (imi/min). A salt gradient of 0-1M NaCl was then 
introduced over 30 minutes, monitoring the progress at 280nm. Fractions absorbing at 
280nm were examined using HPLC (Aquapore C 4). 
Resource Phe analysis of SCD 
Column conditions - Analysis was carried out using a Resource PheTM column which 
was equilibrated with 50mM Tris pH 7.5, 10mM CaC12 , 0.1mM ZnC12 containing 0-
XM (NH4)2 SO4  (a number of runs were attempted applying varying concentrations 
(X) of(N}Li)2 SO4). 
Protein samples, dissolved in 50mM Tris buffer and containing XM (NH 4)2 SO4 were 
loaded onto the column which was run isocratically for 5 minutes (lml/min). A 
gradient of X-OM (NH4 2 SO4 was then introduced over 30 minutes, the progress 
monitored at 280nm. 
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Activity analysis of chemically denatured recombinant SCD 
Activated recombinant SCD (10.tl, conc. 0.6mg/mi) was incubated with various 
concentrations of urea, 50mM Tris pH 7.5 for 1 hour at room temperature. To each 
sample was then added Mca-peptide (1 Op1. 10 -3M stock) and the change in 
fluorescence over 5 minutes was measured (Ex. 325nm/Ern. 393nm). 
Conc. of urea Change in fluorescence 
OM 132.5-903.4 (154 units/mm.) 
1M 188.7-804.4 (123 units/mm.) 
2M 116.6-749.1(126 units/mm.) 
4M 125.7-627.0 (100 units/mm.) 
6M 85.9-386.2 (60 units/mm) 
8M 62.8-73.7 ('-P2 units/mm.) 
5.4 Convergent Synthesis of SCD - Fragment Condensation 
Notes 
Solid support - The general procedure used for preparation of all Fmoc amino 
acid functionalised CI-Trityl resins is as described in section 5.2.2.2. 
Fragment preparation - The syntheses and coupling of all the side-chain 
protected peptides used in the study were all very similar in that - 
. each synthesis employed single coupling cycles using HOCt. 
. all resins were washed and dried using the same solvent systems. 
• peptides were cleaved from the solid support using AcOWTFEIDCM 
(1:1:8) and the work-up involved TFEI1 -120 reprecipitation. 
• the couplings were carried out in the minimal quantity of DMF using 
an excess (3-5 equivalents) of the protected fragment. 
As a result, the following procedures are brief, for detailed experimental information 
refer to the preparation of H 2N-G1y79-Thr' 73-OH (26). 
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Coupling conditions - During coupling, the reaction mixture was maintained at a 
pH between 6 and 7. This was normally achieved by the addition of a molar equivalent 
of DIEA however, in some cases, further portions of base were necessary. In order to 
monitor the pH of the DMF solution, an aliquot was removed and spotted on 
moistened pH paper. This gave a good indication of the reaction conditions. 
HPLC - Conditions used for the analysis of the majority of side-chain protected 
peptides were identical. The conditions used are described below - 
• Vydac C 18 , 250x4.6mm, 5j.tm. or Aquapore C4, 100x4.6mm, 7.tm. 
• A=H20, B=CH3CN, 0.1%TFA. 
• 2m1 loop, flow rate I ml/min. 
• 0-2min 10%B, 2-32mm 10-90%B. 
• 2=214 and 300nm (determine Fmoc content). 
Preparation of %N-Pro"-Thr' 73-OH (Lys'06-(2-C1-Z)) (26) 
The synthesis was carried out on a 0.125mmol scale using Fmoc-Thr functionalised 
Wang resin (650mg, 0.2mmol/g). The amino acids were all coupled in single cycles 
using the HOCt method and their side-chain functionalities protected as previously 
described with the exception of Lys' 06  where immol of Fmoc-Lys(2-CI-Z)-OH was 
used. The completed Fmoc-peptide-resin (1.65g, 0.047mmolIg) was treated with 20% 
piperidinefDMF/ 1 ,4-dioxan (1:1, 1 OmI) removing the NaF moc  protection before it 
was filtered and washed with DMF, 1 ,4-dioxan, DCM then ether and dried in vacuo. 
The peptide-resin was then stored in 1 ,4-dioxan at 5°C until further use. 
The peptide-resin (200mg) was deprotected and cleaved from the solid support by 
stirring the resin in 95% aq. TFA (lOmi) containing thioanisole (0.5m1), EDT (2m1) 
and phenol (750mg). After 4 hours stirring under nitrogen, the resin was removed by 
filtration and the peptide precipitated by adding dropwise to ice-cold ether. The crude 
precipitate was washed in ether and dried under vacuum before being dissolved in 
10% AcOH and lyophilised (76mg). H 2N-Pro90-Thr' 73-OH was then redissolved in 
10% AcOH (5mg/mi) and incubated overnight with N-methylmercapto-acetamide 
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(M1MA, 5 equivs., 1 .7pi) at 37 °C (26) was then purified by preparative HPLC (ABI 
aquapore RP300 C 8, 250x10mm,, 20.im; 5m1 loop, 8m1/min; 0-2min 10%B, 2-42mm 
10-90%B; ?.=2 1 4nm) R3 I mm, 69%B, 46mg. 
HPLC (Vydac C8) R=21.4min 62%B. m/z (MALDI-TOF) 9,455.68 (MH, 
C420H619N10901 37S 1 C11 requires 9,454.71), 9,481.99 (MNa' 9477.70), 9,499.77 (MK 
9,493.81). Amino acid analysis (30 hours hydrolysis) Ala 5 5.54, Ar92 2.0 1, ASXI3 
11.88, G1y7 6.45, G1x7 6.99, His5 5.36, 11e4 3.86, Leu 1 0 9.89, Lys i 1.12, Met 1 0.89, 
Phe4 4.15, Pr06 6.20, Ser6 4.41, Thrg 6.3 1, Trp 1 N/D, Tyr3 2.89, Va! 1 1.12. 
Preparation of 112N-G1y 79-Thr' 73-OH (28) 
1. 	 )-APro-Gly-OH (27) 
The synthesis was carried out on a 0.25mmol scale using Fmoc-GIy functionalised Cl-
Trity! resin (650mg, 0.4mmol/g). The amino acids were all single coupled using the 
HOCt method with no extended coupling necessary. On completion of the synthesis, 
the Fmoc-peptide-resin (1.05g. 0.29mmol/g) was washed with DMF, 1,4-dioxan, 
DCM then ether. The resin was then stored under vacuum until use. 
(27) (200mg, 0.29mmolIg) was cleaved from the solid support by sonicating the resin 
in AcOH/TFEIDCM (1:1:8, lOmi) at room temperature for 30 minutes. The resin was 
then filtered and washed with the same solvent system as used for coupling before the 
filtrate was concentrated to 3-5m! in vacuo. The crude peptide was then precipitated 
by triturating in ice-cold ether. In order to remove trace AcOH the dried, crude 
product was dissolved in TFE (0.5m1), reprecipitated (H 2O) and washed with copious 
amounts of H20 and finally dried using ether to give the desired peptide as a white 
solid (79mg). 
HPLC 1. Side-chain protection (s.c.p) intact (Vydac C18) R=27.8min, 78.5%B; 2. 
s.c.p removed R=21.8min, 62.5%B. m/z (MALDI-TOF) 1,347.16 (MHtTrt 
1,347.67); (FAB) 1,590 (MT{ C 86H 105N 14 016 requires 1,589.78), 1,348 (MW-Trt). 
Amino acid analysis (24 hours hydrolysis) Ala3 3.14, Asn1 0.88, G1y2 1.85, His, 
0.96, Leu 1 0.98, Pro 1 0.95, Tyr i 0.95, Va! 1 0.99. 
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Coupling of FmocGly 79-G1y89-0H (27) to H 2N-Pro"-Thr' 73-resin 
(27) (37mg, 23.5p.mol) was dissolved in DMF (200pi) and mixed with HOCt (3.7mg, 
23.5p.mol) dissolved in DMF (SOp.!). The solution was then added to H 2N-Pro 90-
Thr173-resin (100mg, 0.047mmol/g, 4.7p.mol) and, after mixing, DIC (3.7p.l, 
23.5p.mol) was added and the mixture was sonicated at room temperature, with 
overnight stirring. DIEA (4.Op.l, 23.5 p.mol) was added to the reaction, dropwise over 
the first 15 minutes of coupling and the pH of the solution was monitored during and 
after addition. The peptide-resin was then filtered and washed with copious amounts 
of DMF, 1,4-dioxan, DCM then ether. 
In order to monitor the coupling progress, Fmoc-peptide-resin (-5mg) was treated 
with 20% piperidinefDMF/1,4-dioxan (1:1, 2m1 - in order to avoid using large 
quantities of peptide-resin, 2m1 of solution was used. Obviously the change in 
quantities was considered when the calculation was made) for 10 minutes. The 
coupling efficiency and resulting resin functionality was calculated as before (see 
section 5.2.3). 
Coupling efficiency (based on Fmoc deprotection) 79%. 
N-Terminal sequencing - estimated 86% coupling. 
Residue 1 2 3 4 5 
Major Gly 12.2pmol / I Leu 15.9pmol / 
Minor Pro 1.4pmol I I Asn3.2pmol / 
Purification of H 2N-G1y 79-Thr' 73-OH (28) 
On completion of coupling, the NuF moc protection was removed and the resin 
(80mg, 0.034mmollg) was treated with Tbfmoc-C1 (section 5.2.5). The peptide was 
then cleaved and deprotected by treating the resin with aq. TFA (95%, 5m1), EDT 
(1 ml) and thioanisole (0.25m1) for 4 hours under nitrogen. The resin was removed by 
filtration and the peptide precipitated from ice-cold ether and dried before the crude 
mixture (40mg) was dissolved in 6M Gdm.HCII1-propanol (1:1, 5ml) and purified 
using Tbflnoc-carbon affinity purification (section 5.2.5, 30mg carbon). On removal 
of the Tbfmoc moiety and charcoal, the supernatant was concentrated in vacuo to 
remove i-propanol and Gdm.HC1 was then removed by dialysis (Mwt.CO 1,000, 
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against H20) and lyophilised before (28) was isolated as a fluffy white solid after 
semi-preparative HPLC (Aquapore Cg, 2500.0mm, 7pm; 2m1 loop, 2m1/min; 0-2mm 
10%B, 2-42mm 10-90%B; A.=214nm) R=24min,, 54%B, (-P3mg). 
HPLC (Aquapore C4) Rt=19.5m4 56%B. mlz (MALDI-TOF) 10,598.8 (M1{ 
C468H690N 1230 1 52S1C11 requires 10,500.44, TFA salt). Amino acid analysis (30 hours 
hydrolysis) Ala8 7.89, Ar92 2.04, Asx 14 12.17, G1y9 9.14, G1x7 7.60, His6 6.19, 11e4 
4.07, Leu 1 1 11.14, Lys i N/A, Met 1 0.86, Phe4 4.31, Pr07 7.23, Ser6 5.83, Thr8 7.32, 
Tyr4 3.05, Va12 2.14. 
Preparation of H2N-G1y 70-Thr' 73-resin 
ly-Asn (Trt) 
(29) 
The synthesis was carried out on a 0.22mmol scale, using Fmoc-Gly functionalised 
CI-Trityl resin (560mg, 0.4mmol/g). On completion, the Fmoc-peptide-resin (200mg, 
0.1 8mmol/g) was treated with AcOHITFEIDCM (1:1:8, 20m1) before the crude (29) 
was precipitated and dried to yield the title peptide as a white solid (97mg). 
HPLC 1. side-chain protection (s.c.p) intact (Aquapore C 4) R=32min, 90%B; 2. s.c.p 
removed (Vydac C 18) R 25.2mm, 71.8%B. mlz 1. s.c.p intact (FAB) 2,998 (MH 
2,996.49), 2,774 (MIHI-Fmoc 2,773.42), 2,755 (MW-Trt 2,753.37), 2,532 (MHI-
Fmoc-Trt 2,530.30). 2. s.c.p removed (FAB) 2,288 (MH 2,287.01), (MALDI-TOF) 
2,288.25 (MW), 2,064.94 (MW-Fmoc 2,064.95). HRMS (FAB) 2,996.49204 (MW 
C 166H201N23030 requires 2,996.49087). Amino acid analysis (24 hours hydrolysis) 
Ala3 2.90, Asx3 3.06, G1y4 4.10, His, 0.97, Leu 1 0.85, Phe2 1.70, Pr03 2.71, Tyr2 1.79, 
Va11 0.98. 
Coupling of FmocGly 70-G1y89-OH (29) to H 2N-Pro90-Th r' 73-resin 
(29) (31.7mg, 11 .5tmo1) was dissolved in DMF (100d) and mixed with HOCt 
(1.8mg, 11 .5.tmol) dissolved in DMF (50tl). The solution was then added to H 2N-
Pro90-Thr' 73-resin (50mg, 0.047mmoIIg, 2.3i.tmol) and, after mixing, DIC (1.8p.l, 
11 .5j.mol) was added. DIEA (1 .9p.l, 11 .5p.mol) was gradually added over the first 15 
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minutes of coupling which was then sonicated at room temperature, stirring the 
reaction overnight. 
Coupling efficiency (based on Fmoc deprotection) 14%. 
N-Terminal sequencing - estimated 17% coupling. 
Residue 1 2 3 4 5 
Major Pro I lie 3.6pmoi Mn Gly 
Minor Gly I PheO.74pmol Tyr Pro 
Preparation of H 2N-Phe504hr' 73-resin 
FmocPheSer(Bu')Arg(PmC)-LeU-TYr(B u')-Glu-(Bu')-Gly-Glu(Bu')-Ala-ASP 
(Trt)-Ala-Tyr (Bu')-Ala-Pro-Gly-OH (30) 
The synthesis was carried out on a 0.11 mmol scale using FmocG1y 70-G1y 9-Cl-Trt-
resin (600mg, 0.18mmolIg). On completion, Fmoc-peptide-resin (380mg, 
0.1 2mmol/g) was treated with AcOH/TFEIDCM (1:1:8, 20m1), precipitated and dried 
to yield the title peptide as a white solid (231mg). 
HPLC (Aquapore C4) R=32min, 90%B. m/z No peaks were observed by either 
MALDI-TOF or FAB. Amino acid analysis (24 hours hydrolysis) Ala 5 4.9, Arg2 
1.32, Asx4 3.5 8, G1u3 2.45, G1y5 5.1, His2 2.05, 11e2 1.46, Leu2 1.72, Met 1 0.6, Phe4 
3.32, Pr03 3.35, Ser2 1. 12, Tyr3 2.60, Va!2 2.09. 
Coupling of FmocPhe50-G1y89-OH (30) to H 2N-Pro90-Thr' 73-resin 
(30) (155mg, 23.5p.mol) was dissolved in DMF (1.0ml) and mixed with HOCt 
(3.7mg, 23.5 jimol) as a solution in DMF (50p.l). The solution was then added to H 2N-
Pro90-Thr' 73-resin (100mg, 0.047mmoIIg, 4.7tmol) and, after mixing, DIC (3.7p.l, 
23.5tmol) was added. At this point, a further 0.5m1 of DMF was added (to dilute 
'gel-like' solution) and, following addition of DIEA (4.0.tl, 23.5.tmol), the mixture 
was sonicated at room temperature, stirring the reaction overnight. 
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N-Terminal sequencing - Phe-Ser-Arg was not observed, hence coupling was deemed 
unsuccessful. 
Preparation of H2N-Asn804hr' 73-resin 
(31) 
The synthesis was carried out on a 0.26mmol scale using Fmoc-Gly functionalised Cl-
Trityl resin (850mg, 0.3mmollg). On completion, Fmoc-peptide-resin (400mg, 
0.18mmoI/g) was treated with AcOHITFEJDCM (1:1:8, lOml) before (31) was 
precipitated from ice-cold ether, reprecipitated (TFE/H 20) and dried to yield the title 
peptide as a white solid (182mg). 
HPLC 1. side-chain protection (s.c.p) intact (Vydac C 1 8) R24min, 68.5%B; 2. s.c.p 
removed R=14.7min, 44%B. m/z I. s.c.p intact (MALDI-TOF) 1,801.16 (MH 
1,775.88, Na salt), 1,816.65 (IC salt); (FAB) 1,775 (MiH), 1,533 
(MITF_Trt 
1,531.75). 2. s.c.p removed (MALDI-TOF) 1,239.99 (MH 1,235.60); (FAB) 1,235 
(MIH). HRMS (FAB) 1,775.87613 (M1H C 103H11 6N13015 requires 1,775.87915). 
Amino acid analysis (24 hours hydrolysis) Ala3 2.89, Asx 1 1.02, Gly i 1.13, His 1 
0.93, Leu 1 1.12, Pro 1 0.99, Tyr i 1.06, Va11 1.02. 
Coupling of FmocAsn80-G1y89-OH (31) to H 2N-Pro"*-Thr' 73-resin 
(31) (41.3mg, 23.3.tmol) was dissolved in DMF (1 50tl) and mixed with HOCt 
(3.6mg, 23.3tmol) as a solution in DMF (50111). The solution was then added to H 2N-
Pro90-Thr' 73  -resin (75mg, 0.062mmolIg, 4.7tmo1), and, after mixing, DIC (3.6p.l, 
23.3mol) was added. DIEA (4.81il, 27.9p.mol) was gradually added over the first 15 
minutes of coupling which was then somcated at room temperature, stirring the 
reaction overnight. 
Coupling efficiency (based on Fmoc deprotection) 73%. 
N-Terminal sequencing - estimated 91% coupling. 
Residue 1 2 3 
Major Mn 610.5 lpmol Val 887.88pmol Leu 570.72pmol 
Minor Pro 66.56pmol Gly 95.82pmoi lie 39.34pmoi 
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Preparation of H2N-Asp 71-Thr' 73-resin 
1. FmocAsp(Bu')-Phe-Tyr(B u')-Pro-Phe-Asp(Bu')-Gly-PrO-GIY-OH (32) 
Initial attempts to synthesise FmocAsp 71 -G1y79-OH failed, with a large drop in the 
coupling efficiency (70%) observed between Gly 77 and Pr0 78 . This has been observed 
in the synthesis of other peptides with Pro-Gly-OH situated at the C-terminus. It is 
postulated that, on removal of the Fmoc-Pro 78  N'-protection, the resulting amine 
attacks the C-terminal carboxyl and releases the dipeptide from the solid support. In 
order to avoid this diketopiperazine formation from occurring, G1y 77-Pro 78 was 
separately prepared and coupled as the dipeptide to G1y 79-resin. 
FmocGly77-Pro 78-OH (350mg, 0.89mmol) and HOCt (139.7mg, 0.89mmol) was 
dissolved in DMF (2m1) before DIC (140p.l, 0.89mmol) was added. Following 15 
minutes sonication, the solution was added to Gly-Ci-Trityl-resin (850mg, 
0.59mmolIg, 0.5mmol), mixed, and DIEA added dropwise (154tl, 0.89mmol). The 
mixture was then somcated for 3 hours and the coupling efficiency measured using the 
Fmoc UV method (89% coupling, resin functionality 0.41mmol/g). The resin was then 
capped (section 5.2.4.1) and washed with DMF, 1,4-dioxan and DCM before being 
transferred to the reaction vessel ready for the coupling of the remaining amino acids. 
On completion of the synthesis, Fmoc-peptide-resin (1.1g, 0.25mmoIIg) was treated 
with AcOHJTFE/DCM (1:1:8, 20m1) for 30 minutes before (32) was precipitated 
from ether, reprecipitated (TFEIH 20) and dried to yield the title peptide as a white 
solid (387mg). 
HPLC 1. side-chain protection (s.c.p) intact (Vydac C 1 8) R21.7min, 62.5%B; 2. 
s.c.p removed Rt16.8nlin, 49%B. m/z 1. s.c.p intact (FAB) 1,405 (MIH 
C76H94N9017 requires 1,404.68), 1,389 (MI{ 1 -H20 1,386.67), 1,354 (M1{-Bu 
1,347.61), 1,297 (MHt2Bu' 1,290.54). 2. s.c.p removed (FAB) 1,250 (Mil 
1,236.49). Amino acid analysis (24 hours hydrolysis) Asx2 2.03, G1y2 1.09, Phe2 
2.00, Pr02 1.06, Tyr i 1.10. 
2. Coupling of FmocAsp 71-G1y 79-OH (32) to 11 2N-Asn80-Thr' 73-resin 
(32) (70.7mg, 50.4tmo1) was dissolved in DMF (600.t1) and mixed with HOCt 
(7.9mg, 50.4.tmol) dissolved in DMF (100.tl). The solution was then added to H 2N- 
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Asn80-Thr' 73-resin (400mg, 0.042jimoIlg, 16.8jtmo1) and, after mixing, DIC (7.9.d, 
50.4tmo1) was added. DIEA (8.6j.tl, 50mo1) was gradually added over the first 15 
minutes of coupling, monitoring the pH throughout, and the coupling mixture was 
then sonicated at room temperature, stirring the reaction overnight. 
Coupling efficiency (based on Fmoc deprotection) 77%. 
N-Terminal sequencing - estimated 72% coupling. 
Residue 1 2 3 
Major Asp 151.03pmol Phe 119.86pmol Tyr 75.18pmol 
Minor Mn 51.44pmol Val 41.41pmol Leu 37.14pmol 
Preparation of H2N-Va1664hr' 73-resin 
FmocVal-Arg(Pmc)-Glu(Bu')-His(Trt)-Gly-OH (33) 
The synthesis was carried out on a 0.32mmol scale, using Fmoc-Gly functionalised 
CI-Trityl resin (700mg, 0.46mmoI/g). On completion, Fmoc-peptide-resin (500mg, 
0.21 mmol/g) was treated with AcOWTFE/DCM (1:1:8, 1 Oml) before the crude 
peptide was precipitated from ether, reprecipitated and dried using ether to yield the 
title peptide as a white solid (2 17mg). 
HPLC 1. side-chain protection (s.c.p) intact (Vydac C 18) R=22min, 63.5%B; 2. s.c.p 
removed R1 1mm, 34%B. m/z 1. s.c.p intact (MALDI-TOF) 1,386.2 (MW 
1,384.65), 1,139.59 (MHtTrt 1,140.53); (FAB) 1,385 (MET), 1,142 (MH-Trt), 
1,118 (MH-Pmc 1,117.55), 876 (MW-Pmc-Trt 877.46). 2. s.c.p removed (MALDI-
TOF) 817.88 (MET 819.38); (FAB) 819 (MET). HRMS (FAB) 1,384.64986 (NEW 
C76H93N 100 13 S 1 requires 1,384.65214). Amino acid analysis (24 hours hydrolysis) 
Arg 1 0.82, Glx 1 1. 11, G1y 1 1. 19, His s 0.87, Val, 0.95. 
Coupling of FmocVal66-G1y 70-OH (33) to H 2H-Asp 71-Thr' 73-OH 
(33) (12mg, 8.7tmol) was dissolved in DMF (100p.1) and mixed with HOCt (1.37mg, 
8.7p.mol) dissolved in DMF (20p.l). The solution was then added to H 2N-Asp 71 - 
Thr' 73-resin (50mg, 0.035mmol/g, 1.75p.mol) and, after mixing, DIC (1.4p.l, 8.7p.mol) 
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was added. DIEA (1.541, 8.74mo1) was the added to the coupling mixture which was 
then sonicated at room temperature, stirring the reaction overnight. 
Coupling efficiency (based on Fmoc deprotection) 73%. 
N-Terminal sequencing - estimated 93% coupling. 
Residue 1 2 3 
Major Val 638.7lpmol Arg 122.78pmol Glu 171.5 lpmol 
Minor Asp 17.53pmol Phe 20.33pmol Tyr 9.74pmol 
Preparation of H2N-Phe64-Thr' 73-resin 
1.FmocPhe-Ala-Val-Arg(Pmc)-Glu(Bu')-His(Trt)-Gly-OH (34) 
The synthesis was carried out on a 0.3mmol scale, using Fmoc-Gly functionalised Cl-
Trityl-resin (594mg, 0.52mmoI/g). On completion., Fmoc-peptide-resin (820mg, 
0.1 6mmol/g) was treated with AcOH/TFEIDCM (1:1:8, 20m1) before (34) was 
precipitated from ether, reprecipitated (TFE/H20) and dried to yield the title peptide 
as a white solid (3 75mg). 
HPLC 1. side-chain protection (s.c.p) intact (Vydac C 18) R=22.5%, 65%B; 2. s.c.p 
removed R 1 4mm, 42%B. m/z 1. s.c.p intact (MALDI-TOF) 1,621.85 (MJ{+H 20 
1,620.77), 1,354.71 (MW-Trt 1,359.64), 1,335.52 (MHtPmc 1,335.66); (FAB) 
1,603 (MiH), 1,361 (MH-Trt), 1,336 (MiH-Pmc), 1,094 (MHtPmcTrt 1,092.54). 
2. s.c.p removed (MALDI-TOF) 1,037.8 (MH 4 1,037.48); (FAB) 1,038 
HRMS (FAB) 1,602.75433 (ME44 C88H106N 1 2015S1 requires 1,602.76213). Amino 
acid analysis (24 hours hydrolysis) Ala 1 1.08, Arg i N/D, G1x 1 1.20, Glyi 1.16, His1 
0.83, Phe 1 0.93, Va1 1 0.99. 
2. Coupling of FmocPhe-Gly 70-0H (34) to H 2N-Asp 71-Thr' 73-resin 
(34) (14mg, 8.7tmol) was dissolved in DMF (lOOp.l) and mixed with HOCt (1.36mg, 
8.7imol) dissolved in DMF (20p.l). The solution was then added to H 2N-Asp 71 -
Thr' 73-resin (50mg, 0.035mmoI/g, 1.7j.xmol) and, after mixing, DIC (1.4i.tl, 8.7.tmol) 
was added. DIEA (1 .Spi, 8.7p.mol) was then added and the coupling mixture was 
sonicated at room temperature, stirring the reaction overnight. 
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Coupling efficiency (based on Fmoc deprotection) 35%. 
N-Terminal sequencing - estimated 66% coupling. 
Residue 1 2 3 
Major Phe 38.32pmol Ala 25.65pmol Val 15.5 8pmol 
Minor Asp 17.56pmol Phe 15.96pmol Tyr 7.7lpmol 
Preparation of %N-11e 62-Thr' 73-resin 
Fmoclle-Ser(Bu')-Phe-Ala-OH (35) 
The synthesis was carried out on a 0.36mmol scale, using Fmoc-Ala functionalised Cl-
Trityl resin (850mg, 0.42mmol/g). On completion, Fmoc-peptide-resin (1.08g) was 
treated with AcOH/TFEIDCM (1:1:8, 20m1), precipitated from ether, reprecipitated 
(TFE/1-120) and dried to yield the title peptide as a white solid (265mg). 
HPLC 1. side-chain protection (s.c.p) intact (Vydac C 8, 250x4.6mm, 5tm; imi/min, 
2m1 loop; 0-2min 10%B, 2-32mm 10-90%B; ?214&300nm) R25.5min, 72.5%B; 
s.c.p removed R=18.5min, 53.5%. m/z 1. s.c.p intact (FAB) 715 (MR 715.37), 
493 (NEW-Fmoc 492.29), 437 (MHtBu' -Fmoc 435.22) . 2. s.c.p removed (MALDI-
TOF) 659.97 (MH4 659.31); (FAB) 659 (Mu 4 ). HRMS (FAB) 715.37025 (MH 
C40H51 N408 requires 715.37069). Amino acid analysis (8 hours hydrolysis) Ala 1 
10, Ile i 0.30, Phe1 1.00, Seri 0.80. 
Coupling of FmodHe62-A1a65-OH (35) to H 2N-Val"6-Th r' 73-resin 
(35) (7.5mg, 10.5J.Lmol) was dissolved in DMF (lOOj.tl) and mixed with HOCt 
(1.65mg, 10.5mo1) dissolved in DMF (50.l). The solution was then added to H 2N-
Va166-Thr' 73-resin (50mg, 0.021mmoIIg, 1.05.tmol) and, after mixing DIC (1.7.tl, 
10.54mol) was added. DIEA (1.8p.l, 10.5.tmo1) was then added and the coupling 
mixture was somcated at 0 °C. 
Coupling efficiency (based on Fmoc deprotection) 93%. 
N-Terminal sequencing - estimated 89%. 
Residue 1 2 3 
Major Ile 124.95pmol Ser 82.12pmor Phe 87.03pmol 
Minor Val 36.04pmol Arg 2.90pmol Glu 6.95pmol 
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5.5 Convergent Synthesis of SCD - Azide Condensation 
Notes 
HPLC - Conditons employed for the analysis of the peptide purifications and 
couplings are described below - 
• Vydac Cs, 250x4.6mm, 5p.m. 
• A=H20, B=CH3CN, 0.1%TFA. 
• 2m1 loop, 1 ml/min. 
• 0-2min 10%B, 2-32mm 10-90%B. 
• ?.=214 and 300nm (determine Fmoc content). 
Preparation of C-terminal hydrazide - The C-terminal hydrazide functionality 
was incorporated into the peptide using the versatile dibenzocycloheptadiene linker 
(section 5.6.2). Modification of the linker is described below: 
Dibenzo La,dI 	 resin 
(41) 
t-Butyloxycarbonyl carbonate (800mg, 6.06mmol), dissolved in DCM (75m1), was 
added to dibenzo[a, resin (750mg, 
1 .23mmol/g, 0.92mmol). Following addition of benzenesullonic acid (15 5mg, 
0.97mmol), the reaction was refluxed, while stirring under nitrogen, for 24 hours. The 
resin was then filtered, washed using DCM, DMF, DCM then ether and dried in 
vacuo (1.02g). 
IR : (KBr disc) v= 3419 (NH), 3100-2950 (CH arom.), 2900-2750 (CH2), 1736 
(C=0, amide), 1602, 1493cm 1 (CC). 
Dibenzo [a,dJ cycloheptad ien-5-Fmoc-G ly-hyd razide-(2-oxy-methylpolyStyrefle) 
resin (42) 
To a solution of Fmoc-Gly-OH (2.17g, 7.3mmol), dissolved in DCM (75m!), was 
added freshly distilled thionyl chloride (5m!, 73mmol) and DMF (500p.l). The mixture 
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was stirred at room temperature until a clear solution was obtained (--30-60 minutes, 
indicating complete dissolution of all reactants) before the excess thionyl chloride was 
removed in vacuo. In order to remove trace quantities of SOC1 2, the resulting residue 
was washed in twice in DCM (30m1), the solvent in each case was removed in vacuo. 
The residue was then dissolved in DCM (lOmi), added to (41) (1g. 0.92mmol), 
previously swollen in DCM (50m1) and pyridine (2.6m1), and the mixture stirred at 
room temperature for 1 hour under nitrogen. The resin was then filtered and washed 
using copious amounts of DCM, DMF, DCM then ether and dried in vacuo (1.46g, 
estimated functionality 0.61mmoI/g). 
IR: (KBr disc) v= 3420-3270 (NH), 3100-2950 (CH arom.), 2900-2750 (CH2), 
1720 (C=O, amide), 1685 (CO 3 ester), 1602, 1502, 1449cm' (CC). 
Attempted preparation of H 2N-Trp42-Thr' 73-OH (azide coupling) 
Preparation of H2N-Pro90-Thr' 73-0H (Lys 
106_(2-CI-Z)) (26) 
The synthesis, purification and characterisation for (26) is described in section 5.4. 
Fmoc Trp42-G1y89-NHNH2 (43) 
The synthesis was carried out on a 0.25mmol scale using Fmoc-Gly functionalised 
hydrazide resin (42) (450mg, 0.61mmoI/g). All amino acids were coupled in single 
cycles via the corresponding HBTU activated esters with the side-chain functionalities 
protected as previously described. On completion, the resin (930mg) was washed 
using DMF, DCM then ether. Fmoc-peptide-resin was then stored in 1 ,4-dioxan at 
5°C until further use. 
(43) (490mg) was deprotected and cleaved from the solid support by stirring the resin 
in 95%aq. TFA (lOml) containing thioanisole (0.5m1) and EDT (0.5m1) for 3 hours 
under nitrogen. The resin was then removed by filtration and the peptide precipitated 
by adding to ice-cold ether. The crude peptide was then washed in ether, dried, 
dissolved in 10% AcOH and lyophilised to yield the title peptide as a fluffy white solid 
(290mg). (43) was then isolated using preparative HPLC (ABI Aquapore C 18 , 
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250xlOmm, 20.tm; 5m1 loop, 8m1/min; 0-2min 30%B, 2-32mm 30-80%B; 
?=2 1 4&300nm) R=24.8min, 68%B, 32.5mg. 
HPLC (Vydac C 8) R4=22.5min,, 64.7%B. m/z (MALDI-TOF) 5,606.07 (MH' 
C263H365N62074S1 requires 5,607.64). Amino acid analysis (30 hours hydrolysis) Ala 5 
4.86, Ar92 2.07, Asx4 4.20, G1x5 4.93, G1y5 5.14, His2 2.39, 11e2 1.81, Leu3 3.00, Met 1 
0.3, Phe4 3.84, Pr04 4.47, Ser2  1.97, Thr2 1.83, Trp 1 NID, Tyr3 1.44, Va!3 2.72. 
3. Coupling of FmocTrp42-G1y89-NHNH2 (43) and H 2N-Pro90-Thr' 73-OH (26) 
Azide formation - (43) (5mg, 0.89mol), dissolved in DMF (100 PI), was cooled to 
-20°C in an acetone/thy-ice bath. 4M HC1 in 1 ,4-dioxan (0.62p.l, 2.67p.mol - 6.il of 
4M HC1 was diluted to 100.d using 1 ,4-dioxan, 1 0.t1 of this was used) was then 
added and the solution was warmed to -15°C. t-Butyl nitrite (0.15p.l, 0.89tmo1 - 15p1 
of t-Bu'-ONO diluted to 1 ml DMF, 1 0.tl used) was then introduced, the temperature 
was raised to -10 °C and left stirring for 10 minutes, allowing the formation of the 
azide. HPLC analysis was used to confirm that complete conversion had occurred. 
HPLC (Vydac C 8) R=22.9min, 65.7%B (azide). 
Coupling - Following formation of the azide, (26) (5mg, 0.52mol), dissolved in 
DMF (lOOj.il) and cooled to -10 °C, was carefully added dropwise to the azide 
solution. A stock solution of DIEA (15.d in imi DMF) was prepared from which SpJ 
was added to the reaction every 30 minutes over the first 3 hours (2.67p.mol of DIEA 
added). A second portion of azide and base (2.5mg hydrazide was converted using the 
above conditions) were added after 3 hours, using the same procedure, and the 
temperature of the reaction was maintained at 0 °C overnight. After 24 hours coupling, 
a third portion of azide and base (2.5mg hydrazide, 1 .3j.trnol DIEA) were added and 
the mixture was incubated at 0 °C for a further 24 hours before the coupling mixture 
was analysed. 
5. Experimental 
5.6 Chemical Ligation 
Notes 
1. HPLC - analysis of all the peptides in this section employed a C 18 column with one 
of 3 gradient systems - 
• Vydac C18, 250x4.6mm, 5p.m. 
• A=1120, B=CH3CN, 0.1%TFA. 
• 2m1 loop, flow rate 1 ml/min, ?2 1 4nm. 
1. 0-10mm 10%B, 10-40mm 10-90%B. 
2. 0-5min 10%B, 5-35mm 10-90%B. 
3. 0-2min O%B, 2-32mm 0-60%B, 32-34mm 60-90%B. 
2. General procedure for the bromo/iodoacetylation of peptides 5 
Preparation of anhydride - Bromo/iodoacetic acid (2mmol) in DCM (5m1), treated 
with DIC (1 mmol), was stirred for 15 minutes at room temperature. During this time 
a white precipitate formed (NN-diisopropyl urea) which was removed before the 
filtrate was evaporated to approximately 2m1 by bubbling the solution with nitrogen 
gas. The volume was then adjusted to 6m1 using DIvIF before the remaining DCM was 
removed. 
Acetylation - To a solution of peptide-resin (Fmoc removed) in ME (5m1) was 
added the freshly prepared solution containing bromo/iodoacetic anhydride (immol). 
The mixture was then sonicated for 1 hour at room temperature before the resin was 
filtered and washed with copious amounts of DMF, DCM then ether and dried in 
vacuo. 
Ninhydrin Assay - In order to confirm that the acetylation was 100% complete, a 
sample of resin was assayed for the presence of free amines. 
To 1mg of resin bound peptide was added - 
Phenol/aqueous ethanol 76% w/w (75tl). 
0.0002M potassium cyanide/pyridine (lOOp.!). 
0.28M nmnhydrin/ethanol (75 p.!). 
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This mixture was then heated for 5 minutes (100-105 °C). Blue colouration indicated 
the presence of free amines. 
3. C-terminal modified peptides - All peptides prepared containing the C-terminal 
thiol functionality were synthesised using the modified dibenzocycloheptadiene linker, 
the synthesis of which is described below: 
S- [2(TriphenylmethYl)thiOl ethyla mine (65)6 
2-Mercaptoethylamifle hydrochloride (5g, 44mmol) and triphenylmethanol (11 .5g, 
44.5mmol) were stirred in TFA (40m1) at room temperature for 30 minutes before 
the mixture was evaporated to a brown oil. Trituration of the oil with ether (250m1) 
gave the trifluoracetic salt as a white precipitate that was filtered and washed with 
ether. The washing were cooled to give a second crop. The salt was then separated 
between NaOH (1M, 250m1) and ether (250m1). Evaporation of the organic layer in 
vacuo followed by recrystallisation (ether/hexane) yielded the product as a white solid 
(8.35g, 26.15mmol, 59%). 
TLC Rf 0.56-0.70 (n-butanol/AcOH/H20, 3:1:1). m/z (FAB) 320 (MW 320.15). 
HRMS (FAB) 320.14647 (C 21 1122N 1 S1 requires 320.14730). MP 94-96°C (lit6 93-
94°C). 'II NMR (CDC13, 200MHz): 6 1.31 (s, 2H, N}), 2.31 (t, 211, J=6.4Hz, 
CS), 2.58 (t, 211, J=5.7Hz, NH2C), 7.15-7.5 (in, 15H, arom.). IR: v.,,= 3305 
(NH), 3055-3000 (CH, arom.), 2970-2850 (CH 2), 1488, 1443cm' (CH). 
SE2(FriphenyImethy1)thiO1NflU0renY1methoYcarb0nYlethYamme (66) 
A solution of (65) (3g, 9.39mmol) in triethylamine (80ml) was cooled in an ice bath 
before the addition of Fmoc-OSu (3g, 9.3mmol) in 1 ,4-dioxan (80m1). The reaction 
mixture was stirred for 2 hours at 0 °C then overnight at room temperature after which 
time any precipitate present was removed before the solution was concentrated in 
vacuo. The resulting yellow oil was then dissolved in DCM (lSOml), washed with 
1120 (2x50m1) and dried (MgSO 4) before solvent was removed to yield the required 
compound as a yellow oil which was used without any further purification. 
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TLC Rf 0.68-0.75 (DCMIMeOH, 95:0.5). m/z (FAB) 564 (MFV 542.22, Na salt). 
HRMS (FAB) 542.21468 (C 36H32N,02S1 requires 542.21538). 'H NMR (CDC13 , 
200MHz): 6 2.41 (t, 2H, J=6.5Hz, C1S), 3.01 (dd, 211, J12.4 and 6.2Hz, NHCH2), 
4.20 (t, 111, J='6.8Hz, CH), 4.35 (d, 211, J=6.7Hz, Cj), 4.80 (t, 1H, J=5.7Hz, NH), 
7.16-7.35 (m, 1511, Trt arom. CH), 7.35-7.77 (m., 8H, Fmoc arom. CH). IR: Vmax 
3431, 3337 (NH), 3050-3000 (CH, arom.), 2950-2820 (CH 2), 1715 (C0), 1509 
(C=C), 1244,1 142cm' (C-O). 
NF1uoreny1methoxyCarbOflY1am1n0ethYt -2th0I (62) 
Crude (66) (3g, 5.53mmol) was added to a solution containing TFAIH20 (9:1, 20m1) 
and TIPS (2.26m1, 11 .O8mmol) and the reaction mixture was stirred at room 
temperature for 1 hour. The white precipitate formed was removed and the filtrate 
concentrated in vacuo. The resulting yellow oil was dissolved in ether (lOOmi), 
washed (H20, 2xlOOml), the organic layer dried (MgSO4) and concentrated in vacuo 
to yield the crude product. The product was then purified by wet flash 
chromatography eluting with 2% MeOH in DCM (680mg, 2.23mmol, 40%). 
TLC Rf 0.55-0.66 (DCM/MeOH, 9.5:0.5). m/z (FAB) 300 (MI{ 300.11). HRMS 
(FAB) 300.10618 (C 17H 18N,02S1 requires 300.10583). 'II NMR (CDC13, 200MHz): 
6 2.64 (dd, 211, J=14.5 and 6.6Hz, C1S), 3.35 (dd, 2H, J12.5 and 6.5Hz, NHCFI2), 
4.21 (t, 111, J=6.7Hz, CH), 4.44 (d, 2H, J=6.7Hz, Crn), 5.24 (b, 1H, Nil), 7.25-7.7 
(m, 8H, Fmoc arom. CH). IR: v= 3430, 3348 (NH), 2941 (CH), 1707 (C0), 1513 
(CC), 1249, 1144cm' (C-O). 
Dibenzo[ad] cyc1oheptadiene5one-(2-OXY_IIIethYlP0lY5tYre) resin (69) 
To a solution containing 2-hydroxydibenzo[a, d] cycloheptadien-5 -one (2.0g, 
8.92mmol), dissolved in t-butanol/H20 (1:1, 80m1), was added caesium hydroxide 
(1.5g, 8.8mmol). After stirring for 10 minutes, t-butanol was removed in vacuo. The 
caesium salt was dried by azeotropic distillation using pyridine (2x80m1) followed by 
DMF (2x80m1). The salt was then dissolved in DMF (30m1) and added to 
chloromethylpolystyrene resin (CMP) (1.5g, 1 .6mmol/g, 2.4mmol) previously swollen 
in DMF (20m1). The reaction mixture was stirred mechanically under nitrogen at 60 °C 
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for 4 days. After this time, the resin was filtered off, washed with copious amounts of 
DMF, i-propanol, H20, DMF and finally i-propanol and dried in vacuo to yield (69) 
as an off-white solid (1.95g. 100%). 
IR: (KBr disc) v= 3100-3000 (CH, arom.), 3000-2850 (CH 2), 1635 (C0), 1603, 
1582, 1492 (C=C), 1445cm' (CH 2). Cl analysis - found less than 0.55%Cl (CMIP 
4.2%). est. functionality 1.108mmoI/g. 
Dibenzola, dj cycloheptadien5_ol(2_OXY_met11YlP0lY5tYre11e) resin (61) 
Linker-resin (69) (0.5g, 1.108mmol/g, 0.55mmol) was added to dry THY (30m1) 
along with LiBEL (100mg, 5.58mmoI) and the mixture was heated, while stirring, at 
reflux under nitrogen for 1 hour. The resin was then filtered, washed with TI{F, 
MeOH, H20, MeOH and ether and dried in vacuo to yield (61) as white solid (0.48g). 
IR: (KBr disc) v' 3566, 3404 (OH), 3100-2980 (CH, arom), 2980-2840 (CH2), 
1602, 1581, 1491 (C=C), 1445cm' (CH 2). 
Dibenzo[a,dcycloheptadiefl-5-(FmOC-amifl0ethYl2 -thio)-(2-oxymethyl- 
polystyrene) resin (63) 
Benzenesulfonic acid (78mg, 0.49mmol) was added to (62) (ig, 3.34mmol) along 
with (61) (0.45g, 1.108mmolIg, 0.49mmol) previously swollen in DCM (25m1) and 
the reaction mixture was stirred for 1 hour, at room temperature, under an 
atmosphere of nitrogen. The resin was then filtered and washed with DCM and ether 
and dried in vacuo yielding (63) as a pale yellow solid (0.63g, estimated functionality 
0.77mmoIIg). 
IR: (KBr disc) v= 3412, 3333 (NH), 3075-2980 (CH, arom.), 2980-2840 (CH 2), 
1703 (C=O), 1602, 1488 (C=C), 1446cm' (CH2). 
H2NGly-Phe-Ala-NH-(CH2)2-SH (70) 
The peptide was synthesised using the thiol derivatised cycloheptadiene linker (63) 
(300mg, 0.89mmoIIg, 0.27mmol). This peptide was synthesised manually using the 
nitrogen bubbler apparatus, however the sequence of events did not differ from 
peptides synthesised on the machine. Each amino acid was coupled via the activated 
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HOBt ester (coupling time 1.5 hours) and the coupling efficiency was monitored 
using Fmoc UV analysis (section 5.2.3). On completion of the synthesis, the peptide 
was deprotected and cleaved from the solid support by stirring the resin in 95%aq. 
TFA (lOmi) containing thioanisole (0.5m1) for 1 hour. On removal of the resin by 
filtration, ether precipitation yielded the crude peptide as a white solid. 
HPLC (gradient system 3) R 4=13.5min, 23%B; R=23.5min, 43%B (dimer). m/z 
(MALDI-TOF) 353.72 (Iv1H 353.16). HRMS (FAB) 353.16367 (MW C 16H25N403 
requires 353.16474). Amino acid analysis (8 hours hydrolysis) Ala i 1.04, Glyi 1.04, 
Phe 1 0.92. 
Preparation of H 2NThr'AspGlu-Thr-Leu-HiS-LeU-Val-N11-(CH2)rS 
CH2 COLeu-Arg-Leu-Arg-GIy-G1Y' 6-OH (74) 
TbfmocTh r'-Asp-Glu-Th r-Leu-His-Leu-Va1 8-NH-(CH2)2-SH (73) 
The synthesis was carried out on a 0.25mmol scale using thiol derived resin (63) 
(320mg, 0.78mmol/g). The amino acids were all coupled in single cycles using HOBt 
activated esters. On completion, Fmoc-peptide-resin (573mg, 0.32mmol/g) was 
washed with DMF then DCM before the NaF moc  protection was removed (20% 
piperidine) and the resin treated with Tbfmoc-Cl (section 5.2.5). The peptide was then 
deprotected and cleaved from the solid support by stirring resin (200mg) in 95%aq. 
TFA (5m1) containing thioanisole (0.25ml) and EDT (0.25m1) for 1 hour. On ether 
precipitation, the crude peptide was yielded as a white solid (84mg). 
HPLC (gradient system 1) R=38.5min, 86%B. m/z (MALDI-TOF) 1,411.7 (MW 
1,408.63); (FAB) 1,410 (MIfl. HRMS (FAB) 1,408.62776 (MH C 73H90N 11 016S1 
requires 1,408.62877). Amino acid analysis (24 hours hydrolysis) Aspi 1.10, G1u 
1.02, His 1 1.01, Leu2 2.18, Thr2 1.93, Va1 1 0.96. 
BrCH 2-CO-Leu"-Arg-Leu-Arg-GlY-GlY' 6MH (72) 
The synthesis was carried out on a 0.3 immol scale using Fmoc-Gly functionalised 
Wang resin (500mg, 0.63mmol/g). The peptide was assembled on the solid support 
using HOBt activated amino acids (single coupling). On completion of the synthesis, 
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NaFmoc protection was removed (20% piperidine) and the peptide was 
bromoacetylated (section 5.6.2). A sample of the peptide-resin (200mg) was cleaved 
and deprotected by stirring the resin in 95%aq. TFA (5m1) containing anisole (0.25m1) 
for 1 hour. The resin was then removed by filtration, the crude peptide precipitated 
using ether and dried in vacuo (78mg). 
HPLC (gradient system 1) R=23.2niin, 45.2%B. m/z (MALDI-TOF) 792.3 (MW 
C30H56N 12O8Br1 requires 791.35). Prior to bromoacetylation (FAB) 671 (MW 
671.43). HRMS (FAB) 671.43166 (MITe C28H55N1207 requires 671.43167). Amino 
acid analysis (20 hours hydrolysis) Ar92 2.18, G1y2 2.01, Leu 2 2.10. 
3. Ligation of TbfmocThr'-Va1 8-SH (73) and Br-Leu 1 '-Gly 16-0H (72) 
ThfmocThr'-Va18-SH (10mg) was dissolved in TFE (2m1) before 6M Gdm.HC1 (2m1), 
buffered at pH 7.0 (0. 1M sodium phosphate), was added. To this solution was added 
Br-Leu"-Gly' 6-OH (10mg), previously dissolved in TFE/6M Gdm.HC1 pH 7.0 (1:1. 
2m1). The ligation mixture was then sonicated overnight at room temperature under 
nitrogen. The progress of the ligation was monitored throughout using HPLC 
analysis. On completion, the ligation product was isolated as a flufl,' white solid after 
semi-preparative HPLC (Aquapore C8, 2500.0mm4 7pm; 5m1 loop, 2m1/min; 0-5mm 
10%B, 5-10nth 10-30%B, 10-30mm 	30-60%B, 30-32mm 	60-90%B; 
?.=214&365nm), R25.4min, 53%B, 8.3mg. 
HPLC (gradient system 1) R=34.6min, 75.6%B. mlz (MALDI-TOF) 2,121.3 (MH 
C 103 H 145N23024 S1 requires 2,120.06). Amino acid analysis (40 hours hydrolysis) 
Ar92 2.46, Asp, 1.03, G1u 1 1.03, G1y2 2.09, His, 1.02, Leu 4 3.71, Thr2 1.94, Va1 1 
0.91. 
Tbfmoc removal - Tbfmoc-peptide (6mg), dissolved in 6M Gdm.HCl/i-propanol 
(1:1, 2m1), was mixed with piperidine (0.2m1) and sonicated for 15 minutes before the 
mixture was neutralised using AcOH. The product was then isolated using semi-
preparative HPLC (same column as above, 0-5min 10%B, 5-35mm 10-60%B, 35-
37mm 60-90%B) R15.8min, 29%B, —3mg. 
m/z (MALDI-TOF) 1,701.9 (MW C72H 128N23022S1 requires 1,698.93). 
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Nucleophilic substitution of (72) and (75) 
The preparation of the bromo (72) and iodoacetylated (75) peptides were identical, 
refer to the synthesis of Br-Leu"-Gly' 6-OH (72) for experimental details. Following 
deprotection and cleavage from the solid support, both peptides (10mg) were 
separately dissolved in 6M Gdm.HC1, 0.1 M sodium phosphate pH 7/TFE (1:1, 2m1), 
before aminoethanethiol (10mg, 88.02jtmol) was added to each solution. The 
coupling progress was then monitored using HPLC analysis. 
HPLC (gradient system 2) R20.2 mm, 50.5%B (peptides (72) and (75)), 
R=19.1min, 47%B (peptide (76)). 
Preparation of H2N-GIu'-AIa-GIu-Asp-Leu-GIn-VaI-GlY-GIfl-Val-GlU- 
AIa-Leu-Glu-GIy-Ser-Leu-G1n31-OH (80) 
1. TbfmocGlu hALa Glu*Asp*Leu *Gln  * Val-Gly-Gin *Val..Glu ..Leu'2..NH.. 
(CH2)2-SH (78) 
The synthesis was carried out on a 0.25mmol scale using thiol derived resin (63) 
(320mg, 0.79mmoIIg). All amino acids were coupled via the HOCt activated ester 
employing double coupling cycles where indicated (*). On completion, Fmoc-peptide-
resin (593mg, 0.26mmoIIg) was washed before the NaF moc  protection was removed 
(20% piperidine) and the resin treated with Tbfmoc-Cl (section 5.2.5). The peptide 
was then deprotected and cleaved from the solid support by treating the resin 
(150mg) with 95% aq. TFA (5m1) containing thioanisole (0.25ml) and EDT (0.25m1), 
stirring the solution for 2 hours. On precipitation, the crude peptide was yielded as a 
white solid (64mg). 
HPLC (gradient system 2) R=32min, 82%B. mlz (FAB) 1,812 (MIH 
C89H117N 15 024 S1 requires 1,811.81). Amino acid analysis (20 hours hydrolysis) Ala 1 




Ser-Leu-G1n 31-OH (79) 
The synthesis was carried out on a 0.25mmol scale using Fmoc-Gln functionalised 
Wang resin (500mg, 0.52mmoIlg). All amino acids were coupled via the HOCt 
activated ester employing double coupling cycles (except Gly - single coupling). On 
completion, Fmoc-peptide-resin (785mg, 0.1 8mmol/g) was washed before the N"-
Fmoc protection was removed (20% piperidine) and the peptide iodoacetylated 
(section 5.6.2). A sample of resin (150mg) was then cleaved and deprotected using 
95%aq. TFA (5m1) containing anisole (0.5m1), stirring the mixture for 2 hours before 
the filtrate was isolated and the crude peptide precipitated using ice-cold ether 
(57mg). 
HPLC (gradient system 2) R=20.4min, 51%B. m/z (MALDI-TOF) 1,760.33 (MH' 
C71 H117N 1 902511 requires 1,762.75). Amino acid analysis (28 hours hydrolysis) Ala2 
1.85, G1x3 2.93, G1y4 4.24, Leu4 4.07, Pr02 2.31, Ser2 1.91. 
Ligation of TbfmocGlu'-Leu' 2-SH (78) and I-Gly' 5-G1n31-OH (79) 
TbffiiocGlu'-Leu12-SH (60mg), dissolved in TFE (4m1), was added to 6M Gdm.HC1 
buffered at pH 7.5 (4m1, 03M sodium phosphate). After mixing, I-Gly' 5-G1y31 -OH 
(30mg) was added and the ligation solution was sonicated in an atmosphere of 
nitrogen overnight. The progress of the ligation was monitored throughout using 
HPLC analysis. 
HPLC (gradient system 2) R=29.2, 74.5%B. m/z (MALDI-TOF) 3,478.4 (MIEr 
C i 60H233N34O49 S1 requires 3,446.65). 
Tbfmoc purification: 1. Adsorption - On completion, PGC (200mg) was added to 
ligation mixture. The solution was then stirred, monitoring the adsorption using 
HPLC (X=365nm). Once all of the Tbfmoc was adsorbed, the mixture was centrifuged 
and the supernatant removed. 
2. Wash (2 times) - PGC was washed using i-propanoll6M Gdm.HC1 (1:1, 1 Omi). 
After mixing, the solution was centrifuged and the supernatant removed. 
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3. Tbfmoc removal - 10% piperidine in i-propanol/6M Gdm.HC1 (1:1, lOmI) was 
added to the carbon and mixed vigorously for 15 minutes. Following centrifugation, 
the supernatant was collected and i-propanol removed in vacuo. The pH of the 
solution was then altered using AcOH (pH 6-7), before separating the ligation 
product (80) from the peptide fragment (78) using preparative HPLC (Aquapore C 8 , 
2500.0mm,, 7pm; 2m1 loop, 5m1/min; 0-5min 10%B, 5-35mm 10-60%B, 35-37mm 
60-90%B; ?=214nm) R1=19.4min, 34.0%B, 27mg (product), R=21.4min, 36.8%B, 
21mg (fragment). 
HPLC (gradient system 2) R 1 20.5mm, 51.3%B (product); R4 21.4m4 53.8%B 
(fragment). mlz (MALDI-TOF) 3,025.4 (MIEr C 129H215N34047S1 requires 3,024.52 - 
product), 2,773.3 (MH 1,389.45 - dimer of fragment). Amino acid analysis (28 
hours) Ala3 3.08, Asp i 1.12, G1x8 9.05, G1y5 4.92, Leu6 4.9 1, Pr02 1.96, Ser2 1.67, 
Va!2 2.19. 
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Appendix 
The Naturally Occurring Amino Acids 
PH2NCO2H 
Amino Acid 3 letter code 1 letter code R group 
Alanine Ala A -CH3 
Arginine Mg R -(CH2)3NHC(NH)NH2 
Asparagine Mn N -CH2CONH2 
Aspartic acid Asp D -CH2CO2H 
Cysteine Cys C -CH2SH 
Glutamic acid Glu E -(CH2)2CO2NH2 
Glutamine Gin Q -(CH2)2CO2H 
Glycine Gly G -H 
Histidine His H -CH2(4-imidazolyl) 
Isoleucine lie I -CH(CH3)CH2CH3 
Leucine Leu L -CH2CH(CH3)2 
Lysine Lys K 
Methionine Met M -(CH2)2SCH3 
Phenylalanine Phe F -CH2P1i 
Proline Pro p pyrolidine-2L- 
carboxylic acid 
Serine Ser S -CH20H 
Threonine Thr T -CH(CH3)OH 
Tryptophan Trp W -CH2(3-indolyl) 
Tyrosine Tyr y -CH2(4-hydroxypheflyl) 
Valine Val V -CH(CH3)2 
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